Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
Patent Information
- Application Number
- JP2023533650
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-15
- Filing Date
- 2021-11-30
- Publication Date
- 2024-12-04
AI Technical Summary
Current treatments for muscle invasive urothelial carcinoma (MIUC) often result in recurrence and high mortality rates, with no effective adjuvant therapies improving survival, necessitating improved neoadjuvant and adjuvant treatment approaches.
Administering a therapeutic regimen comprising specific hypervariable regions (HVR) sequences of PD-1 axis binding antagonists, such as atezolizumab, based on the presence of circulating tumor DNA (ctDNA) in patients to identify and treat those likely to benefit from adjuvant therapy.
Significantly improves disease-free survival and overall survival in patients with MIUC by targeting ctDNA-positive individuals with PD-1 axis binding antagonists, enhancing treatment efficacy.
Abstract
Description
Cross-reference of related applications
[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 120,643, filed on 2 December 2020, and U.S. Provisional Patent Application No. 63 / 210,950, filed on 15 June 2021, the entire contents of which are incorporated herein by reference.
[0002] Sequence List This application includes a sequence listing submitted electronically in ASCII format, the entirety of which is incorporated herein by reference. The name of the ASCII copy, created on November 29, 2021, is 50474_242 WO3_Sequence_Listing_11_29_21_ST25, and its size is 9,574 bytes. [Technical Field]
[0003] Field of Invention The present invention relates to methods and compositions for use in treating urothelial carcinoma (UC) in patients by administering a treatment regimen to the patient that includes, for example, a PD-1 axis-coupled antagonist (e.g., atezolizumab). [Background technology]
[0004] Background of the Invention UC is the most common cancer of the urinary tract worldwide. The majority of cases originate in the bladder. UC can be diagnosed as non-muscle-invasive, muscle-invasive, or metastatic disease, with one in three new cases being diagnosed as muscle-invasive disease (cT2-T4a Nx M0 according to the Tumor, Lymph Node and Metastasis (TNM) classification). Muscle-invasive UC (MIUC) is a collective term for muscle-invasive bladder cancer (MIBC) and muscle-invasive urothelial carcinoma (UTUC). In 2018, there were an estimated 549,393 new cases and 199,922 deaths of bladder cancer worldwide. In Europe, there were an estimated 197,110 new cases and 64,970 deaths of bladder cancer, including 164,450 new cases and 52,930 deaths in the 28 member states of the European Union. In the United States, it is estimated that there were 81,400 new cases and 17,980 deaths from bladder cancer in 2020. The median age of patients diagnosed with UC in the U.S. was 73 years, the highest age at diagnosis for all tumor types.
[0005] In cases of MIBC, radical cystectomy with bilateral pelvic lymph node dissection is the core of management. The surgery involves the removal of the bladder, adjacent organs, and regional lymph nodes. There are also gender-based differences in the surgical approach; in males, the surgery includes the removal of the prostate and seminal vesicles, while in females, the surgery includes the removal of the uterus, cervix, ovaries, and anterior vagina. Urinary diversion is required after bladder removal. When cystectomy is performed at a core facility, the perioperative mortality rate is approximately 2%–3%.
[0006] Despite this surgery, MIBC recurs in many patients, who present with constitutional symptoms such as pain or fatigue, weight loss, loss of appetite, and severe frailty. Approximately half of patients with MIBC develop local and / or metastatic recurrence of the disease within two years of cystectomy and ultimately die from the disease. For high-risk individuals (pT3-T4a or pN+) who have not received neoadjuvant chemotherapy (NAC), the 5-year overall survival rate ranges from 10% to 40%. Despite numerous clinical trials, no adjuvant therapy has demonstrated an improvement in survival rates for MIBC to date.
[0007] Therefore, improved neoadjuvant and adjuvant treatment approaches for UC are still needed in this field. [Overview of the project]
[0008] The present invention relates, in particular, to methods, compositions (e.g., pharmaceutical compositions), uses, kits, and products for adjuvant therapy of ulcerative colitis (UC).
[0009] In one aspect, the present invention relates to a method for treating muscle-invasive urothelial carcinoma (MIUC) in a patient requiring treatment of MIUC, comprising administering to the patient an effective amount of a therapeutic regimen comprising an anti-PD-L1 antibody, wherein the anti-PD-L1 antibody is (a) the hypervariable region (HVR)-H1 and HVR-H of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively. The method comprises (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively, wherein the treatment regimen is adjuvant therapy, and the patient has been identified as likely to benefit from the treatment regimen based on the presence of circulating tumor DNA (ctDNA) in a biological sample obtained from the patient.
[0010] In another aspect, the present invention provides a method for treating MIUC in a patient requiring treatment of MIUC, comprising: (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a therapeutic regimen comprising a PD-L1 antibody; and (b) administering to the patient an effective amount of a therapeutic regimen comprising a PD-L1 antibody based on the presence of ctDNA in the biological sample. The treatment regimen is adjuvant therapy, and the method is characterized by administering to the patient a treatment regimen comprising a PD-L1 antibody, wherein the anti-PD-L1 antibody comprises (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively.
[0011] In another aspect, the present invention relates to a method for identifying a patient having MIUC who may benefit from a therapeutic regimen comprising an anti-PD-L1 antibody, comprising determining whether ctDNA is present in a biological sample obtained from the patient, wherein the presence of ctDNA in the biological sample identifies the patient as one who may benefit from treatment with a therapeutic regimen comprising an anti-PD-L1 antibody, the therapeutic regimen being an adjuvant therapy, and the anti-PD-L1 antibody comprising (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively.
[0012] In another aspect, the present invention relates to a method for selecting a treatment for a patient having MIUC, comprising: (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising an anti-PD-L1 antibody; and (b) selecting a treatment regimen comprising an anti-PD-L1 antibody based on the presence of ctDNA in the biological sample. The treatment regimen is adjuvant therapy, and the method is characterized by selecting a treatment regimen comprising an anti-PD-L1 antibody comprising (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively.
[0013] In another aspect, the present invention relates to a method for monitoring the response of a patient having MIUC who has been administered at least a first dose of a therapeutic regimen comprising an anti-PD-L1 antibody, wherein the therapeutic regimen is a neoadjuvant therapy or an adjuvant therapy, and ctDNA is present in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen, and it is determined whether ctDNA is present in a biological sample obtained from the patient at a time after the administration of the first dose of the therapeutic regimen. The method comprises monitoring the patient's response, wherein the anti-PD-L1 antibody comprises (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively. In some embodiments, the treatment regimen is neoadjuvant therapy. In other embodiments, the treatment regimen is adjuvant therapy.
[0014] In another aspect, the present invention relates to a method for identifying a patient having MIUC who may benefit from a therapeutic regimen comprising an anti-PD-L1 antibody, wherein the therapeutic regimen is a neoadjuvant therapy or adjuvant therapy, the patient has been administered at least a first dose of the therapeutic regimen, ctDNA is present in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen, and the method comprises determining whether ctDNA is present in a biological sample obtained from the patient at a time after the administration of the first dose of the therapeutic regimen. The absence of ctDNA in the biological sample identifies the patient as one who may benefit from treatment with a therapeutic regimen comprising an anti-PD-L1 antibody, characterized in that the anti-PD-L1 antibody comprises (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively. In some embodiments, the therapeutic regimen is neoadjuvant therapy. In other embodiments, the therapeutic regimen is adjuvant therapy.
[0015] In another aspect, the present invention is an anti-PD-L1 antibody or pharmaceutical composition comprising an anti-PD-L1 antibody for use in the treatment of MIUC in a patient who requires treatment of MIUC, wherein the treatment comprises administration of a treatment regimen comprising an effective amount of an anti-PD-L1 antibody, the treatment regimen is an adjuvant therapy, the patient has been identified as likely to benefit from the treatment regimen based on the presence of ctDNA in a biological sample obtained from the patient, and the anti-PD-L1 antibody comprises (a) HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively.
[0016] In another aspect, the present invention relates to an anti-PD-L1 antibody or a pharmaceutical composition comprising an anti-PD-L1 antibody for use in the treatment of MIUC in a patient requiring treatment for MIUC, wherein the treatment comprises (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising an anti-PD-L1 antibody; and (b) administering to the patient an effective amount of a treatment regimen comprising an anti-PD-L1 antibody based on the presence of ctDNA in the biological sample. The treatment regimen is adjuvant therapy, and the anti-PD-L1 antibody is characterized by administering to the patient a treatment regimen comprising an anti-PD-L1 antibody or a pharmaceutical composition comprising an anti-PD-L1 antibody, wherein the treatment regimen is adjuvant therapy, and the anti-PD-L1 antibody comprises (a) the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7), and QQYLYHPAT (SEQ ID NO: 8), respectively.
[0017] In another aspect, the present invention provides an anti-PD-L1 antibody or a pharmaceutical composition comprising an anti-PD-L1 antibody for use in the treatment of a patient with MIUC who has been administered at least a first dose of a treatment regimen comprising an anti-PD-L1 antibody, wherein the treatment regimen is neoadjuvant therapy or adjuvant therapy, ctDNA is present in a biological sample obtained from the patient before or simultaneously with the first dose of the treatment regimen, and the response of the patient is monitored by a method comprising determining whether ctDNA is present in a biological sample obtained from the patient at a time point after administration of the first dose of the treatment regimen, and the anti-PD-L1 antibody comprises (a) HVR-H1, HVR-H2 and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4) and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) HVR-L1, HVR-L2 and HVR-L3 sequences of RASQDVSTAVA (SEQ ID NO: 6), SASFLYS (SEQ ID NO: 7) and QQYLYHPAT (SEQ ID NO: 8), respectively. In some embodiments, the treatment regimen is neoadjuvant therapy. In other embodiments, the treatment regimen is adjuvant therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] [Figure 1] Figure 1A is a schematic diagram showing the inclusion criteria for the ctDNA biomarker evaluable population (BEP) in the IMvigor010 study. Figures 1B and 1C are a series of graphs showing Kaplan-Meier plots comparing patients treated with atezolizumab (dark grey) to observation (light grey) for the probability of disease-free survival (DFS) (Figure 1B) and the interim probability of overall survival (OS) (Figure 1C) in the ctDNA BEP population stratified by lymph node status, PD-L1 status and tumor stage. HR, hazard ratio [Figure 2] Figures 2A-2D are a series of Kaplan-Meier plots comparing the ctDNA(+) (dark gray) state with the ctDNA(-) (light gray) state at C1D1 for DFS in the atezolizumab group (Figure 2A), DFS in the observation group (Figure 2B), OS in the atezolizumab group (Figure 2C), and OS in the observation group (Figure 2D). The probabilities of DFS and OS are shown on the y-axis. C1D1, day 1 of cycle 1. [Figure 3] Figure 3 is a histogram plot showing the distribution of the time between the C1D1ctDNA(+) test and radiological recurrence for patients within the C1D1ctDNA(+) subgroup. [Figure 4] Figures 4A and 4B are a series of Kaplan-Meier plots showing DFS (Figure 4A) comparing ctDNA(+) patients treated with atezolizumab with ctDNA(+) patients in the observation group and ctDNA(-) patients treated with atezolizumab with ctDNA(-) patients in the observation group, and provisional OS (Figure 4B) in patients assessed for ctDNA status, comparing ctDNA(+) patients treated with atezolizumab with ctDNA(+) patients in the observation group and ctDNA(-) patients treated with atezolizumab with ctDNA(-) patients in the observation group. The probabilities of DFS and OS are shown on the y-axis. [Figure 5]Figures 5A and 5B are a series of forest plots showing DFS (Figure 5A) and OS (Figure 5B) in BEP, comparing atezolizumab versus observation in subgroups defined by established prognostic factors. Subgroups are shown defined by baseline clinical features and tissue immunobiotics, including lymph node status, tumor stage, number of resected lymph nodes, previous neoadjuvant chemotherapy, PD-L1 status by histoimmunohistochemistry (IHC), TMB status by whole exome sequencing (WES), as well as transcriptome signatures including tGE3, TBRS, angiogenesis, and TCGA subtype. The forest plots show HRs for recurrence or death estimated using a univariate Cox proportional hazards model, with the 95% confidence interval of the HR represented by horizontal bars. Figure 5C is a bar plot showing the association of baseline prognostic factors with ctDNA(-) status (light gray) and ctDNA(+) status (dark gray). Lymph node-positive patients were concentrated in terms of ctDNA positivity (47.5% of lymph node-positive patients were ctDNA-positive, while 25.2% of lymph node-negative patients were ctDNA-positive). [Figure 6] Figures 6A and 6B are a series of forest plots showing DFS in atezolizumab versus observation for ctDNA(+) patients (Figure 6A) and ctDNA(-) patients (Figure 6B). Subgroups are shown defined by baseline clinical features and tissue immunobiological biomarkers, including lymph node status, tumor stage, number of resected lymph nodes, prior neoadjuvant chemotherapy, PD-L1 status by tissue IHC, TMB status by tissue WES, and transcriptome signatures including tGE3, TBRS, angiogenesis, and TCGA subtype. The forest plots show HR for mortality estimated using a univariate Cox proportional hazards model, with the 95% confidence interval of the HR represented by horizontal bars. [Figure 7]Figures 7A and 7B are a series of forest plots showing OS in atezolizumab versus observation for ctDNA(+) patients (Figure 7A) and ctDNA(-) patients (Figure 7B). Subgroups are shown defined by baseline clinical features and tissue immunobiological biomarkers, including lymph node status, tumor stage, number of resected lymph nodes, prior neoadjuvant chemotherapy, PD-L1 status by tissue IHC, TMB status by tissue WES, and transcriptome signatures including tGE3, TBRS, angiogenesis, and TCGA subtype. The forest plots show HR for mortality estimated using a univariate Cox proportional hazards model, with the 95% confidence interval of the HR represented by horizontal bars. [Figure 8]Figures 8A–8H are a series of graphs showing Kaplan-Meier plots for the TMB or PD-L1 subgroup. Figures 8A and 8C are a series of graphs showing Kaplan-Meier plots for DFS in all ctDNA BEP patients (Figure 8A) and OS in all ctDNA BEP patients (Figure 8C) for patients who are TMB(+) and atezolizumab, TMB(+) and observation, TMB(-) and atezolizumab, and TMB(-) and observation. Figures 8B and 8D are a series of graphs showing Kaplan-Meier plots for DFS in ctDNA(+) patients (Figure 8B) and OS in ctDNA(+) patients (Figure 8D) for patients who are TMB(+) / high and atezolizumab, TMB(+) / high and observation, TMB(-) / low and atezolizumab, and TMB(-) / low and observation. TMB was measured by WES. Figures 8E and 8G are a series of graphs showing Kaplan-Meier plots for DFS (Figure 8E) and OS (Figure 8G) in all ctDNA BEP patients for patients who were PD-L1(+) and atezolizumab group, PD-L1(+) and observation group, PD-L1(-) and atezolizumab group, and PD-L1(-) and observation group. Figures 8F and 8H are a series of graphs showing Kaplan-Meier plots for DFS (Figure 8F) and OS (Figure 8H) in ctDNA(+) patients for patients who were PD-L1(+) / high and atezolizumab group, PD-L1(+) / high and observation group, PD-L1(-) / low and atezolizumab group, and PD-L1(-) / low and observation group. TMB, tumor gene mutational load. PD-L1 expression on tumor-infiltrating immune cells (IC) induced by PD-L1 IC and IHC. [Figure 9]Figures 9A and 9B are a series of Kaplan-Meier plots showing DFS in patients with ctDNA(-) and TMB(+) in the atezolizumab group and observation group (Figure 9A), and OS in patients with ctDNA(-) and TMB(+) in the atezolizumab group and observation group (Figure 9B). [Figure 10] Figures 10A and 10B are a series of Kaplan-Meier plots showing DFS in patients with ctDNA(-) and PD-L1(+) in the atezolizumab group and the observation group, DFS in patients with ctDNA(-) and PD-L1(-) in the atezolizumab group and the observation group (Figure 10A), and OS in patients with ctDNA(-) and PD-L1(+) in the atezolizumab group and the observation group, and OS in patients with ctDNA(-) and PD-L1(-) in the atezolizumab group and the observation group (Figure 10B). [Figure 11] Figures 11A-11D are a series of Kaplan-Meier plots comparing ctDNA(+) (dark gray) in the C3D1 state with ctDNA(-) (light gray) in the atezolizumab group (DFS) (Figure 11A), the atezolizumab group (OS) (Figure 11B), the observation group (DFS) (Figure 11C), and the observation group (OS) (Figure 11D). [Figure 12]Figure 12A is a graph showing the proportion of patients who were ctDNA(+) at C1D1 and converted to ctDNA(-) by C3D1 (Pos>Neg; excluded) compared to patients who remained ctDNA(+) at C3D1 (Pos>Pos) in the atezolizumab group and the observation group. C3D1, day 1 of cycle 3; Pos, ctDNA(+); Neg, ctDNA(-). Figures 12B-12E are a series of Kaplan-Meier plots showing different ctDNA dynamics from C1D1 to C3D1 for the atezolizumab group (blue) (Figure 12B), the observation group (Figure 12C), the atezolizumab group (Figure 12D), and the observation group (Figure 12E). These plots include patients who were ctDNA(+) at C1D1 and eliminated ctDNA by C3D1 (Pos>Neg; dark solid line), patients who were ctDNA(-) at C1D1 and remained ctDNA(-) at C3D1 (Neg>Neg; light solid line), and patients who were ctDNA(-) at C1D1 and became ctDNA(+) at C3D1 (Neg>Pos; light dashed line). Figure 12F is a bar plot showing the proportion of ABACUS trial participants who were ctDNA(+) (dark gray) or ctDNA(-) (light gray) compared to patients who responded to atezolizumab neoadjuvant therapy (pathological complete response (pCR) / major pathological response (MPR), left) and patients who did not respond (non-responders, right). Pre-treatment and post-treatment time points are shown (x axis). Figure 12G is a box plot showing ctDNA concentrations (sample MTM / mL) in ABACUS study participants who were ctDNA(+) and ctDNA(-) compared to patients who responded to atezolizumab neoadjuvant therapy (pCR / MPR, left) and patients who did not respond (non-responders, right). Pre-treatment and post-treatment time points are shown (x axis). The sample sizes for the box plots are n=17, 15, 23, and 15 from left to right. The box plot shows the median with a central line, the lower and upper hinges at the first and third quartiles respectively, and the whiskers at the minimum and maximum values within a 1.5 × interquartile range, with the remaining outlier data points plotted individually.Figure 12H is a bar plot showing the percentage of ctDNA(+) patients who had ctDNA elimination (dark gray) or non-elimination (light gray) by the post-treatment time point, comparing patients who responded to atezolizumab neoadjuvant therapy (pCR / MPR, left) with patients who did not respond (non-responders, right). [Figure 13]Figure 13A is a scatter plot showing ctDNA concentration measured by sample mean tumor molecules per 1 mL of plasma (sample MTM / mL) against DFS expressed in months. Black dots indicate events, and white dots indicate censoring. Observation group ctDNA(+) patients are shown. Figure 13B is a Kaplan-Meier plot showing DFS in patients with high ctDNA concentration (dark gray; median sample MTM / mL ≥ (i.e., sample MTM / mL ≥ median)) versus patients with low ctDNA concentration (light gray; median sample MTM / mL < (i.e., sample MTM / mL < median)). Observation group ctDNA(+) patients are shown. Figure 13C is a forest plot showing DFS in patients with high ctDNA levels versus patients with low ctDNA levels, using different quantile thresholds for splitting sample MTM / mL, including the 10th, 25th, 50th (median), 75th, and 90th percentiles. The observation group ctDNA(+) patients are shown. The forest plot shows the HR for recurrence or death estimated using a univariate Cox proportional hazards model, with the 95% confidence interval of the HR represented by horizontal bars. Figure 13D is a scatter plot showing OS (x-axis) in months versus ctDNA concentration measured by sample MTM / mL. Black dots represent events, and white dots represent censoring. The observation group ctDNA(+) patients are shown. Figure 13E is a Kaplan-Meier plot showing OS in patients with high ctDNA concentrations (dark gray; median sample MTM / mL ≥ (i.e., sample MTM / mL ≥ median)) versus patients with low ctDNA concentrations (light gray; median sample MTM / mL < (i.e., sample MTM / mL < median)). The observation group ctDNA(+) patients are shown. Figure 13F is a forest plot showing OS in patients with high ctDNA concentrations versus patients with low ctDNA concentrations, using different quantile thresholds for splitting ctDNA sample MTM / mL, including the 10th, 25th, 50th (median), 75th, and 90th percentiles. The observation group of ctDNA(+) patients is shown.The forest plot shows the hazard ratio (HR) for recurrence or death estimated using a univariate Cox proportional hazards model, with the 95% confidence interval for the HR represented by horizontal bars. [Figure 14] Figure 14A is a bar plot showing the percentage of patients who were ctDNA(+) at C1D1 and had decreased ctDNA by C3D1 in the atezolizumab group (dark gray) and the observation group (light gray). Decrease was assessed in C1D1 ctDNA(+) patients during C1 / C3 BEP and was defined as a decrease in sample MTM / mL from C1 to C3. Figures 14B–14E are a series of Kaplan-Meier plots showing patients with decreased ctDNA ("decreased"; dark gray) compared to patients with increased ctDNA levels ("not decreased"; light gray (hrasy)) for DFS in the atezolizumab group (Figure 14B), DFS in the observation group (Figure 14C), OS in the atezolizumab group (Figure 14D), and OS in the observation group (Figure 14E). The decrease was evaluated in C1D1 ctDNA(+) patients during C1 / C3 BEP and was defined as a decrease in sample MTM / mL from C1D1 to C3D1. [Figure 15]Figure 15A is a Kaplan-Meier plot showing DFS, divided into patients with reduced ctDNA that were eliminated ("reduced with elimination"; dark gray, solid line) and patients with reduced ctDNA without elimination ("reduced without elimination"; dark gray, dashed line). Patients with increased ctDNA are also shown ("increased"; light gray, solid line). Figure 15B is a forest plot showing DFS comparing patients with reduced ctDNA (from elimination (-100% change) to slight decrease in ctDNA (<0% change)) using different thresholds for percentage change in sample MTM / mL, including a -100% change (reduced with elimination vs. reduced without elimination), a -50% change, a -25% change, and a -10% change. Note that the percentage change scale ranges from -100% (elimination) to infinity, with negative values indicating a decrease and positive values indicating an increase. Figure 15C is a Kaplan-Meier plot showing OS, divided into patients with reduced ctDNA that was eliminated ("reduced with elimination"; dark gray, solid line) and patients with reduced ctDNA without elimination ("reduced without elimination"; dark gray, dashed line). Patients with increased ctDNA are also shown ("increased"; light gray, solid line). Figure 15D is a forest plot showing OS comparing patients with reduced ctDNA (from elimination (-100% change) to slight decrease in ctDNA (<0% change)) using different thresholds for percentage change in sample MTM / mL, including a -100% change (reduced with elimination vs. reduced without elimination), a -50% change, a -25% change, and a -10% change. Note that the percentage change scale ranges from -100% (elimination) to infinity, with negative values indicating a decrease and positive values indicating an increase. [Figure 16]Figure 16A is a scatter plot showing ctDNA concentration (C1D1 sample MTM / mL) versus C1D1 collection time (days post-surgery) in patients with muscle-invasive bladder cancer (MIBC). Figure 16B is a box plot showing C1D1 collection time (y axis, day post-surgery) for ctDNA-negative (x axis, left box plot, n=339) and ctDNA-positive (x axis, right box plot, n=199) MIBC patients. No difference was observed between collection times for ctDNA-negative and ctDNA-positive patients (Wilcoxon P=0.18, two-sided). In the box plot, the center line is the median, the lower and upper hinges correspond to the first and third quartiles, the upper whisker extends from the hinge to the maximum value not exceeding 1.5 × IQR from the hinge, and the lower whisker extends from the hinge to the minimum value at the maximum 1.5 × IQR of the hinge. Data beyond the ends of the whiskers are individually plotted outliers. Figure 16C is a bar plot showing the percentage of patients who were ctDNA positive (dark gray area) for patients with C1D1 collection times below the median collection time (x-axis, left bar plot) and above the median collection time (x-axis, right bar plot). MIBC patients are shown. Figure 16D is a histogram showing the time (days) between surgery and C1D1 for MIBC patients. [Figure 17] Figure 17A is a consort diagram showing how patients in the ctDNA biomarker evaluable population (BEP, n=40) were identified from the total ABACUS study population (n=95). Figure 17B is a Kaplan-Meier plot comparing relapse-free survival of ctDNA-positive patients (light gray) to ctDNA-negative patients (dark gray) at baseline (C1D1) before neoadjuvant treatment. Figure 17C is a Kaplan-Meier plot comparing relapse-free survival of ctDNA-positive patients (light gray) to ctDNA-negative patients (dark gray) at a point after neoadjuvant treatment. [Figure 18]Figure 18A is a volcano plot showing differential gene expression analysis in ctDNA BEP, indicating genes associated with ctDNA positivity (ctDNA+) and ctDNA negativity (ctDNA-). Figure 18B is a graph showing the results of Hallmark gene set enrichment analysis in ctDNA BEP, indicating pathways associated with ctDNA positivity (ctDNA+; dark gray) and ctDNA negativity (ctDNA-; light gray). Figure 18C is a graph showing the results of Hallmark gene set enrichment analysis in ctDNA(+) patients in the atezolizumab group, indicating pathways associated with relapse and non-relapse: DN, Down; EMT, Epithelial-mesenchymal transition. Figures 18D–18F are a series of Kaplan-Meier plots showing OS for ctDNA(+) patients in the atezolizumab and observation groups within subgroups defined by immunobiometric markers for response to immunotherapy (Figure 18D) and resistance (Figures 18E and 18F). The immunotherapy response biomarker tGE3 gene expression signature (Figure 18D) is shown. Immunotherapy resistance immune biomarkers, pan-TBRS gene expression signatures (Figure 18E), and angiogenesis gene expression signatures (Figure 18F) are shown. High biomarker expression is indicated by darker shading. Low biomarker expression is indicated by lighter shading. [Figure 19] Figures 19A–19C are a series of Kaplan-Meier plots showing DFS for ctDNA(+) patients in the atezolizumab and observation groups within subgroups defined by immunobiomarkers for response to immunotherapy (Figure 19A) and resistance (Figures 19B and 19C). The immunotherapy response biomarker tGE3 gene expression signature (Figure 19A) is shown. Immunobiotics for resistance to immunotherapy, the pan-TBRS gene expression signature (Figure 19B) and the angiogenesis gene expression signature (Figure 19C) are shown. High biomarker expression is indicated by darker shading. Low biomarker expression is indicated by lighter shading. Figure 19D is a graph showing the results of Hallmark gene set enrichment analysis in ctDNA+ patients in the observation group, comparing non-relapsed patients (light gray) with relapsed patients (dark gray). [Figure 20] Figures 20A–20C are a series of Kaplan-Meier plots showing ctDNA(-) patients in the atezolizumab and observation groups for DFS (left) and OS (right). Transcriptome signatures, including tGE3 (Figure 20A), pan-F-TBRS (Figure 20B), and angiogenesis (Figure 20C), are shown. High biomarker expression is indicated by darker shading. Low biomarker expression is indicated by lighter shading. [Figure 21] Figure 21A is a heatmap showing that hierarchical clustering in a ctDNA biomarker evaluable population summarizes the TCGA subtypes of urothelial carcinoma. APM, antigen-presenting mechanism; ECM, extracellular matrix; IC, tumor-infiltrating immune cells; TC, tumor cells. Figures 21B–21E are a series of Kaplan-Meier plots showing OS for patients in the atezolizumab and observation groups. For luminal papilla (Figure 21B), luminal invasion (Figure 21C), lumen (Figure 21D), and basal / squamous epithelium (Figure 21E), ctDNA status in BEP and prognosis and / or predictive values for TCGA subtypes are shown. ctDNA(-) and ctDNA(+) statuses are shown. Figure 21F is a volcano plot showing differential gene expression analysis in observation (Obs) group ctDNA(-) patients showing genes associated with relapse (left) and non-relapse (right). ECM, extracellular matrix; IFN, interferon. Figure 21G is a graph showing the results of Hallmark gene set enrichment analysis in observational (Obs) ctDNA(-) patients, illustrating pathways associated with relapse and non-relapse. Figures 21H and 21I are a series of bar plots showing the distribution of TCGA subtypes binned by relapse (left) or non-relapse (right) in (combined groups) ctDNA(-) patients (Figure 21H), and the proportion of patients who are ctDNA(+) (dark gray) and ctDNA(-) (light gray) binned by either distant relapse (left) or local relapse (right) in (combined groups) relapsed patients (Figure 21I). [Figure 22]Figures 22A and 22B are a series of bar plots showing the distribution of patients in TCGA subgroups compared between the ctDNA(-) and ctDNA(+) populations (Figure 22A), and between the PD-L1 status populations (IC01 and IC23) (Figure 22B). Figures 22C–22H are a series of Kaplan-Meier plots showing DFS (Figures 22C–22F) for ctDNA(+) (dark shadows) and ctDNA(-) (light shadows) patients in the atezolizumab and observation groups for the TCGA subgroups, as well as DFS (Figure 22G) and OS (Figure 22H) for neuronal TCGA subgroups. [Figure 23] Figure 23 shows the trial scheme of the IMvigor011 Phase III double-blind randomized trial comparing atezolizumab versus placebo as adjuvant therapy in high-risk muscle-invasive bladder cancer patients who are ctDNA-positive after cystectomy. Min., minimal; NAC, neoadjuvant chemotherapy; SOC, standard treatment; Cx, cystectomy; WES, whole exome sequencing. [Modes for carrying out the invention]
[0019] Detailed description of the invention This disclosure provides methods and compositions for the treatment of urothelial carcinoma. The present invention is at least in part based on the finding in a prospective analysis of the Phase III IMvigor010 trial that baseline ctDNA positivity was associated with significantly improved DFS and OS in patients with urothelial carcinoma receiving adjuvant therapy including a PD-1 axis-conjugated antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) (see, for example, Example 1). The present invention is also at least in part based on the finding that the rate of ctDNA elimination was higher than observed in patients receiving neoadjuvant or adjuvant therapy including a PD-1 axis-conjugated antagonist, and that elimination was associated with improved DFS and OS in the Phase III IMvigor010 and Phase II ABACUS trials of atezolizumab therapy, which is a neoadjuvant (see, for example, Example 1). Therefore, the methods and compositions provided herein enable the identification and treatment of patients who may benefit from neoadjuvant or adjuvant therapy containing a PD-1 axially coupled antagonist (e.g., atezolizumab), including patients with MIBC (e.g., high-risk MIBC) who are ctDNA positive after surgical resection (e.g., cystectomy). The methods and compositions provided herein also enable monitoring of patient responses to neoadjuvant or adjuvant therapy containing a PD-1 axially coupled antagonist.
[0020] I. Definition As used herein, “circulating tumor DNA” and “ctDNA” refer to tumor-derived DNA in the circulating system that is not associated with cells. ctDNA is a type of cell-free DNA (cfDNA) that may originate from tumor cells or circulating tumor cells (CTCs). ctDNA may be found, for example, in the bloodstream of a patient or in biological samples obtained from a patient (e.g., blood, serum, plasma, or urine). In some embodiments, ctDNA may include abnormal mutations (e.g., patient-specific variants) and / or methylation patterns.
[0021] The term "PD-1 axis-binding antagonist" refers to a molecule that inhibits the interaction of a PD-1 axis-binding partner with one or more of its binding partners in order to eliminate T cell dysfunction caused by signaling on the PD-1 signaling axis, thereby restoring or enhancing T cell function (e.g., proliferation, cytokine production, and / or target cell death). As used herein, a PD-1 axis-binding antagonist includes a PD-L1 binding antagonist, a PD-1 binding antagonist, and a PD-L2 binding antagonist. In some examples, a PD-1 axis-binding antagonist includes a PD-L1 binding antagonist or a PD-1 binding antagonist. In preferred aspects, a PD-1 axis-binding antagonist is a PD-L1 binding antagonist.
[0022] The term "PD-L1-binding antagonist" refers to a molecule that reduces, blocks, inhibits, represses, or interferes with signaling resulting from the interaction of PD-L1 with one or more of its binding partners, such as PD-1 and / or B7-1. In some examples, a PD-L1-binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partner. In a specific context, a PD-L1-binding antagonist inhibits the binding of PD-L1 to PD-1 and / or B7-1. In some examples, PD-L1-binding antagonists include anti-PD-L1 antibodies, their antigen-binding fragments, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, repress, or interfere with signaling resulting from the interaction of PD-L1 with one or more of its binding partners, such as PD-1 and / or B7-1. In one example, PD-L1-binding antagonists reduce negative costimulatory signals mediated by or via cell surface proteins expressed on T lymphocytes via PD-L1-mediated signaling, thereby mitigating dysfunction in dysfunctional T cells (e.g., enhancing the effector response to antigen recognition). In some examples, PD-L1-binding antagonists bind to PD-L1. In some examples, PD-L1-binding antagonists are anti-PD-L1 antibodies (e.g., anti-PD-L1 antagonist antibodies). Examples of anti-PD-L1 antagonist antibodies include atezolizumab, MDX-1105, MEDI4736 (durvalumab), MSB0010718C (avelumab), SHR-1316, CS1001, emvafolimab, TQB2450, ZKAB001, LP-002, CX-072, IMC-001, KL-A167, APL-502, cosivelimab, rhodapolimab, FAZ053, TG-1501, BGB-A333, BCD-135, AK-106, LDP, GR1405, HLX20, MSB2311, RC98, PDL-GEX, KD036, KY1003, YBL-007, and HS-636.In some contexts, the anti-PD-L1 antibody is atezolizumab, MDX-1105, MEDI4736 (durvalumab), or MSB0010718C (avelumab). In one specific context, the PD-L1-binding antagonist is MDX-1105. In another specific context, the PD-L1-binding antagonist is MEDI4736 (durvalumab). In yet another specific context, the PD-L1-binding antagonist is MSB0010718C (avelumab). In other contexts, the PD-L1-binding antagonist may be a small molecule, e.g., GS-4224, INCB086550, MAX-10181, INCB090244, CA-170, or ABSK041, which may be administered orally in some cases. Other exemplary PD-L1-binding antagonists include AVA-004, MT-6035, VXM10, LYN192, GB7003, and JS-003. In a favorable scenario, the PD-L1-binding antagonist is atezolizumab.
[0023] The term “PD-1 binding antagonist” refers to a molecule that reduces, blocks, inhibits, suppresses, or interferes with signaling resulting from the interaction of PD-1 with one or more of its binding partners, such as PD-L1 and / or PD-L2. PD-1 (programmed cell death 1) is also known in the art as “programmed cell death 1,” “PDCD1,” “CD279,” and “SLEB2.” An exemplary human PD-1 is shown in UniProtKB / Swiss-Prot accession number Q15116. In some examples, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to one or more of its binding partners. In certain contexts, a PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1-binding antagonists include anti-PD-1 antibodies, their antigen-binding fragments, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, suppress, or interfere with signaling resulting from the interaction of PD-1 with PD-L1 and / or PD-L2. In one example, a PD-1-binding antagonist reduces negative costimulatory signaling mediated by or via cell surface proteins expressed on T lymphocytes via PD-1-mediated signaling, such as mitigating dysfunction in dysfunctional T cells (e.g., enhancing the effector response to antigen recognition). In some examples, PD-1-binding antagonists bind to PD-1. In some examples, PD-1-binding antagonists are anti-PD-1 antibodies (e.g., anti-PD-1 antagonist antibodies).Examples of anti-PD-1 antagonist antibodies include nivolumab, pembrolizumab, MEDI-0680, PDR001 (spartalizumab), REGN2810 (semiprimab), BGB-108, prorugolimab, canrelizumab, cintilimab, tislerizumab, tripalimab, dostallimab, retifanlimab, sasamlimab, and pemprimab. Examples include CS1003, HLX10, SCT-I10A, zimbererimab, valstilimab, genolimuzumab, BI754091, cetrelimab, YBL-006, BAT1306, HX008, buzicalimab, AMG404, CX-188, JTX-4014, 609A, Sym021, LZM009, F520, SG001, AM0001, ENUM 244C8, ENUM 388D4, STI-1110, AK-103, and hAb21. In certain situations, the PD-1 conjugated antagonist is MDX-1106 (nivolumab). In other specific situations, the PD-1 conjugated antagonist is MK-3475 (pembrolizumab). In other specific contexts, the PD-1 binding antagonist is a PD-L2 Fc fusion protein, e.g., AMP-224. In other specific contexts, the PD-1 binding antagonist is MED1-0680. In other specific contexts, the PD-1 binding antagonist is PDR001 (spartalizumab). In other specific contexts, the PD-1 binding antagonist is REGN2810 (semiprimab). In other specific contexts, the PD-1 binding antagonist is BGB-108. In other specific contexts, the PD-1 binding antagonist is prorugolimab. In other specific contexts, the PD-1 binding antagonist is canrelizumab. In other specific contexts, the PD-1 binding antagonist is cintilimab. In other specific contexts, the PD-1 binding antagonist is tislerizumab. In another specific context, the PD-1 binding antagonist is tripalimab. Other further exemplary PD-1 binding antagonists include BION-004, CB201, AUNP-012, ADG104, and LBL-006.
[0024] The term “PD-L2-binding antagonist” refers to a molecule that reduces, blocks, inhibits, suppresses, or interferes with the signaling of PD-L2, resulting from its interaction with one or more of its binding partners, such as PD-1. PD-L2 (programmed cell death ligand 2) is also known in the art as “programmed cell death ligand 12,” “PDCD1LG2,” “CD273,” “B7-DC,” “Btdc,” and “PDL2.” An exemplary human PD-L2 is shown in UniProtKB / Swiss-Prot accession number Q9BQ51. In some examples, a PD-L2-binding antagonist is a molecule that inhibits the binding of PD-L2 to one or more of its binding partners. In certain contexts, a PD-L2-binding antagonist inhibits the binding of PD-L2 to PD-1. Exemplary PD-L2 antagonists include anti-PD-L2 antibodies, their antigen-binding fragments, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, suppress, or interfere with signaling resulting from the interaction of PD-L2 with one or more of its binding partners, such as PD-1. In one aspect, PD-L2-binding antagonists reduce negative costimulatory signaling mediated by or via cell surface proteins expressed on T lymphocytes via PD-L2-mediated signaling, thereby mitigating dysfunction in dysfunctional T cells (e.g., enhancing effector responses to antigen recognition). In some aspects, PD-L2-binding antagonists bind to PD-L2. In some aspects, PD-L2-binding antagonists are immunoadhesins. In other aspects, PD-L2-binding antagonists are anti-PD-L2 antagonist antibodies.
[0025] In this specification, the terms “programmed cell death ligand 1” and “PD-L1” refer to the naturally occurring human PD-L1 polypeptide. The naturally occurring PD-L1 polypeptide is provided under Uniprot accession number Q9NZQ7. For example, the naturally occurring PD-L1 may have the amino acid sequence described under Uniprot accession number Q9NZQ7-1 (isoform 1). In another example, the naturally occurring PD-L1 may have the amino acid sequence described under Uniprot accession number Q9NZQ7-2 (isoform 2). In yet another example, the naturally occurring PD-L1 may have the amino acid sequence described under Uniprot accession number Q9NZQ7-3 (isoform 3). PD-L1 is also referred to in the art as “programmed cell death ligand 1,” “PDCD1LG1,” “CD274,” “B7-H,” and “PDL1.”
[0026] The Kabat numbering system is generally used when referring to residues within the variable domain (approximately light chain residues 1-107 and heavy chain residues 1-113) (e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The "EU numbering system" or "EU index" is generally used when referring to residues in the constant region of the immunoglobulin heavy chain (e.g., Kabat et al., the EU index reported above). "EU index as in Kabat" refers to the residue numbering of human IgG1 EU antibodies.
[0027] In this specification, “atezolizumab” is a PD-L1-conjugated, Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin containing the heavy chain sequence of SEQ ID NO: 1 and the light chain sequence of SEQ ID NO: 2. Atezolizumab contains a single amino acid substitution (asparagine to alanine) (N297A) at position 297 on the heavy chain using EU numbering of Fc region amino acid residues, resulting in a non-glycosylated antibody with minimal binding to the Fc receptor. Atezolizumab is listed in WHO Drug Information (International Nonproprietary Names for Pharmaceutical Substances), Proposed INN: List 112, Vol. 28, No. 4, published January 16, 2015 (see page 485).
[0028] The term "cancer" refers to a disease caused by the uncontrolled division of abnormal cells in a part of the body. For example, urothelial carcinoma is a type of cancer. Cancer can be locally advanced or metastatic. In some cases, cancer is locally advanced. In other cases, cancer is metastatic. In some cases, cancer can be unresectable (e.g., unresectable locally advanced or metastatic cancer).
[0029] As used herein, “urothelial carcinoma” and “UC” refer to a type of cancer that typically occurs in the urinary tract, including muscle-invasive bladder cancer (MIBC) and muscle-invasive urothelial carcinoma (UTUC). UC is also known in the art as transitional cell carcinoma (TCC).
[0030] As used herein, “tumor, lymph node and metastasis classification” and “TNM classification” refer to the cancer staging classifications described in the Joint Commission on Cancer (AJCC) Manual of Cancer Staging, 7th Edition.
[0031] The terms "ineligible for treatment with platinum-based chemotherapy" or "unsuitable for treatment with platinum-based chemotherapy" mean that, in the judgment of the attending physician, or in accordance with standardized criteria for eligibility for platinum-based chemotherapy known in the art, the subject is ineligible or unsuitable for treatment with platinum-based chemotherapy. For example, cisplatin ineligibility may be defined by any one of the following criteria: (i) renal impairment (glomerular filtration rate (GFR) < 60 mL / min); GFR may be assessed by direct measurement (i.e., creatinine clearance or ethylenediamine tetraacetate) or, if unavailable, by calculation from serum / plasma creatinine (Cockcroft-Gault formula); (ii) hearing loss of 25 dB at two adjacent frequencies (measured by audiometry); (iii) peripheral neuropathy of grade 2 or higher (i.e., parasthesis, including stabbing); and (iv) ECOG performance status of 2.
[0032] As used herein, “to treat” includes effective cancer treatment with an effective dose of a therapeutic agent (e.g., a PD-1 axis-conjugated antagonist (e.g., atezolizumab)) or a combination of therapeutic agents (e.g., a PD-1 axis-conjugated antagonist and one or more additional therapeutic agents). Treatments as used herein include, among other things, adjuvant therapy, neoadjuvant therapy, non-metastatic cancer therapy (e.g., locally advanced cancer therapy) and metastatic cancer therapy. Treatment may be first-line treatment (e.g., the patient may not have been treated previously or may not have received prior systemic treatment), second-line treatment, or later. In a preferred example, treatment is adjuvant therapy. In another preferred example, treatment is neoadjuvant therapy.
[0033] In this specification, “effective dose” means the amount of a therapeutic agent (e.g., a PD-1 axis-binding antagonist (e.g., atezolizumab)) or a combination of therapeutic agents (e.g., a PD-1 axis-binding antagonist and one or more additional therapeutic agents)) that achieves a therapeutic outcome. In some examples, the effective dose of a therapeutic agent or combination of therapeutic agents is the amount of the active agent or combination of active agents that achieves clinical endpoints such as improved overall response rate (ORR), complete response (CR), pathological complete response (pCR), partial response (PR), improved survival (e.g., disease-free survival (DFS), disease-specific survival (DSS), metastasis-free survival, progression-free survival (PFS), and / or overall survival (OS)), improved duration of response (DOR), improved time to decline in function and quality of life (QoL), and / or ctDNA elimination. Improvements (for example, with respect to response rate (e.g., ORR, CR and / or PR), survival (e.g., DFS, DSS, metastasis-free survival, PFS and / or OS), DOR, time to decline in function and QoL, and / or ctDNA elimination) may be compared to appropriate criteria, e.g., observation or standard treatment (e.g., treatment without a PD-1 axis-binding antagonist (e.g., placebo)). In some cases, improvements (for example, with respect to response rate (e.g., ORR, CR and / or PR), survival (e.g., DFS, DSS, metastasis-free survival, PFS and / or OS), DOR, time to decline in function and QoL, and / or ctDNA elimination) may be compared to observation.
[0034] As used herein, "complete response" and "CR" refer to the disappearance of all target lesions.
[0035] As used herein, “partial response” or “PR” refers to a reduction of at least 30% in the sum of the longest diameters (SLD) of target lesions, relative to the baseline SLD before treatment.
[0036] As used herein, "overall response rate," "objective response rate," and "ORR" interchangeably refer to the sum of the complete response rate and the partial response rate.
[0037] As used herein, “disease-free survival” and “DFS” refer to the length of time after primary treatment (e.g., surgical resection) in which a patient survives without recurrence of cancer. In some cases, DFS is defined as the time from randomization to the first occurrence of a DFS event, which is defined as any of the following: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause.
[0038] As used herein, “disease-specific survival” and “DSS” refer to the length of time a patient is not dead from a specific disease (e.g., UC). In some cases, DSS may be defined as the time from randomization to death due to UC (e.g., by the investigator’s assessment of the cause of death).
[0039] As used herein, “distant metastasis-free survival” refers to the length of time from either the date of diagnosis or the start of treatment in which a patient is still alive and the cancer has not spread to other parts of the body. In some examples, distant metastasis-free survival is defined as the time from randomization to the diagnosis of distant (i.e., non-local) metastasis or death from any cause.
[0040] As used herein, “progression-free survival” and “PFS” refer to the length of time during and after treatment in which the cancer does not progress. PFS may include the amount of time a patient experiences complete response (CR) or partial response (PR), and the amount of time a patient experiences stable disease.
[0041] As used herein, “overall survival” and “OS” refer to the length of time from the date of diagnosis or the date of commencement of treatment for the disease (e.g., cancer) during which the patient is still alive. For example, OS may be defined as the time from randomization to death from any cause.
[0042] As used herein, “duration of response” and “DOR” refer to the length of time from the recording of tumor response to disease progression or death from any cause, whichever comes first.
[0043] As used herein, “time to decline in function and QoL” refers to the length of time from either the date of diagnosis or the date of initiation of treatment to a decline in function or a decline in quality of life. In some examples, time to decline in function and QoL is defined as the time from randomization to the date of the first score decrease of 10 points or more from baseline in a patient on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Function Scale, Role Functioning Scale, and Global Health Status (GHS) / QoL Scale (separately).
[0044] As used herein, the term “ctDNA elimination” refers to the elimination of ctDNA from a patient or population of patients who were determined to be ctDNA-positive at baseline. In some examples, ctDNA elimination may be defined as the proportion of patients who were ctDNA-positive at baseline and ctDNA-negative on cycle 3, day 1 or cycle 5, day 1.
[0045] As used herein, the term “chemotherapeutic agent” refers to a compound useful in the treatment of cancers such as urothelial carcinoma. Examples of chemotherapeutic agents include EGFR inhibitors (small molecule inhibitors (e.g., erlotinib (TARCEVA®, Genentech / OSI Pharm.); PD 183805 (CI1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA®) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382(N8-(3-chloro-4-fluorophenyl)-N2-(1-methyl-piperidine-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidine-6-yl]-phenol); (R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine); CL-387785(N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butinamide); EKB-569(N-[4-[(3-chloro-4-fluorophenyl)amino]-3-shea This includes dual EGFR / HER2 tyrosine kinase inhibitors such as [no-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); AG1571 (SU5271; Pfizer); and lapatinib (TYKERB®, GSK572016 or N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6[5[[2-methylsulfonyl])ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine); tyrosine kinase inhibitors (e.g., EGFR inhibitors; small molecule HER2 tyrosine kinase inhibitors such as TAK165 (Takeda);Oral selective inhibitors of ErbB2 receptor tyrosine kinase, such as CP-724 and 714 (Pfizer and OSI); dual HER inhibitors such as EKB-569 (available from Wyeth), which preferentially binds to EGFR but inhibits both HER2 and EGFR overexpressing cells; pan-HER inhibitors such as PKI-166 (Novartis) and canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as the antisense agent ISIS-5132 (ISIS Pharmaceuticals), which inhibits Raf-1 signaling; non-HER-targeted tyrosine kinase inhibitors such as imatinib mesylate (GLEEVEC®, Glaxo SmithKline); multi-target tyrosine kinase inhibitors such as sunitinib (SUTENT®, Pfizer); and batalanib (PTK787 / ZK222584, Novartis / Schering). VEGF receptor tyrosine kinase inhibitors such as AG; MAPK extracellular regulatory kinase I inhibitor CI-1040 (Pharmacia); quinazolins such as PD153035 and 4-(3-chloroanilino)quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines such as CGP59326, CGP60261 and CGP62706; pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidines; curcumin (diferuloylmethane, 4,5-bis(4-fluoroanilino)phthalimide); tyrophostine containing a nitrothiophene moiety; PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to HER coding nucleic acids); quinoxaline (US Patent No. 5,804,396); triphostine (US Patent No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787 (Novartis / Schering AG); CI-1033 (Pfizer) and other pan-HER inhibitors; Affinitac (ISIS3521; Isis / Lilly); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474 (AstraZeneca);PTK-787 (Novartis / Schering AG); INC-1C11 (Imclone); and rapamycin (sirolimus, RAPAMUNE®); bortezomib (VELCADE®, Millennium Proteasome inhibitors such as Pharm.; disulfiram; epigallocatechin gallate; salinosporamide A; carfilzomib; 17-AAG (geldanamycin); radicicol; lactate dehydrogenase A (LDH-A); fulvestrant (FASLODEX®, Astrazeneca); letrozole (FEMARA®, Novartis), finasnate (VATALANIB®, Novartis); oxaliplatin (ELOXATIN®, Sanofi); 5-FU (5-fluorouracil); leucovorin; ronafamib (SCH66336); sorafenib (NEXAVAR®, Bayer) Labs); alkylating agents such as AG1478, thiotepa, and CYTOXAN® cyclophosphamide; alkylsulfonates such as busulfan, improsulfan, and pigosulfan; aziridines such as benzodopa, carbocone, metsuredopa, and uredopa; ethyleneimines and methylamelamines including altoretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylomellamine; acetogenins (especially bratacin and bratacinone); camptothecin (including topotheca and irinotecan); bryostatins; Calistatin; CC-1065 (including its synthetic analogues adzeresin, karzeresin, and bizeresin); Cryptophycin (especially cryptophycin 1 and cryptophycin 8); Adrenocortical steroids (including prednisone and prednisolone); Cyproterone acetate; 5α-reductase including finasteride and dutasteride; Vorinostat, Romidepsin, Panobinostat, Valproic acid, Mosetinostat; Dorastatin; Aldesleukin, Talc; Duocalmycin (including synthetic analogues, KW-2189, and CB1-TM1); Erytherobin; Pancratistatin; Sarcodicin; Spongestatin;Nitrogen mustards such as chlorambucil, chromafazine, chlorophosphamide, estramustine, ifosfamide, mechloretamine, mechloretamine oxide hydrochloride, melphalan, nobembichin, fenestrine, prednimustine, trophosphamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimustine; engine antibiotics (e.g., calicheamicin, especially calicheamicin γ1 and calicheamicin γ1) Antibiotics such as mycin ω1); dynemycin including dynemycin A; bisphosphonates such as clodronate; esperamycin; also, neocardinostatin chromophore and related pigment proteins (endiin antibiotic chromophore), acrasinomycin, actinomycin, anthramycin, azaserin, kactinomycin, carabicin, kaminomycin, cardinophilin, chromomycin, dactinomycin, detrubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin (Cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin such as mitomycin C, mycophenolic acid, nogaramycin, olibomycin, peplomycin, porphyromycin, puromycin, keramycin (quelamycin), rhodorubicin, streptonigrin, streptozocin, tubercidine, ubenimex, dinostatin, zolubicin; methotrexate and 5-fluoro Antimetabolites such as uracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimethrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and phloxuridine; androgens such as carsterone, dromostanolone propionate, epithiostanol, mepitiostane, and testactone;Anti-adrenal agents such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as frolinic acid; acegraton; aldofamide glycoside; aminolevulinic acid; eniluracil; amsacrin; bestrabusil; bisanthren; edatraxate; defofamine; demecolsin; diazicon; erhomitin; eriptinium acetate; epotilon; etogluside; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitosine; mitoxantrone; mopidamnol; nitraerine; pentostatin; fenamet; pirarubicin; losoxantrone; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark) polysaccharide complex (JHS Natural Products); Lazoxane; Rhizoxin; Schizofuran; Spirogermanium; Tenuazonic Acid; Triadicone; 2,2',2''-Trichlorotriethylamine; Trichothecene (especially T-2 toxin, Veraculine A, Loridine A and Angidin); Urethane; Vindesine; Dacarbazine; Mannomustine; Mitobronitol; Mitractol; Pipobroman; Gacitosine; Arabinoside ("Ara-C"); Cyclophosphamide; Thiotepa; Chlorambucil; GEMZAR (Registered Trademark) (GEMZAR) Examples include mucitabine; 6-thioguanine; mercaptopurine; methotrexate; etoposide (VP-16); ifosfamide; mitoxantrone; novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA®); ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and any pharmaceutically acceptable salts, acids, prodrugs, and derivatives of the above.
[0046] Furthermore, as chemotherapeutic agents, (i) anti-hormone agents that act to regulate or inhibit the hormonal effects on tumors, such as anti-estrogen drugs and selective estrogen receptor modulators (SERMs) including tamoxifen (NOLVADEX®; including tamoxifen citrate), raloxifene, droxifene, iodoxifene, 4-hydroxytamoxifen, trioxyfen, keoxyfen, LY117018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit aromatase, an enzyme that regulates estrogen production in the adrenal gland, such as 4(5)-imidazole, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozol, RIVISOR® (borozol), FEMARA® (letrozole; Novartis), and AR (iii) Antiandrogens, e.g., flutamide, nilutamide, bicalutamide, leuprolide and goserelin; buserelin, trypterelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all-trans retinoic acid, fenretinide and troxacitabine (a1,3-dioxolane nucleoside cytosine analog); (iv) Protein kinase inhibitors; (v) Lipids (vi) Kinase inhibitors; (vi) Antisense oligonucleotides, particularly those that inhibit gene expression in signaling pathways involved in abnormal cell proliferation, e.g., PKC-alpha, Ralf, and H-Ras; (vii) Ribozymes, e.g., VEGF expression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors; (viii) Vaccines, such as gene therapy vaccines, e.g., ALLOVECTIN®, LEUVECTIN®, and VAXID®;(ix) Growth inhibitors including vinca (e.g., vincristine and vinblastine), NAVELBINE (registered trademark) (vinorelbine), taxanes (e.g., paclitaxel, nab-paclitaxel, and docetaxel), topoisomerase II inhibitors (e.g., doxorubicin, epirubicin, daunorubicin, etoposide and bleomycin), and DNA alkylating agents (e.g., tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil and ara-C); and (x) pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above are included.;
[0047] As used herein, the term "cytotoxic agent" refers to any agent that is harmful to cells (e.g., causes cell death, inhibits proliferation, or otherwise interferes with cell function). Cytotoxic agents include radioisotopes (e.g., At 211 、I 131 、I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 、Pb 212Examples of cytotoxic agents include, but are not limited to, low molecular weight toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including radioisotopes of Lu; chemotherapeutic agents; enzymes and their fragments, such as nucleases; and toxins, such as low molecular weight toxins or enzymatically active toxins, of bacterial, fungal, plant or animal origin, including their fragments and / or variants. Exemplary cytotoxic agents may be selected from antimicrotubule agents, platinum coordination complexes, alkylating agents, antibiotics, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormone analogs, signaling pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, apoptosis promoters, LDH-A inhibitors, fatty acid biosynthesis inhibitors, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and cancer metabolism inhibitors. In one example, a cytotoxic agent is a platinum-based chemotherapeutic agent (e.g., carboplatin or cisplatin). In one example, the cytotoxic agent is an EGFR antagonist, e.g., N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazoline-4-amine (e.g., erlotinib). In another example, the cytotoxic agent is a RAF inhibitor, e.g., a BRAF and / or CRAF inhibitor. In yet another example, the RAF inhibitor is vemurafenib. In yet another example, the cytotoxic agent is a PI3K inhibitor.
[0048] Chemotherapy agents also include "platinum-based" chemotherapeutic agents, which contain organic compounds with platinum as an integral part of the molecule. Typically, platinum-based chemotherapeutic agents are platinum coordination complexes. Platinum-based chemotherapeutic agents are sometimes referred to as "platins" in the art. Examples of platinum-based chemotherapeutic agents include, but are not limited to, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, lipoplatin, and satraplatin. In some cases, platinum-based chemotherapeutic agents (e.g., cisplatin or carboplatin) may be administered in combination with one or more additional chemotherapeutic agents, such as nucleoside analogs (e.g., gemcitabine).
[0049] As used herein, “platinum-based chemotherapy” refers to a chemotherapy regimen comprising a platinum-based chemotherapeutic agent. For example, platinum-based chemotherapy may comprise a platinum-based chemotherapeutic agent (e.g., cisplatin or carboplatin) and optionally one or more additional chemotherapeutic agents, such as nucleoside analogs (e.g., gemcitabine).
[0050] The term "patient" refers to a human patient. For example, a patient may be an adult.
[0051] In this specification, the term "antibody" specifically includes monoclonal antibodies (such as full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, insofar as they exhibit the desired biological activity. In one example, the antibody is a full-length monoclonal antibody.
[0052] As used herein, the terms IgG “isotype” or “subclass” mean any of the subclasses of immunoglobulins defined by the chemical and antigenic properties of the constant region of the immunoglobulin.
[0053] Depending on the amino acid sequence of the constant domain of the heavy chain of an antibody (immunoglobulin), antibodies (immunoglobulins) can be assigned to different classes. There are five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, some of which can be further classified into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, γ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known and are generally described, for example, in Abbas et al. Cellular and Mol. Immunology, 4th ed. (WBSaunders, Co., 2000). Antibodies may be part of a larger fusion molecule formed by the covalent or non-covalent binding of an antibody to one or more other proteins or peptides.
[0054] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used herein synonymously to refer to an antibody in its substantially intact form, not to the antibody fragments described below. This term refers to an antibody containing an Fc region.
[0055] The term “Fc region” as used herein is used to define the C-terminal region of an immunoglobulin heavy chain that includes at least a portion of the constant region. This term includes the native sequence Fc region and the mutant Fc region. In one aspect, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Thus, by expression of certain nucleic acid molecules encoding a full-length heavy chain, antibodies produced by host cells may contain the full-length heavy chain or cleaved variants of the full-length heavy chain. This may be the case when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447). Thus, the Fc region may or may not contain C-terminal lysine (Lys447), or C-terminal glycine (Gly446) and lysine (Lys447). The amino acid sequence of the heavy chain containing the Fc region is shown herein without the C-terminal lysine (Lys447) unless otherwise indicated. In one aspect, the heavy chain containing the Fc region as specified herein, as contained in the antibodies disclosed herein, comprises a further C-terminal glycine-lysine dipeptide (G446 and K447). In one aspect, the heavy chain containing the Fc region as specified herein, as contained in the antibodies disclosed herein, comprises a further C-terminal glycine residue (G446). In one aspect, the heavy chain containing the Fc region as specified herein, as contained in the antibodies disclosed herein, comprises a further C-terminal lysine residue (K447). In one embodiment, the Fc region comprises a single amino acid substitution N297A in the heavy chain. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region follows the EU numbering scheme, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0056] A "naked antibody" refers to an antibody that is not conjugated with a heterogeneous moiety (e.g., a cytotoxic moiety) or a radiolabel. Naked antibodies may be present in pharmaceutical compositions.
[0057] An "antibody fragment" preferably comprises a portion of an intact antibody, including its antigen-binding region. In some examples, the antibody fragments described herein are antigen-binding fragments. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments.
[0058] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, with the exception of possible variant antibodies, such as naturally occurring mutations or variants that occur during the production of the monoclonal antibody preparation and are usually present in small amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies directed toward different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed toward a single determinant on one antigen. Therefore, the modifier “monoclonal” indicates a characteristic of the antibody that it is obtained from a substantially homogeneous population of antibodies, and should not be interpreted as requiring the production of the antibody by any particular method. For example, monoclonal antibodies according to the present invention can be produced by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus.
[0059] As used herein, the terms “hypervariable region” or “HVR” refer to each of the regions of an antibody variable domain that are hypervariable in the sequence and determine antigen-binding specificity, such as “complementarity-determining regions” (CDRs).
[0060] Generally, an antibody contains six CDRs, three located in the VH (CDR-H1, CDR-H2, CDR-H3) and three located in the VL (CDR-L1, CDR-L2, CDR-L3). Illustrative CDRs as used herein include: (a) Hypervariable loops arising from amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs generated at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) Antigen contact occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J.Mol.Biol.262:732-745 (1996)).
[0061] Unless otherwise specified, the CDR is determined in accordance with Kabat et al. above. Those skilled in the art will understand that the notation of the CDR may also be determined in accordance with Chothia above, McCallum above, or any other scientifically accepted naming system.
[0062] "Framework" or "FR" refers to variable domain residues other than the complementarity-determining region (CDR). The variable domain FR generally consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, the CDR and FR sequences in VH (or VL) generally follow this sequence: FR1-CDR-H1(CDR-L1)-FR2-CDR-H2(CDR-L2)-FR3-CDR-H3(CDR-L3)-FR4.
[0063] The terms “Kabat-like variable domain residue numbering” or “Kabat-like amino acid position numbering,” and their variations, refer to the numbering system used in the heavy-chain or light-chain variable domains of the antibody edits described above by Kabat et al. Using this numbering scheme, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortenings of the FR or HVR of the variable domain, or insertions into the FR or HVR of the variable domain. For example, the heavy-chain variable domain may contain a single amino acid insertion after H2 residue 52 (Kabat-like residue 52a) and a residue inserted after heavy-chain FR residue 82 (e.g., Kabat-like residues 82a, 82b, and 82c). The Kabat numbering of residues can be determined for a given antibody by the alignment of the antibody sequence with the homologous region of the sequence numbered by “standard” Kabat.
[0064] The term “package insert” is used to refer to the instructions that are customarily included in the market packaging of a therapeutic product, which include information relating to the indications, use, dosage, administration, combination therapy, contraindications, and / or warnings for the use of such therapeutic product.
[0065] As used herein, “in combination with” means the administration of a treatment regimen that includes, in addition to another treatment, one treatment, for example, a PD-1 axial antagonist (e.g., atezolizumab) and an additional therapeutic agent. Therefore, “in combination with” means the administration of one treatment before, during, or after the administration of another treatment to the patient.
[0066] Drugs administered "concurrently" with one or more other drugs are administered on the same treatment day as one or more other drugs, and optionally at the same time as one or more other drugs, within the same treatment cycle. For example, in cancer therapy administered every three weeks, each drug administered concurrently is administered on day 1 of the three-week cycle.
[0067] The term "detection" includes any means of detection, including direct and indirect detection.
[0068] As used herein, the term “biomarker” refers to an indicator that can be detected in a sample, such as an indicator of prediction, diagnosis, and / or prognosis, e.g., ctDNA, PD-L1, or tissue tumor mutational load (tTMB). In some contexts, a biomarker is the presence or level of ctDNA in a biological sample obtained from a patient. A biomarker may function as an indicator of a particular subtype of disease or disorder (e.g., cancer) characterized by certain molecular, pathological, histological, and / or clinical features. In some contexts, a biomarker may function as an indicator of the potential therapeutic benefit. Examples of biomarkers include, but are not limited to, molecular markers based on polynucleotides (e.g., DNA and / or RNA), polynucleotide copy number variations (e.g., DNA copy number), polypeptides, polypeptide and polynucleotide modifications (e.g., post-translational modifications), carbohydrates, and / or glycolipids.
[0069] The “amount” or “level” of a biomarker (e.g., ctDNA) associated with increased clinical benefit to a patient is a detectable level in the biological sample. These can be measured by methods known to those skilled in the art and disclosed herein. The presence, expression level, or amount of the biomarker being evaluated can be used to determine the response to treatment.
[0070] The terms “level of expression” or “expression level” are generally used interchangeably and typically refer to the amount of a biomarker in a biological sample. “Expression” generally refers to the process by which information (e.g., information encoded by genes and / or epigenetic information) is converted into structures that are present in and function within a cell. Thus, as used herein, “expression” may refer to transcription to polynucleotides, translation to polypeptides, or further to polynucleotide and / or polypeptide modifications (e.g., post-translational modifications of polypeptides). Furthermore, fragments of transcribed polynucleotides, translated polypeptides, or polynucleotide and / or polypeptide modifications (e.g., post-translational modifications of polypeptides) should be considered expressed whether they originate from transcripts produced by alternative splicing or degraded transcripts, or from post-translational processing of polypeptides by, for example, proteolysis. “Expressed genes” include those transcribed to polynucleotides as mRNA and subsequently translated to polypeptides, as well as those transcribed to RNA but not translated to polypeptides (e.g., transfer and ribosomal RNAs).
[0071] "Increased expression," "increased expression level," "increased level," "elevated expression," "increased expression level," or "increased level" refers to increased expression or increased levels of a biomarker in a patient compared to one or more individuals without cancer (e.g., urothelial carcinoma) or a control such as an internal control (e.g., a housekeeping biomarker).
[0072] "Reduced expression," "reduced expression level," "reduced level," "lowered expression," "reduced expression level," or "reduced level" refers to reduced expression or reduced levels of a biomarker in a patient compared to one or more individuals without cancer (e.g., urothelial carcinoma) or a control such as an internal control (e.g., a housekeeping biomarker). In some embodiments, reduced expression means little to no expression.
[0073] The term “housekeeping biomarker” refers to a biomarker or group of biomarkers (e.g., polynucleotides and / or polypeptides) that are typically similarly present in all cell types. In some embodiments, a housekeeping biomarker is a “housekeeping gene.” “Housekeeping gene” as used herein refers to a gene or group of genes that encodes a protein whose activity is essential for maintaining cellular function and which is typically similarly present in all cell types.
[0074] As used herein, the term “sample” refers to a composition obtained from or derived from a patient of interest, containing cellular and / or other molecular entities that will be characterized and / or identified, for example, based on physical, biochemical, chemical and / or physiological characteristics. For example, the phrase “disease sample” and its variations refer to any sample obtained from a patient of interest that is expected to contain, or is known to contain, cellular and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysates, and tissue extracts such as tissue culture media, homogenized tissue, tumor tissue, cell extracts, and combinations thereof. In some cases, the sample may be a blood sample, plasma sample, serum sample, urine sample, cerebrospinal fluid (CSF) sample, nasal swab sample, saliva sample, stool sample, or vaginal fluid sample.
[0075] A “tissue sample” or “cell sample” means a collection of similar cells obtained from the patient’s tissue. Sources of tissue or cell samples may be solid tissues such as fresh, frozen, and / or preserved organs, tissue samples, biopsy material, and / or aspirates; blood or any blood components such as plasma; bodily fluids such as cerebrospinal fluid, amniotic fluid, ascites, or interstitial fluid; or cells from any stage in the patient’s pregnancy or development. A tissue sample may also be primary or cultured cells or cell lines. Optionally, a tissue or cell sample may be obtained from diseased tissue / organ. For example, a “tumor sample” is a tissue sample obtained from a tumor (e.g., a liver tumor) or other cancerous tissue. A tissue sample may contain a mixed population of cell types (e.g., tumor cells and non-tumor cells, cancerous cells and non-cancerous cells). A tissue sample may contain compounds not naturally mixed with the tissue, such as preservatives, anticoagulants, buffers, fixatives, nutrients, and antibiotics.
[0076] "Tumor-infiltrating immune cells," as used herein, refers to any immune cells present in a tumor or a sample thereof. Tumor-infiltrating immune cells include, but are not limited to, intratumor immune cells, peritumor immune cells, other tumor stromal cells (e.g., fibroblasts), or any combination thereof. Such tumor-infiltrating immune cells may include, for example, T lymphocytes (such as CD8+ T lymphocytes and / or CD4+ T lymphocytes), B lymphocytes, or granulocytes (e.g., neutrophils, eosinophils, and basophils), monocytes, macrophages, dendritic cells (e.g., finger-shaped dendritic cells), histiocytes, and other myeloid cells, including natural killer cells.
[0077] As used herein, “tumor cells” means any tumor cells present in a tumor or a sample thereof. Tumor cells can be distinguished from other cells that may be present in a tumor sample, such as stromal cells and tumor-infiltrating immune cells, using methods known in the art and / or described herein.
[0078] "Reference level," "reference sample," "reference cell," "reference tissue," "control sample," "control cell," or "control tissue" as used herein refers to a level, sample, cell, tissue, or standard used for comparative purposes. In one example, a reference level, reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-disease portion (e.g., tissue or cell) of the same patient's body. For example, a reference level, reference sample, reference cell, reference tissue, control sample, control cell, or control tissue may be a healthy and / or non-disease cell or tissue adjacent to a diseased cell or tissue (e.g., a cell or tissue adjacent to a tumor). In another example, a reference sample is obtained from an untreated tissue and / or cell of the same patient's body. In yet another example, a reference level, reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-disease portion (e.g., tissue or cell) of an individual that is not a patient. In another embodiment, reference levels, reference samples, reference cells, reference tissues, control samples, control cells, or control tissues are obtained from untreated tissues and / or cells of a non-patient individual.
[0079] In this specification, “section” of a tissue sample means a single part or piece of a tissue sample, for example, a thin slice of tissue or cells excised from a tissue sample (e.g., a tumor sample). It should be understood that multiple sections of a tissue sample may be taken and subjected to analysis, however, the same section of a tissue sample may be analyzed at both the morphological and molecular levels, or with respect to polypeptides (e.g., by immunohistochemistry) and / or polynucleotides (e.g., by in situ hybridization).
[0080] "Correlation" means comparing, in any way, the performance and / or results of a first analysis or protocol with the performance and / or results of a second analysis or protocol. For example, the results of a first analysis or protocol may be used when performing a second protocol, and / or the results of a first analysis or protocol may be used to determine whether a second analysis or protocol should be performed. With respect to embodiments of polypeptide analysis or protocols, the results of polypeptide expression analysis or protocols may be used to determine whether a particular therapeutic regimen should be performed. With respect to embodiments of polynucleotide analysis or protocols, the results of polynucleotide expression analysis or protocols may be used to determine whether a particular therapeutic regimen should be performed.
[0081] When used herein, the phrase "based on" means that information about one or more biomarkers is used to convey treatment decisions, information provided in package inserts, or marketing / promotional guidelines, etc.
[0082] As used herein, the terms “mutation weighting,” “mutation load,” “gene mutation load,” “tumor mutation load score,” “TMB score,” “tissue tumor mutation load score,” and “tTMB score,” which may be used interchangeably, refer to the level (e.g., number) of changes (e.g., one or more changes, e.g., one or more somatic changes) per given unit (e.g., per megabase) within a given set of genes (e.g., within the coding region of a given set of genes) detected in a tumor tissue sample (e.g., formalin-fixed paraffin-embedded (FFPE) tumor sample, stored tumor sample, fresh tumor sample, or frozen tumor sample). The tTMB score may be measured, for example, on a whole-genome or exome basis, or on a genome or exome subset basis. In some embodiments, a tTMB score measured based on a genome or exome subset may be extrapolated to determine a whole-genome or exome mutation load. In some embodiments, the tTMB score refers to the level of accumulated somatic mutations in a patient. The tTMB score may refer to accumulated somatic mutations in a patient with cancer (e.g., urothelial carcinoma). In some embodiments, the tTMB score refers to the accumulated mutations throughout the patient's genome. In some embodiments, the tTMB score refers to the accumulated mutations within a specific tissue sample taken from the patient (e.g., a tumor tissue biopsy, e.g., a urothelial carcinoma tumor sample).
[0083] The terms “somatic variant,” “somatic mutation,” or “somatic change” refer to genetic alterations occurring in somatic tissues (e.g., cells outside the germline). Examples of genetic modifications include, but are not limited to, point mutations (e.g., exchange of a single nucleotide with another (e.g., silent mutations, missense mutations, and nonsense mutations)), insertions and deletions (e.g., addition and / or removal of one or more nucleotides (e.g., indels)), amplification, gene duplication, copy number changes (CNAs), rearrangements, and splice variants. The presence of certain mutations may be associated with disease conditions (e.g., cancer, e.g., urothelial carcinoma).
[0084] The term "patient-specific variant" refers to a variant (e.g., somatic variant) present in the tumor of a given patient. Patient-specific variants can be detected in ctDNA, for example, using a personalized ctDNA multiplexed polymerase chain reaction (mPCR) approach. It should be understood that a given patient-specific variant may be unique to that patient or may be present in the tumors of other individuals who are not that patient.
[0085] As used herein, the term “reference tTMB score” refers to a tTMB score compared to another tTMB score, for example, to make a diagnosis, prediction, prognosis, and / or treatment decision. For example, a reference tTMB score may be a tTMB score in a reference sample, a reference population, and / or a given value. In some examples, the reference tTMB score is a cutoff value that significantly separates a first subset of patients in the reference population who have been treated with PD-1 axis-coupled antagonist therapy from a second subset of patients in the same reference population who have not been treated or have been treated with non-PD-1 axis-coupled antagonist therapy, based on a significant difference between a patient’s response in the absence of therapy or to treatment with PD-1 axis-coupled antagonist therapy and a patient’s response to treatment with non-PD-1 axis-coupled antagonist therapy. In some cases, patient response to PD-1 axis-coupled antagonist therapy is significantly improved above the cutoff value compared to patient response in the absence of treatment or to non-PD-1 axis-coupled antagonist therapy. In some cases, patient response in the absence of treatment or to non-PD-L1 axis-coupled antagonist therapy is significantly improved below the cutoff value compared to patient response to PD-1 axis-coupled antagonist therapy.
[0086] Those skilled in the art will understand that the numerical values relative to the standard tTMB score may vary depending on the type of cancer, the methodology used to measure the tTMB score, and / or the statistical method used to generate the tTMB score.
[0087] The term “equivalent TMB value” refers to a numerical value corresponding to the tTMB score, which can be calculated by dividing the number of somatic variants by the number of sequenced bases. In some cases, the entire exome is sequenced. In other cases, the number of sequenced bases is approximately 1.1 Mb (e.g., approximately 1.125 Mb), as assessed by, for example, a FOUNDATIONONE® panel. It should be understood that, in general, the tTMB score is linearly related to the size of the sequenced genomic region. Such equivalent tTMB values indicate a comparable degree of tumor mutational load compared to the tTMB score and can be used interchangeably in the methods described herein, for example, to predict a cancer patient’s response to a PD-1 axis-linked antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab). As an example, in some cases, the equivalent tTMB value is a normalized tTMB value, which can be calculated by dividing the number of somatic variants (e.g., somatic mutations) by the number of sequenced bases. For example, an equivalent tTMB value can be expressed as the number of somatic mutations counted over a specified number of sequenced bases (e.g., approximately 1.1 Mb (e.g., approximately 1.125 Mb) when evaluated by a FOUNDATIONONE® panel). For example, a tTMB score of approximately 25 (determined as the number of somatic mutations counted over approximately 1.1 Mb) corresponds to an equivalent tTMB value of approximately 23 mutations / Mb. It should be understood that the tTMB scores described herein (e.g., the TMB score expressed as the number of somatic mutations counted over a specified number of sequenced bases, e.g., when evaluated by a FOUNDATIONONE® panel, e.g.In some cases, the tTMB score, determined as the number of somatic mutations counted over a specified number of sequenced bases in a subset of the genome or exome (e.g., a given set of genes) (e.g., approximately 1.1 Mb (e.g., approximately 1.125 Mb) as assessed by a FOUNDATIONONE® panel), deviates by approximately 30% or less (e.g., less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%) from the tTMB score determined by whole exome sequencing. See, for example, Chalmers et al. Genome Medicine 9:34, 2017.
[0088] II. Methods and compositions for the treatment of urothelial carcinoma Methods, compositions, and uses for neoadjuvant and / or adjuvant therapy for urothelial carcinoma (e.g., MIUC) in patients requiring neoadjuvant and / or adjuvant therapy are provided herein. These methods, compositions, and uses may include administering a PD-1 axis-coupled antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) to a patient based on the presence and / or level of ctDNA in a biological sample obtained from the patient. In some examples, these methods, compositions, and uses may include determining whether ctDNA is present or absent in a biological sample obtained from the patient (in other words, whether the biological sample is ctDNA-positive or ctDNA-negative). In other examples, these methods, compositions, and uses may include determining the level of ctDNA in a biological sample that can be compared to a reference ctDNA level.
[0089] In one aspect, a method for treating urothelial carcinoma (e.g., MIUC) in a patient requiring treatment of the disease is provided herein, comprising administering to the patient an effective amount of a therapeutic regimen comprising a PD-1 axis-coupled antagonist, wherein the therapeutic regimen is an adjuvant therapy, and the patient has been identified as likely to benefit from the therapeutic regimen based on the presence of ctDNA in a biological sample obtained from the patient.
[0090] In another context, a method for treating urothelial carcinoma (e.g., MIUC) in a patient requiring treatment of the urothelial carcinoma (e.g., MIUC) is provided herein, comprising: (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising a PD-1 axis-binding antagonist; and (b) administering to the patient an effective amount of a treatment regimen comprising a PD-1 axis-binding antagonist, based on the presence of ctDNA in the biological sample, the treatment regimen comprising an adjuvant therapy.
[0091] In another context, the present invention provides a PD-1 axially coupled antagonist, or a pharmaceutical composition comprising a PD-1 axially coupled antagonist, for use in the treatment of urothelial carcinoma (e.g., MIUC) in a patient requiring treatment for urothelial carcinoma (e.g., MIUC), wherein the treatment comprises the administration of an effective amount of a therapeutic regime comprising the PD-1 axially coupled antagonist, the therapeutic regime being an adjuvant therapy, and the patient has been identified as likely to benefit from the therapeutic regime based on the presence of ctDNA in a biological sample obtained from the patient.
[0092] In another context, a PD-1 axially coupled antagonist, or a pharmaceutical composition comprising a PD-1 axially coupled antagonist, for use in the treatment of urothelial carcinoma (e.g., MIUC) in a patient requiring treatment for urothelial carcinoma (e.g., MIUC), wherein the treatment comprises (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising a PD-1 axially coupled antagonist; and (b) administering to the patient an effective amount of a treatment regimen comprising a PD-1 axially coupled antagonist, based on the presence of ctDNA in the biological sample, the treatment regimen being an adjuvant therapy.
[0093] In another context, a method for treating urothelial carcinoma (e.g., MIUC) in a patient requiring treatment of the urothelial carcinoma (e.g., MIUC) is provided herein, comprising administering to the patient an effective amount of a therapeutic regimen comprising a PD-1 axis-coupled antagonist, wherein the therapeutic regimen is an adjuvant therapy and is above a reference level for ctDNA, and the level of ctDNA in a biological sample obtained from the patient indicates that the patient is likely to benefit from the therapeutic regimen comprising the PD-1 axis-coupled antagonist.
[0094] In another context, a method for treating urothelial carcinoma (e.g., MIUC) in a patient requiring treatment of the urothelial carcinoma (e.g., MIUC) is provided herein, comprising: (a) determining the level of ctDNA in a biological sample obtained from the patient such that the level of ctDNA in the biological sample is above a reference level for ctDNA, indicating that the patient is likely to benefit from a treatment regimen comprising a PD-1 axis-binding antagonist; and (b) administering to the patient an effective amount of a treatment regimen comprising a PD-1 axis-binding antagonist, based on the level of ctDNA in the biological sample, wherein the treatment regimen is an adjuvant therapy.
[0095] In another context, the present invention provides a PD-1 axially coupled antagonist, or a pharmaceutical composition comprising a PD-1 axially coupled antagonist, for use in the treatment of urothelial carcinoma (e.g., MIUC) in a patient requiring treatment for urothelial carcinoma (e.g., MIUC), wherein the treatment comprises the administration of an effective amount of a therapeutic regime comprising the PD-1 axially coupled antagonist, the therapeutic regime is adjuvant therapy, and the level of ctDNA in a biological sample obtained from the patient is above a reference level for ctDNA, indicating that the patient is likely to benefit from the therapeutic regime comprising the PD-1 axially coupled antagonist.
[0096] In another context, a PD-1 axially coupled antagonist, or a pharmaceutical composition comprising a PD-1 axially coupled antagonist, is provided herein for use in the treatment of urothelial carcinoma (e.g., MIUC) in patients requiring treatment for urothelial carcinoma (e.g., MIUC), wherein the treatment comprises (a) determining the level of ctDNA in a biological sample obtained from the patient, which is above a reference level for ctDNA, indicating that the patient is likely to benefit from a treatment regimen comprising a PD-1 axially coupled antagonist; and (b) administering to the patient an effective amount of a treatment regimen comprising a PD-1 axially coupled antagonist, based on the level of ctDNA in the biological sample, wherein the treatment regimen is an adjuvant therapy.
[0097] In another context, a method is provided herein for identifying a patient having urothelial carcinoma (e.g., MIUC) who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, comprising determining whether ctDNA is present in a biological sample obtained from the patient, wherein the presence of ctDNA in the biological sample identifies the patient as one who may benefit from treatment with a treatment regimen comprising a PD-1 axis-coupled antagonist, and the treatment regimen is adjuvant therapy. In some examples, the method further comprises administering an effective amount of the treatment regimen comprising a PD-1 axis-coupled antagonist to the patient.
[0098] In another context, a method is provided herein for identifying a patient having urothelial carcinoma (e.g., MIUC) who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, the method comprising determining the level of ctDNA in a biological sample obtained from the patient, wherein a level of ctDNA in the biological sample that is above a reference level for ctDNA indicates that the patient is likely to benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, and the treatment regimen is an adjuvant therapy. In some examples, the method further comprises administering an effective amount of the treatment regimen comprising a PD-1 axis-coupled antagonist to the patient.
[0099] In another context, a method for selecting a treatment for a patient having urothelial carcinoma (e.g., MIUC) is provided herein, comprising: (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist; and (b) selecting a treatment regimen comprising a PD-1 axis-coupled antagonist based on the presence of ctDNA in the biological sample, the treatment regimen comprising an adjuvant therapy. In some examples, the method further comprises administering an effective amount of the treatment regimen comprising a PD-1 axis-coupled antagonist to the patient.
[0100] In another context, a method for selecting a treatment for a patient having urothelial carcinoma (e.g., MIUC) is provided herein, comprising: (a) determining the level of ctDNA in a biological sample obtained from the patient such that a level of ctDNA in the biological sample that is above a reference level for ctDNA indicates that the patient is likely to benefit from a treatment regimen comprising a PD-1 axis-binding antagonist; and (b) selecting a treatment regimen comprising a PD-1 axis-binding antagonist based on the presence of ctDNA in the biological sample, wherein the treatment regimen is an adjuvant therapy. In some examples, the method further comprises administering an effective amount of the treatment regimen comprising a PD-1 axis-binding antagonist to the patient.
[0101] In some cases, the biological sample is obtained before or concurrently with the administration of the first dose of the treatment regimen. In some cases, the biological sample is obtained on day 1 of cycle 1 of the treatment regimen (C1D1). In some cases, the biological sample is obtained within approximately 60 weeks of surgical excision (e.g., within approximately 60 weeks, 55 weeks, 50 weeks, 45 weeks, 40 weeks, 35 weeks, 30 weeks, 25 weeks, 20 weeks, 19 weeks, 18 weeks, 17 weeks, 16 weeks, 15 weeks, 14 weeks, 13 weeks, 12 weeks, 11 weeks, 10 weeks, 9 weeks, 8 weeks, 7 weeks, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, or 1 week). In some cases, biological specimens are obtained within approximately 30 weeks of surgical excision. In other cases, biological specimens are obtained within approximately 20 weeks of surgical excision.
[0102] In some cases, biological samples are available approximately 2 to 20 weeks after surgical excision (e.g., approximately 2 to 20 weeks, approximately 2 to 19 weeks, approximately 2 to 18 weeks, approximately 2 to 17 weeks, approximately 2 to 16 weeks, approximately 2 to 15 weeks, approximately 2 to 14 weeks, approximately 2 to 13 weeks, approximately 2 to 12 weeks, approximately 2 to 11 weeks, approximately 2 to 10 weeks, approximately 2 to 9 weeks, approximately 2 to 8 weeks, approximately 2 to 7 weeks, approximately 2 to 6 weeks, approximately 2 to 5 weeks, approximately 2 to 4 weeks, approximately 2 to 3 weeks, approximately 4 to 20 weeks, approximately 4 to 19 weeks, approximately 4 to 18 weeks). Approximately 4-17 weeks, approximately 4-16 weeks, approximately 4-15 weeks, approximately 4-14 weeks, approximately 4-13 weeks, approximately 4-12 weeks, approximately 4-11 weeks, approximately 4-10 weeks, approximately 4-9 weeks, approximately 4-8 weeks, approximately 4-7 weeks, approximately 4-6 weeks, approximately 4-5 weeks, approximately 6-20 weeks, approximately 6-19 weeks, approximately 6-18 weeks, approximately 6-17 weeks, approximately 6-16 weeks, approximately 6-15 weeks, approximately 6-14 weeks, approximately 6-13 weeks, approximately 6-12 weeks, approximately 6-11 weeks, approximately 6-10 weeks, approximately 6-9 Weeks, approximately 6-8 weeks, approximately 6-7 weeks, approximately 8-20 weeks, approximately 8-19 weeks, approximately 8-18 weeks, approximately 8-17 weeks, approximately 6-16 weeks, approximately 6-15 weeks, approximately 6-14 weeks, approximately 8-13 weeks, approximately 8-12 weeks, approximately 8-11 weeks, approximately 8-10 weeks, approximately 8-9 weeks, approximately 10-20 weeks, approximately 10-19 weeks, approximately 10-18 weeks, approximately 10-17 weeks, approximately 10-16 weeks, approximately 10-15 weeks, approximately 10-14 weeks, approximately 10-13 weeks, approximately 10-12 weeks, approximately It can be obtained in approximately 10-11 weeks, 12-20 weeks, 12-19 weeks, 12-18 weeks, 12-17 weeks, 12-16 weeks, 12-15 weeks, 12-14 weeks, 12-13 weeks, 14-20 weeks, 14-19 weeks, 14-18 weeks, 14-17 weeks, 14-16 weeks, 14-15 weeks, 16-20 weeks, 16-19 weeks, 16-18 weeks, 16-17 weeks, 18-20 weeks, or 18-19 weeks.
[0103] It should be understood that ctDNA can be detected in any suitable biological sample. In some cases, the biological sample is a blood sample, plasma sample, serum sample, urine sample, CSF sample, nasal swab sample, saliva sample, stool sample, or vaginal fluid sample. In some cases, the biological sample is a blood sample, plasma sample, or serum sample. In some cases, the biological sample is a plasma sample.
[0104] In another context, a method is provided herein for monitoring the response of a patient having urothelial carcinoma (e.g., MIUC) who has been administered at least a first dose of a treatment regimen comprising a PD-1 axis-coupled antagonist, wherein the treatment regimen is a neoadjuvant therapy or an adjuvant therapy, and the method comprises determining whether ctDNA is present in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the treatment regimen, and whether ctDNA is present in a biological sample obtained from the patient at a time after the administration of the first dose of the treatment regimen, thereby monitoring the patient's response. In some examples, the absence of ctDNA in the biological sample obtained from the patient at a time after the administration of the first dose of the treatment regimen indicates that the patient is responding to the treatment regimen. In some embodiments, the treatment regimen is a neoadjuvant therapy. In other embodiments, the treatment regimen is an adjuvant therapy.
[0105] In another context, a method is provided herein for monitoring the response of a patient having urothelial carcinoma (e.g., MIUC) who has been administered at least a first dose of a therapeutic regimen comprising a PD-1 axis-coupled antagonist, wherein the therapeutic regimen is a neoadjuvant therapy or an adjuvant therapy, and the method comprises determining the level of ctDNA present in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen, and thereby monitoring the patient's response. In some examples, a decrease in the level of ctDNA in a biological sample obtained from the patient after administration of the first dose of the therapeutic regimen, compared to the level of ctDNA in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen, indicates that the patient is responding to the therapeutic regimen. In some embodiments, the therapeutic regimen is a neoadjuvant therapy. In other embodiments, the therapeutic regimen is an adjuvant therapy.
[0106] In another context, the present invention provides a pharmaceutical composition comprising a PD-1 axis-coupled antagonist or a PD-1 axis-coupled antagonist for use in the treatment of a patient having urothelial carcinoma (e.g., MIUC) who has been administered at least a first dose of a treatment regimen comprising a PD-1 axis-coupled antagonist, wherein the treatment regimen is a neoadjuvant therapy or an adjuvant therapy, and the ctDNA was present in a biological sample obtained from the patient prior to or concurrently with the first dose of the treatment regimen. In some embodiments, the treatment regimen is a neoadjuvant therapy. In other embodiments, the treatment regimen is an adjuvant therapy.
[0107] In another aspect, a method is provided herein for identifying a patient having urothelial carcinoma (e.g., MIUC) who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, wherein the treatment regimen is a neoadjuvant therapy or an adjuvant therapy, the patient has been administered at least a first dose of the treatment regimen, ctDNA is present in a biological sample obtained from the patient before or concurrently with the first dose of the treatment regimen, and a determination is made as to whether ctDNA is present in the biological sample obtained from the patient at a time after the administration of the first dose of the treatment regimen, wherein the absence of ctDNA in the biological sample at a time after the administration of the treatment regimen identifies the patient as one who may benefit from treatment with a treatment regimen comprising a PD-1 axis-coupled antagonist. In some embodiments, the treatment regimen is a neoadjuvant therapy. In other embodiments, the treatment regimen is an adjuvant therapy.
[0108] In another context, a method is provided herein for identifying a patient having urothelial carcinoma (e.g., MIUC) who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, wherein the treatment regimen is a neoadjuvant therapy or an adjuvant therapy, the patient has been administered at least a first dose of the treatment regimen, a level of ctDNA is present in a biological sample obtained from the patient before or concurrently with the first dose of the treatment regimen, and the method comprises determining the level of ctDNA in the biological sample obtained from the patient at a time after the administration of the first dose of the treatment regimen, wherein a decrease in the level of ctDNA in the biological sample at a time after administration of the treatment regimen, compared to the level of ctDNA in the biological sample obtained from the patient before or concurrently with the first dose of the treatment regimen, identifies the patient as one who may benefit from treatment with a treatment regimen comprising a PD-1 axis-coupled antagonist. In some embodiments, the treatment regimen is a neoadjuvant therapy. In other embodiments, the treatment regimen is an adjuvant therapy.
[0109] Any appropriate time after the administration of the first dose of the treatment regimen may be used. For example, in some cases, the time after the administration of the first dose of the treatment regimen may be cycle 2, day 1 (C2D1), cycle 3, day 1 (C3D1), cycle 4, day 1 (C4D1), cycle 5, day 1 (C5D1), cycle 6, day 1 (C6D1), cycle 7, day 1 (C7D1), cycle 8, day 1 (C8D1), cycle 9, day 1 (C9D1), cycle 10, day 1 (C10D1), cycle 11, day 1 (C11D1), cycle 12, day 1 (C12D1), or later cycles. However, it should be understood that the biological sample obtained at the time after administration of the treatment regimen may be taken on any day of the treatment cycle (e.g., any day in a 14-day cycle, any day in a 21-day cycle, or any day in a 28-day cycle).
[0110] In some cases, biological samples obtained from the patient before or concurrently with the first dose of the treatment regimen and / or after the administration of the first dose of the treatment regimen are blood samples, plasma samples, serum samples, urine samples, CSF samples, nasal swab samples, saliva samples, stool samples, or vaginal fluid samples. For example, in some cases, biological samples obtained from the patient before or concurrently with the first dose of the treatment regimen and / or after the administration of the first dose of the treatment regimen are plasma samples.
[0111] In some cases, the benefit relates to improved disease-free survival (DFS), improved overall survival (OS), improved disease-specific survival, or improved distant metastasis-free survival. In some cases, the benefit relates to improved DFS. In some cases, the benefit relates to improved OS. In some cases, the improvement is compared to observation or to adjuvant therapy with placebo.
[0112] The presence and / or level of ctDNA in a biological sample can be determined using any suitable approach, such as any approach known in the art or described in Section V below. For example, in some cases, the presence and / or level of ctDNA is determined by a polymerase chain reaction (PCR)-based approach, a hybridization capture-based approach, a methylation-based approach, or a fragment mix approach.
[0113] In some cases, the presence and / or level of ctDNA is determined by a personalized ctDNA multiplexed polymerase chain reaction (mPCR) approach. In some cases, a personalized ctDNA mPCR approach includes: (a) (i) sequencing DNA obtained from a tumor sample obtained from the patient to generate tumor sequence reads; (ii) sequencing DNA obtained from a normal tissue sample (e.g., buffy coat) obtained from the patient to generate normal sequence reads; (b) identifying one or more patient-specific variants by calling somatic variants identified from the tumor sequence reads and excluding germline variants and / or clonal hematopoietic (CHIP) variants with undetermined potential, wherein the germline variants or CHIP variants are identified from normal sequence reads or from publicly available databases; (c) designing an mPCR assay for the patient to detect a set of patient-specific variants; and (d) analyzing a biological sample obtained from the patient using the mPCR assay to determine whether ctDNA is present in the biological sample. In some cases, sequencing is WES or WGS. In some cases, patient-specific variants are single-nucleotide variants (SNVs) or short indels (base insertions or deletions). In some cases, a set of patient-specific variants contains at least one patient-specific variant. In some cases, a set of patient-specific variants contains at least two patient-specific variants. In some cases, a set of patient-specific variants contains at least eight patient-specific variants. In some cases, a set of patient-specific variants contains 2 to 200 patient-specific variants. In some cases, a set of patient-specific variants contains 8 to 50 patient-specific variants. In some cases, a set of patient-specific variants contains 8 to 32 patient-specific variants. In some cases, a set of patient-specific variants contains 16 patient-specific variants.In some cases, analyzing a biological sample obtained from a patient using an mPCR assay involves sequencing the amplicons produced by the mPCR assay to identify patient-specific variants in the biological sample. In some cases, the personalized ctDNA mPCR approach is the SIGNATERA® ctDNA test or the ArcherDx Personalized Cancer Monitoring (PCM®) test. In some cases, the presence of at least one patient-specific variant in the biological sample identifies the presence of ctDNA in the biological sample. In some cases, the presence of two patient-specific variants in the biological sample identifies the presence of ctDNA in the biological sample.
[0114] In some cases, there are approximately 2 to 200 patient-specific variants, e.g., approximately 2 to 200, approximately 2 to 175, approximately 2 to 150, approximately 2 to 125, approximately 2 to 100, approximately 2 to 75, approximately 2 to 50, approximately 2 to 48, approximately 2 to 46, approximately 2 to 44, approximately 2 to 42, approximately 2 to 40, approximately 2 to 38, approximately 2 to 36, approximately 2 to 34, approximately 2 to 32, approximately 2 to 30, approximately 2 to 28, approximately 2 to 26, approximately 2 to 24, approximately 2 to 22, approximately 2 to 20, approximately 2 to 18, approximately 2 to 16, approximately 2 to 14, approximately 2 to 12, approximately 2 to 10, approximately 2 to 8, approximately 2 to 6, approximately 2 to 4, approximately 4 to 32, approximately 4 to 30, approximately 4-28, approximately 4-26, approximately 4-24, approximately 4-22, approximately 4-20, approximately 4-18, approximately 4-16, approximately 4-14, approximately 4-12, approximately 4-10, approximately 4-8, approximately 4-6, approximately 6-32, approximately 6-30, approximately 6-28, approximately 6-26, approximately 6-24, approximately 6- 22, approximately 6-20, approximately 6-18, approximately 6-16, approximately 6-14, approximately 6-12, approximately 6-10, approximately 6-8, approximately 8-32, approximately 8-30, approximately 8-28, approximately 8-26, approximately 8-24, approximately 8-22, approximately 8-20, approximately 8-18, approximately 8-16, approximately 8-14, approximately 8- 12, approximately 8-10, approximately 10-32, approximately 10-30, approximately 10-28, approximately 10-26, approximately 10-24, approximately 10-22, approximately 10-20, approximately 10-18, approximately 10-16, approximately 10-14, approximately 10-12, approximately 12-32, approximately 12-30, approximately 12-28, approximately 1 2-26, 12-24, 12-22, 12-20, 12-18, 12-16, 12-14, 14-32, 14-30, 14-28, 14-26, 14-24, 14-22, 14-20, 14-18, 14-16 , approximately 16-32, approximately 16-30, approximately 16-28, approximately 16-26, approximately 16-24, approximately 16-22, approximately 16-20, approximately 16-18, approximately 18-32, approximately 18-30, approximately 18-28, approximately 18-26, approximately 18-24, approximately 18-22, approximately 18-20, approximately 20 ~32, approx. 20~30, approx. 20~28, approx. 20~26, approx. 20~24, approx. 20~22, approx. 22~32, approx. 22~30, approx. 22~28, approx. 22~26, approx. 22~24, approx. 24~32, approx. 24~30, approx. 24~28, approx. 24~26, approx. 26~32,Approximately 26–30, 26–28, 28–32, 28–30, or 30–32 patient-specific variants are detected in the biological sample. In some cases, approximately 2–16 patient-specific variants are detected in the biological sample.
[0115] In some cases, the mean allele frequency of a given patient-specific variant in a biological sample is approximately 0.0001% to approximately 99%, for example, approximately 0.0001%, approximately 0.0002%, approximately 0.0003%, approximately 0.0004%, approximately 0.0005%, approximately 0.0006%, approximately 0.0007%, approximately 0.0008%, approximately 0.0009%, approximately 0.001%, approximately 0.002%, approximately 0.003%, approximately 0.004%, approximately 0.005%, approximately 0.006%, approximately 0.007%, approximately 0.008%, approximately 0.009%, approximately 0.01%, approximately 0.02%, approximately 0.03%, approximately 0.04%, approximately 0.0 0.05%, approximately 0.06%, approximately 0.07%, approximately 0.08%, approximately 0.09%, approximately 0.1%, approximately 0.15%, approximately 0.2%, approximately 0.25%, approximately 0.3%, approximately 0.35%, approximately 0.4%, approximately 0.45%, approximately 0.5%, approximately 0.55%, approximately 0.6%, approximately 0.65%, approximately 0.7%, approximately 0.75%, approximately 0.8%, approximately 0.85%, approximately 0.9%, These are approximately 0.95%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. In some cases, the mean allele frequency of a given patient-specific variant in a biological sample ranges from approximately 0.001% to approximately 99%.
[0116] A biological sample may have any appropriate volume. For example, in some cases, a biological sample may have a volume of about 0.02 mL to about 80 mL (e.g., about 0.02 mL, about 0.3 mL, about 0.4 mL, about 0.5 mL, about 0.6 mL, about 0.7 mL, about 0.8 mL, about 0.9 mL, about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, about 10 mL, about 12 mL, about 14 mL, about 16 mL, about 18 mL, about 20 mL, about 22 mL, about 24 mL, about 26 mL, about 28 mL, about 30 mL, about 32 mL, about 34 mL, about 36 mL, about 38 mL, about 40 mL, about 45 mL, about 50 mL, about 55 mL, about 60 mL, about 65 mL, about 70 mL, about 75 mL, or about 80 mL).
[0117] For example, in some cases, the biological sample is approximately 1 mL to approximately 20 mL (e.g., approximately 2 mL to approximately 20 mL, approximately 2 mL to approximately 18 mL, approximately 2 mL to approximately 16 mL, approximately 2 mL to approximately 14 mL, approximately 2 mL to approximately 12 mL, approximately 2 mL to approximately 10 mL, approximately 2 mL to approximately 8 mL, approximately 2 mL to approximately 6 mL, approximately 2 mL to approximately 4 mL, approximately 4 mL to approximately 20 mL, approximately 4 mL to approximately 18 mL, approximately 4 mL to approximately 16 mL, approximately 4 mL to approximately 14 mL, approximately 4 mL to approximately 12 mL, approximately 4 mL to approximately 10 mL, approximately 4 mL to approximately 8 mL, approximately 4 mL to approximately 6 mL, approximately 6 mL to approximately 20 mL, approximately 6 mL to approximately 18 mL, approximately 6 mL to approximately 16 mL, approximately 6 mL to approximately 14 mL, approximately 6 mL to approximately 12 mL, approximately 6 It has a volume of approximately mL to 10 mL, approximately 6 mL to 8 mL, approximately 8 mL to 20 mL, approximately 8 mL to 18 mL, approximately 8 mL to 16 mL, approximately 8 mL to 14 mL, approximately 8 mL to 12 mL, approximately 8 mL to 10 mL, approximately 10 mL to 20 mL, approximately 10 mL to 18 mL, approximately 10 mL to 16 mL, approximately 10 mL to 14 mL, approximately 10 mL to 12 mL, approximately 12 mL to 20 mL, approximately 12 mL to 18 mL, approximately 12 mL to 16 mL, approximately 12 mL to 14 mL, approximately 14 mL to 20 mL, approximately 14 mL to 18 mL, approximately 14 mL to 16 mL, approximately 16 mL to 20 mL, approximately 16 mL to 18 mL, or approximately 18 mL to 20 mL. In some cases, the biological sample has a volume of approximately 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 11 mL, 12 mL, 13 mL, 14 mL, 15 mL, 16 mL, 17 mL, 18 mL, 19 mL, or 20 mL. In some cases, the biological sample has a volume of approximately 2 to 10 mL. In some cases, the biological sample has a volume of approximately 2 to 8 mL.
[0118] A biological sample may contain any appropriate amount of cfDNA (e.g., ctDNA). For example, a biological sample may contain approximately 2 ng to approximately 200 ng (e.g., approximately 2 ng, approximately 5 ng, approximately 10 ng, approximately 15 ng, approximately 20 ng, approximately 25 ng, approximately 30 ng, approximately 35 ng, approximately 40 ng, approximately 45 ng, approximately 50 ng, approximately 55 ng, approximately 60 ng, approximately 65 ng, approximately 70 ng, approximately 80 ng, approximately 85 ng, approximately 90 ng, approximately 95 ng, approximately 100 ng, approximately 105 ng, approximately 1 It may contain cfDNA (e.g., ctDNA) in amounts of 10 ng, approximately 115 ng, approximately 120 ng, approximately 125 ng, approximately 130 ng, approximately 135 ng, approximately 140 ng, approximately 145 ng, approximately 150 ng, approximately 155 ng, approximately 160 ng, approximately 165 ng, approximately 170 ng, approximately 175 ng, approximately 180 ng, approximately 185 ng, approximately 190 ng, approximately 195 ng, or approximately 200 ng. In some examples, a biological sample may contain approximately 10 to approximately 70 ng of cfDNA (e.g., ctDNA).
[0119] In cases where the level of ctDNA is determined, the level of ctDNA can be expressed, for example, as variant allele frequency (VAF) or in terms of mutations / mL.
[0120] In cases where the level of ctDNA is determined, any appropriate reference level for ctDNA may be used. For example, the reference level for ctDNA may be (1) the level of ctDNA in a biological sample obtained from the patient before or concurrently with the administration of a treatment regimen containing a PD-1 axis-coupled antagonist; (2) the level of ctDNA from a reference population; (3) a pre-assigned level for ctDNA; or (4) the level of ctDNA in a biological sample obtained from the patient at a second time point, before or after the first time point.
[0121] In some cases, urothelial carcinoma is MIUC. In some cases, MIUC is muscle-invasive bladder cancer (MIBC) or muscle-invasive urothelial carcinoma (muscle-invasive UTUC). In some cases, MIUC is histologically confirmed and / or the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
[0122] In some cases, patients have been previously treated with neoadjuvant chemotherapy. In some cases, the patient's MIUC is ypT2-4a or ypN+ and M0 at the time of surgical resection. In some cases, patients have not received prior neoadjuvant chemotherapy.
[0123] In other cases, patients are cisplatin ineligible or refuse cisplatin-based adjuvant chemotherapy. In some cases, the patient's MIUC is pT3-4a or pN+ and M0 at the time of surgical resection.
[0124] In some cases, patients have undergone surgical resection with lymph node dissection. In some cases, the surgical resection was a cystectomy or nephroureterectomy.
[0125] In some cases, patients have no evidence of residual disease or metastasis when evaluated by postoperative radiographic imaging.
[0126] In some cases, tumor samples obtained from patients have been determined to have a tissue tumor mutational load (tTMB) score equal to or greater than the baseline tTMB score. In some cases, the baseline tTMB score is a pre-assigned tTMB score. In some cases, the pre-assigned tTMB score is between approximately 8 mut / Mb and approximately 30 mut / Mb. In some cases, the pre-assigned tTMB score is approximately 10 mutations (mut / Mb) per megabase.
[0127] In some cases, tumor specimens are obtained from surgical excision.
[0128] In some cases, patients have elevated expression levels of one or more genes selected from PD-L1, IFNG, and CXCL9 in biological samples obtained from patients, compared to baseline expression levels of said genes.
[0129] In some cases, patients have elevated expression levels of two or more genes selected from PD-L1, IFNG, and CXCL9 in biological samples obtained from the patient, compared to baseline expression levels of those genes. For example, in some cases, patients may have elevated expression levels of PD-L1 and IFNG, PD-L1 and CXCL9, or IFNG and CXCL9, compared to baseline expression levels of two or more genes.
[0130] In some cases, patients have elevated expression levels of PD-L1, IFNG, and CXCL9 compared to baseline expression levels of PD-L1, IFNG, and CXCL9 in biological samples obtained from patients.
[0131] In some examples involving the determination of PD-L1, IFNG, and / or CXCL9 expression levels, an expression level above the baseline expression level, or an elevated or increased expression or number, may refer to an overall increase of approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or more, of the level or number of biomarkers (e.g., proteins, nucleic acids (e.g., genes or mRNA) or cells) detected by methods such as those described herein and / or known in the art, compared to the baseline expression level, baseline sample, baseline cells, baseline tissue, control sample, control cells, or control tissue. In one embodiment, elevated expression or number refers to an increase in the expression level / amount of a biomarker in a sample, where the increase is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, 2.9 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, 500 times, or 1000 times the expression level / amount of each biomarker (e.g., one or more of PD-L1, IFNG, and / or CXCL9) in a reference expression level, reference sample, reference cells, reference tissue, control sample, control cells, or control tissue.In some embodiments, the elevated expression or number was approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, and 2.5 times compared to baseline expression levels, baseline samples, baseline cells, baseline tissues, control samples, control cells, control tissues, or internal controls (e.g., housekeeping genes). This refers to an overall increase in the expression level / amount of a biomarker (e.g., PD-L1, IFNG, and / or CXCL9) by approximately 2.6 times, 2.7 times, 2.8 times, 2.9 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, 500 times, 1,000 times or more.
[0132] In some cases, the expression levels of PD-L1, IFNG, and / or CXCL9 are mRNA expression levels. In other cases, the expression levels of PD-L1, IFNG, and / or CXCL9 may be protein expression levels.
[0133] In some cases, the expression level of the pan-F-TBRS signature can be determined in biological samples obtained from patients. The expression level of the pan-F-TBRS signature can be determined, for example, as described in U.S. Patent Application Publication 2020 / 0263261, which is incorporated herein by reference in its entirety. In other examples, the expression levels of any signature described in U.S. Patent Application Publication 2020 / 0263261 can be determined, including any combination of the genes described in U.S. Patent Application Publication 2020 / 0263261, including 22 genes (e.g., TGFB1, TGFBR2, ACTA2, ACTG2, ADAM12, ADAM19, COMP, CNN1, COL4A1, CTGF, CTPS1, FAM101B, FSTL3, HSPB1, IGFBP3, PXDC1, SEMA7A, SH3PXD2A, TAGLN, TGFBI, TNS1, and / or TPM1) or any signature of six genes (ACTA2, ADAM19, COMP, CTGF, TGFB1, and / or TGFBR2). In another example, the signature may be a pan-F-TBRS signature containing one or more genes selected from ACTA2, ACTG2, TAGLN, TNS1, CNN1, TPM1, CTGF, PXDC1, ADAM12, FSTL3, TGFBI, and ADAM19.
[0134] In some cases, patients have reduced expression levels of one or more pan-F-TBRS genes selected from ACTA2, ACTG2, TAGLN, TNS1, CNN1, TPM1, CTGF, PXDC1, ADAM12, FSTL3, TGFBI, and ADAM19 in biological samples obtained from patients, compared to reference expression levels of the said one or more pan-F-TBRS genes.
[0135] In some cases, patients have reduced expression levels of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 or 12 pan-F-TBRS genes compared to the reference expression levels of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 or 12 pan-F-TBRS genes in biological samples obtained from patients.
[0136] In examples involving a pan-F-TBRS signature, an expression level below the reference expression level, or reduced (decreased) expression or number, may refer to an overall reduction of approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or more, in the level of a biomarker (e.g., protein, nucleic acid (e.g., gene or mRNA), or cell) detected by standard methods known in the art, such as those described herein, compared to the reference expression level, reference sample, reference cell, reference tissue, control sample, control cell, or control tissue. In one embodiment, reduced expression or number refers to a decrease in the expression level / amount of a biomarker in a sample, where the decrease is at least about 0.9 times, 0.8 times, 0.7 times, 0.6 times, 0.5 times, 0.4 times, 0.3 times, 0.2 times, 0.1 times, or 0.01 times the expression level / amount of each biomarker (e.g., one or more of ACTA2, ACTG2, TAGLN, TNS1, CNN1, TPM1, CTGF, PXDC1, ADAM12, FSTL3, TGFBI, and / or ADAM19) in reference expression levels, reference samples, reference cells, reference tissues, control samples, control cells, or control tissues. In some embodiments, the reduced (decreased) expression or number is approximately 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, and 2.9 times compared to a baseline expression level, baseline sample, baseline cells, baseline tissue, control sample, control cells, control tissue, or internal control (e.g., housekeeping gene). This refers to an overall decrease in the expression level / amount of a biomarker (e.g., ACTA2, ACTG2, TAGLN, TNS1, CNN1, TPM1, CTGF, PXDC1, ADAM12, FSTL3, TGFBI, and / or ADAM19) by approximately 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, 500 times, 1,000 times or more.
[0137] In some cases, the expression level of one or more pan-F-TBRS genes is the mRNA expression level. In other cases, the expression level of one or more pan-F-TBRS genes is the protein expression level.
[0138] In some cases, the biological samples obtained from patients are tumor samples.
[0139] In some cases, the patient's tumor has a basal squamous epithelium subtype. In some cases, the basal squamous epithelium subtype may be as assessed by the Cancer Genome Atlas (TCGA) classification. The TCGA classification may be performed as described, for example, in Robertson et al. Cell 171(3):540-556, e25, 2017.
[0140] In some cases, patients have elevated expression levels of one or more genes selected from CD44, KRT6A, KRT5, KRT14, COL17A1, DSC3, GSDMC, TGM1, and PI3, compared to their baseline expression levels.
[0141] Any suitable PD-1 axis-binding antagonist may be used, including any PD-1 axis-binding antagonist known in the art or described in Section IV below. In some examples, the PD-1 axis-binding antagonist is selected from PD-L1-binding antagonists, PD-1-binding antagonists, and PD-L2-binding antagonists. In some examples, the PD-1 axis-binding antagonist is a PD-L1-binding antagonist. In some examples, the PD-L1-binding antagonist is an anti-PD-L1 antibody. In some examples, the anti-PD-L1 antibody is atezolizumab, durvalumab, avelumab, or MDX-1105. In other examples, the PD-1 axis-binding antagonist is PD-1-binding. In some examples, the PD-1-binding antagonist is an anti-PD-1 antibody. In some cases, anti-PD-1 antibodies include nivolumab, pembrolizumab, MEDI-0680, spartalizumab, semiprimab, canrelizumab, cintilimab, tislerizumab, tripalimab, or dostallimab.
[0142] A preferred example is the PD-1 axis-binding antagonist atezolizumab.
[0143] For example, a method for treating MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient who requires treatment of MIUC (e.g., MIBC or muscle-invasive UTUC) in one aspect is provided herein, comprising: (a) determining whether the patient is ctDNA positive; and (b) administering to the patient an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen is adjuvant therapy.
[0144] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in the treatment of MIUC (e.g., MIBC or myometrial uterine ulcerative colitis) in a patient requiring treatment for MIUC (e.g., MIBC or myometrial uterine ulcerative colitis), wherein the treatment comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, the treatment regimen being adjuvant therapy, and the patient being ctDNA positive.
[0145] In another context, atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in the treatment of MIUC (e.g., MIBC or myometrial uterine ulcerative colitis) in patients requiring treatment for MIUC (e.g., MIBC or myometrial uterine ulcerative colitis), wherein the treatment comprises (a) determining whether the patient is ctDNA positive; and (b) administering to the patient an effective dose of a treatment regimen comprising atezolizumab, the treatment regimen being an adjuvant therapy, is provided herein.
[0146] In any of the aforementioned situations, the patient may be determined to be ctDNA positive after surgical resection (e.g., cystectomy).
[0147] For example, the present invention provides a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA-positive after surgical resection, and the method comprises administering to the patient an effective dose of a treatment regimen comprising atezolizumab.
[0148] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA-positive after surgical resection, and the therapy comprises administering an effective dose of a therapeutic regimen comprising atezolizumab.
[0149] In one aspect, a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA positive after surgical resection, and the method comprises administering to the patient an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering to the patient a dose of 1200 mg intravenously (e.g., by infusion) on day 1 of each 21-day cycle, is provided herein.
[0150] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA positive after surgical resection, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1200 mg (e.g., by infusion) on day 1 of each 21-day cycle.
[0151] In one aspect, a method of adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to be ctDNA positive after surgical resection, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1680 mg of atezolizumab intravenously (e.g., by infusion) on day 1 of each 21-day cycle, is provided herein.
[0152] In another context, the present invention provides atezolizumab or a pharmaceutical composition comprising atezolizumab for use in adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to be ctDNA positive after surgical resection, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1200 mg (e.g., by infusion) on day 1 of each 21-day cycle.
[0153] In some of the above scenarios, the treatment regimen includes up to 16 cycles. In other scenarios, the treatment regimen includes more than 16 cycles.
[0154] In one aspect, a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA positive after surgical resection, and the method comprises administering to the patient an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering to the patient a dose of 1680 mg intravenously (e.g., by infusion) on day 1 of each 28-day cycle, is provided herein.
[0155] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to be ctDNA positive after surgical resection, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1680 mg (e.g., by infusion) on day 1 of each 28-day cycle.
[0156] In one aspect, a method of adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to be ctDNA positive after surgical resection, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1680 mg intravenously (e.g., by infusion) on day 1 of each 28-day cycle, is provided herein.
[0157] In another context, the present invention provides atezolizumab or a pharmaceutical composition comprising atezolizumab for use in adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to be ctDNA positive after surgical resection, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1680 mg (e.g., by infusion) on day 1 of each 28-day cycle.
[0158] In some of the above scenarios, the treatment regimen includes up to 12 cycles. In other scenarios, the treatment regimen includes more than 12 cycles.
[0159] In any of the aforementioned situations, the patient's ctDNA status can be determined in any suitable sample, such as a blood sample, plasma sample, serum sample, urine sample, CSF sample, nasal swab sample, saliva sample, stool sample, or vaginal fluid sample. In some cases, the sample is a plasma sample.
[0160] For example, a method for treating MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient who requires treatment of MIUC (e.g., MIBC or muscle-invasive UTUC) in one aspect, comprising: (a) determining whether a plasma sample obtained from the patient is ctDNA positive, such that a ctDNA-positive plasma sample indicates that the patient is likely to benefit from a treatment regimen comprising atezolizumab; and (b) administering to the patient an effective dose of a treatment regimen comprising atezolizumab, based on the ctDNA positiveness of the plasma sample, wherein the treatment regimen is an adjuvant therapy.
[0161] In another context, atezolizumab or a pharmaceutical composition comprising atezolizumab is provided herein for use in the treatment of MIUC (e.g., MIBC or myometrial UTUC) in patients requiring treatment of MIUC (e.g., MIBC or myometrial UTUC), wherein the treatment comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, the treatment regimen being an adjuvant therapy, and the patient has been identified as likely to benefit from the treatment regimen based on the ctDNA positivity of a plasma sample obtained from the patient.
[0162] In another context, atezolizumab or a pharmaceutical composition comprising atezolizumab is provided herein for use in the treatment of MIUC (e.g., MIBC or muscle-invasive UTUC) in patients requiring treatment of MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the treatment comprises (a) determining whether a plasma sample obtained from the patient is ctDNA positive, such that a ctDNA-positive plasma sample indicates that the patient is likely to benefit from a treatment regimen comprising atezolizumab; and (b) administering to the patient an effective dose of a treatment regimen comprising atezolizumab, based on the ctDNA positiveness of the plasma sample, the treatment regimen comprising adjuvant therapy.
[0163] In one aspect, a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient is determined to have a ctDNA-positive plasma sample after cystectomy, and the method comprises administering an effective dose of a therapeutic regimen comprising atezolizumab to the patient, wherein atezolizumab or a pharmaceutical composition comprising atezolizumab is provided herein.
[0164] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the therapy comprises administering an effective dose of a therapeutic regimen comprising atezolizumab.
[0165] In one aspect, a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1200 mg intravenously (e.g., by infusion) on day 1 of each 21-day cycle, is provided herein.
[0166] In another context, the present invention provides atezolizumab or a pharmaceutical composition comprising atezolizumab for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1200 mg (e.g., by infusion) on day 1 of each 21-day cycle.
[0167] In one aspect, a method of adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1680 mg intravenously (e.g., by infusion) on day 1 of each 21-day cycle, is provided herein.
[0168] In another context, the present invention provides atezolizumab or a pharmaceutical composition comprising atezolizumab for use in adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the therapy comprises the administration of an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering atezolizumab to the patient intravenously at a dose of 1200 mg (e.g., by infusion) on day 1 of each 21-day cycle.
[0169] In some of the above scenarios, the treatment regimen includes up to 16 cycles. In other scenarios, the treatment regimen includes more than 16 cycles.
[0170] In one aspect, a method for adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1680 mg of atezolizumab intravenously (e.g., by infusion) on day 1 of each 28-day cycle, is provided herein.
[0171] In another context, the following are provided herein: atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC) in a patient requiring adjuvant therapy for MIUC (e.g., MIBC or muscle-invasive UTUC), wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the therapy comprises the administration of an effective dose of a treatment regimen comprising atezolizumab, wherein the treatment regimen comprises administering atezolizumab to the patient intravenously at a dose of 1680 mg (e.g., by infusion) on day 1 of each 28-day cycle.
[0172] In one aspect, a method of adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the method comprises administering to the patient an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering to the patient a dose of 1680 mg intravenously (e.g., by infusion) on day 1 of each 28-day cycle, is provided herein.
[0173] In another context, atezolizumab, or a pharmaceutical composition comprising atezolizumab, for use in adjuvant therapy for MIBC in a patient requiring adjuvant therapy for MIBC, wherein the patient has been determined to have a ctDNA-positive plasma sample after cystectomy, and the therapy comprises the administration of an effective dose of a therapeutic regimen comprising atezolizumab, wherein the therapeutic regimen comprises administering atezolizumab to the patient intravenously at a dose of 1680 mg (e.g., by infusion) on day 1 of each 28-day cycle, is provided herein.
[0174] In some of the above scenarios, the treatment regimen includes up to 12 cycles. In other scenarios, the treatment regimen includes more than 12 cycles.
[0175] In any of the aforementioned situations, ctDNA positivity can be determined using an individualized mPCR assay (e.g., the Natera SIGNATERA® assay), and plasma samples that are evaluated to have two or more mutations when assessed by an individualized mPCR assay are considered ctDNA positive.
[0176] In any of the aforementioned situations, ctDNA positivity can be determined using a test approved by the Food and Drug Administration.
[0177] In some cases, PD-1 axial antagonists are administered as monotherapy. In other cases, PD-1 axial antagonists are administered in combination with one or more additional therapeutic agents in an effective dose.
[0178] In some examples, the method, PD-1 axis-coupled antagonist for use, pharmaceutical composition for use, or use further comprises administering an additional therapeutic agent to the patient. In some examples, the additional therapeutic agent is selected from the group consisting of immunotherapeutic agents, cytotoxic agents, growth inhibitors, radiotherapeutic agents, anti-angiogenic agents, and combinations thereof.
[0179] In any of the examples above, each medication cycle can have any appropriate length, e.g., about 7 days, about 14 days, about 21 days, about 28 days, or longer. In some examples, each medication cycle is about 14 days. In some examples, each medication cycle is about 21 days. In some examples, each medication cycle is about 28 days (e.g., 28 days ± 3 days).
[0180] The patient is preferably a human.
[0181] As a general suggestion, the therapeutically effective dose of a PD-1 axis-conjugated antagonist (e.g., atezolizumab) administered to humans is in the range of approximately 0.01 to 50 mg per kg of body weight, whether administered in one or more doses.
[0182] In some exemplary embodiments, the PD-1 axis-coupled antagonist is administered in doses of approximately 0.01 to 45 mg / kg, approximately 0.01 to 40 mg / kg, approximately 0.01 to 35 mg / kg, approximately 0.01 to 30 mg / kg, approximately 0.01 to 25 mg / kg, approximately 0.01 to 20 mg / kg, approximately 0.01 to 15 mg / kg, approximately 0.01 to 10 mg / kg, approximately 0.01 to 5 mg / kg, or approximately 0.01 to 1 mg / kg, for example, daily, weekly, every two weeks, every three weeks, or every four weeks.
[0183] In one example, PD-1 axially coupled antagonists are administered to humans in doses of approximately 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, or 1500 mg. In some cases, PD-1 axially coupled antagonists may be administered in doses of approximately 1000 mg to 1400 mg every three weeks (e.g., approximately 1100 mg to 1300 mg every three weeks, or approximately 1150 mg to 1250 mg every three weeks).
[0184] In some cases, patients take a total of 1-50 doses, for example, 1-50 doses, 1-45 doses, 1-40 doses, 1-35 doses, 1-30 doses, 1-25 doses, 1-20 doses, 1-15 doses, 1-10 doses, 1-5 doses, 2-50 doses, 2-45 doses, 2-40 doses, 2-35 doses, 2-30 doses, 2-25 doses, 2-20 doses, 2-15 doses, 2-10 doses, 2-5 doses, 3-50 Doses, 3-45 doses, 3-40 doses, 3-35 doses, 3-30 doses, 3-25 doses, 3-20 doses, 3-15 doses, 3-10 doses, 3-5 doses, 4-50 doses, 4-45 doses, 4-40 doses , 4-35 doses, 4-30 doses, 4-25 doses, 4-20 doses, 4-15 doses, 4-10 doses, 4-5 doses, 5-50 doses, 5-45 doses, 5-40 doses, 5-35 doses, 5-30 doses, 5 ~25 doses, 5~20 doses, 5~15 doses, 5~10 doses, 10~50 doses, 10~45 doses, 10~40 doses, 10~35 doses, 10~30 doses, 10~25 doses, 10~20 doses, 1 For 0~15 doses, 15~50 doses, 15~45 doses, 15~40 doses, 15~35 doses, 15~30 doses, 15~25 doses, 15~20 doses, 20~50 doses, 20~45 doses, 20~40 The patient is administered PD-1 axial antagonist in doses of 20-35, 20-30, 20-25, 25-50, 25-45, 25-40, 25-35, 25-30, 30-50, 30-45, 30-40, 30-35, 35-50, 35-45, 35-40, 40-50, 40-45, or 45-50 doses. In certain cases, the dose may be administered intravenously. In some cases, the patient is administered a total of 16 doses of PD-1 axial antagonist. In other cases, the patient is administered a total of 12 doses of PD-1 axial antagonist.
[0185] In some cases, atezolizumab is administered intravenously to patients at doses of approximately 840 mg every two weeks, approximately 1200 mg every three weeks, or approximately 1680 mg every four weeks. In some cases, atezolizumab is administered intravenously to patients at a dose of 840 mg every two weeks. In some cases, atezolizumab is administered intravenously to patients at a dose of 1200 mg every three weeks. In some cases, atezolizumab is administered on day 1 of each 21-day (±3-day) cycle, whichever comes first, for 16 cycles or one year. In some cases, atezolizumab is administered intravenously to patients at a dose of 1680 mg every four weeks. In some cases, atezolizumab is administered on day 1 of each 28-day (±3-day) cycle, whichever comes first, for 12 cycles or one year.
[0186] PD-1 axially coupled antagonists and / or any additional therapeutic agents may be administered in any suitable manner known in the art. For example, PD-1 axially coupled antagonists and / or any additional therapeutic agents may be administered sequentially (on different days) or simultaneously (on the same day or during the same treatment cycle). In some cases, the PD-1 axially coupled antagonist is administered before the additional therapeutic agent. In other cases, the PD-1 axially coupled antagonist is administered after the additional therapeutic agent. In some cases, the PD-1 axially coupled antagonist and / or any additional therapeutic agent may be administered on the same day. In some cases, the PD-1 axially coupled antagonist may be administered before an additional therapeutic agent administered on the same day. For example, the PD-1 axially coupled antagonist may be administered on the same day before chemotherapy. In other cases, the PD-1 axially coupled antagonist may be administered on the same day before both chemotherapy and another drug (e.g., bevacizumab). In other cases, the PD-1 axially coupled antagonist may be administered after additional therapeutic agents administered on the same day. In yet another case, the PD-1 axially coupled antagonist is administered simultaneously with additional therapeutic agents. In some cases, the PD-1 axially coupled antagonist is present in a separate composition as an additional therapeutic agent. In some cases, the PD-1 axially coupled antagonist is present in the same composition as an additional therapeutic agent. In some cases, the PD-1 axially coupled antagonist is administered via a separate intravenous line from any other therapeutic agents administered to the patient on the same day.
[0187] PD-1 axially coupled antagonists and any additional therapeutic agents may be administered by the same or different routes of administration. In some cases, PD-1 axially coupled antagonists are administered intravenously, intramuscularly, subcutaneously, topically, orally, percutaneously, intraperitoneally, intraorbitally, implantably, by inhalation, intrathecally, intraventricularly, or intranasally. In some cases, additional therapeutic agents are administered intravenously, intramuscularly, subcutaneously, topically, orally, percutaneously, intraperitoneally, intraorbitally, implantably, by inhalation, intrathecally, intraventricularly, or intranasally.
[0188] In preferred embodiments, the PD-1 axially coupled antagonist is administered intravenously. In one example, atezolizumab may be administered intravenously over 60 minutes, and if the initial infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. In some examples, the PD-1 axially coupled antagonist is not administered as an intravenous push or bolus.
[0189] Also provided herein are methods for treating urothelial carcinoma in a patient, comprising administering to the patient a treatment regimen comprising an effective amount of a PD-1 axis-conjugated antagonist (e.g., atezolizumab) in combination with another anticancer agent or cancer treatment. For example, a PD-1 axis-conjugated antagonist may be administered in combination with additional chemotherapy or chemotherapeutic agents (see definition above); targeted therapy or targeted therapeutic agents; immunotherapy or immunotherapeutic agents, e.g., monoclonal antibodies; one or more cytotoxic agents (see definition above); or a combination thereof. For example, a PD-1 axis-conjugated antagonist may be administered in combination with bevacizumab, paclitaxel, protein-conjugated paclitaxel (e.g., nab-paclitaxel), carboplatin, cisplatin, pemetrexed, gemcitabine, etoposide, cobimetinib, vemurafenib, or a combination thereof. The PD-1 axis-conjugated antagonist may be an anti-PD-L1 antibody (e.g., atezolizumab) or an anti-PD-1 antibody.
[0190] For example, when administered with or without bevacizumab chemotherapy, atezolizumab may be administered at a dose of 1200 mg every three weeks prior to chemotherapy and bevacizumab. In another example, after the completion of 4–6 cycles of chemotherapy and once bevacizumab has been discontinued, atezolizumab may be administered at a dose of 840 mg every two weeks, 1200 mg every three weeks, or 1680 mg every four weeks. In yet another example, atezolizumab may be administered at a dose of 840 mg, followed by 100 mg / m². 2Protein-conjugated paclitaxel (e.g., nab-paclitaxel) may be administered, with atezolizumab administered on days 1 and 15 of each 28-day cycle, and protein-conjugated paclitaxel administered on days 1, 8, and 15. In another example, when administered with carboplatin and etoposide, atezolizumab may be administered at a dose of 1200 mg every three weeks prior to chemotherapy. In yet another example, after completion of four cycles of carboplatin and etoposide, atezolizumab may be administered at doses of 840 mg every two weeks, 1200 mg every three weeks, or 1680 mg every four weeks. In another example, after completing a 28-day cycle of cobimenitib and vemurafenib, atezolizumab may be administered orally at a dose of 840 mg every two weeks, cobimenitib at a dose of 60 mg once daily (21 days on, 7 days off), and vemurafenib at a dose of 720 mg twice daily.
[0191] In some cases, the treatment may further include additional treatments. Any suitable additional treatment known in the art or described herein may be used. Additional treatments may include radiotherapy, surgery, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplantation, nanotherapy, monoclonal antibody therapy, gamma irradiation, or a combination thereof.
[0192] In some cases, additional treatment involves the administration of side effect limiters (e.g., medications intended to reduce the occurrence and / or severity of side effects of treatment, such as anti-nausea agents, corticosteroids (e.g., prednisone or equivalent, e.g., at doses of 1-2 mg / kg / day), hormone replacement therapy, etc.).
[0193] III. Evaluation of PD-L1 expression PD-L1 expression may be evaluated in patients treated according to any of the methods and compositions for use described herein. The methods and compositions for use may include determining the expression level of PD-L1 in a biological sample (e.g., tumor sample) obtained from the patient. In other examples, the expression level of PD-L1 in a biological sample (e.g., tumor sample) obtained from the patient is determined before or after the initiation of treatment. PD-L1 expression may be determined using any suitable approach. For example, PD-L1 expression may be determined as described in U.S. Patent Application Publications 15 / 787,988 and 15 / 790,680. Any suitable tumor sample, such as formalin-fixed paraffin-embedded (FFPE) tumor samples, stored tumor samples, fresh tumor samples, or frozen tumor samples may be used.
[0194] For example, PD-L1 expression can be determined as the percentage of tumor-infiltrating immune cells in a tumor sample expressing detectable levels of PD-L1, and / or as the percentage of tumor cells in a tumor sample expressing detectable levels of PD-L1, with respect to the percentage of tumor-infiltrating immune cells in the tumor sample expressing detectable levels of PD-L1. In any of the above examples, it should be understood that the percentage of tumor sample composed of tumor-infiltrating immune cells may be, for example, the percentage of tumor area covered by tumor-infiltrating immune cells in a section of a patient-derived tumor sample, as assessed by IHC using an anti-PD-L1 antibody (e.g., SP142 antibody). For example, any suitable anti-PD-L1 antibody, including SP142 (Ventana), SP263 (Ventana), 22C3 (Dako), 28-8 (Dako), E1L3N (Cell Signaling Technology), 4059 (ProSci, Inc.), h5H1 (Advanced Cell Diagnostics), and 9A11, may be used. In some cases, the anti-PD-L1 antibody is SP142. In other cases, the anti-PD-L1 antibody is SP263.
[0195] In some cases, tumor samples obtained from patients have detectable levels of PD-L1 in less than 1% of tumor cells, more than 1% of tumor cells, between 1% and less than 5% of tumor cells, more than 5% of tumor cells, between 5% and less than 50% of tumor cells, or more than 50% of tumor cells.
[0196] In some cases, tumor samples obtained from patients have PD-L1 at detectable expression levels in tumor-infiltrating immune cells, including less than 1% of the tumor samples, more than 1% of the tumor samples, 1% to less than 5% of the tumor samples, more than 5% of the tumor samples, 5% to less than 10% of the tumor samples, or more than 10% of the tumor samples.
[0197] In some cases, tumor samples may be scored for PD-L1 positivity in tumor-infiltrating immune cells and / or tumor cells, according to the criteria for diagnostic evaluation shown in Table A and / or Table B, respectively. [Table A] [Table B]
[0198] IV. PD-1 Axis Coupling Antagonist PD-1 axially coupled antagonists may include PD-L1-coupled antagonists, PD-1-coupled antagonists, and PD-L2-coupled antagonists. Any suitable PD-1 axially coupled antagonist may be used.
[0199] A. PD-L1 binding antagonist In some cases, PD-L1-binding antagonists inhibit the binding of PD-L1 to one or more of its ligand-binding partners. In other cases, PD-L1-binding antagonists inhibit the binding of PD-L1 to PD-1. In yet another case, PD-L1-binding antagonists inhibit the binding of PD-L1 to B7-1. In some cases, PD-L1-binding antagonists inhibit the binding of PD-L1 to both PD-1 and B7-1. PD-L1-binding antagonists can be, but are not limited to, antibodies, their antigen-binding fragments, immunoadhesins, fusion proteins, oligopeptides, or small molecules. In some cases, PD-L1-binding antagonists are small molecules that inhibit PD-L1 (e.g., GS-4224, INCB086550, MAX-10181, INCB090244, CA-170, or ABSK041). In some cases, the PD-L1-binding antagonist is a small molecule that inhibits PD-L1 and VISTA. In some cases, the PD-L1-binding antagonist is CA-170 (also known as AUPM-170). In some cases, the PD-L1-binding antagonist is a small molecule that inhibits PD-L1 and TIM3. In some cases, the small molecule is a compound described in International Publication No. 2015 / 033301 and / or International Publication No. 2015 / 033299.
[0200] In some examples, the PD-L1 conjugated antagonist is an anti-PD-L1 antibody. Various anti-PD-L1 antibodies are intended and described herein. In any of the examples herein, the isolated anti-PD-L1 antibody can conjugate to human PD-L1, e.g., human PD-L1 as shown in UniProtKB / Swiss-Prot accession number Q9NZQ7-1, or a variant thereof. In some examples, the anti-PD-L1 antibody can inhibit the binding between PD-L1 and PD-1 and / or between PD-L1 and B7-1. In some examples, the anti-PD-L1 antibody is a monoclonal antibody. In some examples, the anti-PD-L1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')2 fragments. In some examples, the anti-PD-L1 antibody is a humanized antibody. In some examples, the anti-PD-L1 antibody is a human antibody. Examples of anti-PD-L1 antibodies include atezolizumab, MDX-1105, MEDI4736 (durvalumab), MSB0010718C (avelumab), SHR-1316, CS1001, emvafolimab, TQB2450, ZKAB001, LP-002, CX-072, IMC-001, KL-A167, APL-502, cosivelimab, rhodapolimab, FAZ053, TG-1501, BGB-A333, BCD-135, AK-106, LDP, GR1405, HLX20, MSB2311, RC98, PDL-GEX, KD036, KY1003, YBL-007, and HS-636. Examples of anti-PD-L1 antibodies useful in the methods of the present invention and methods for producing them are described in International Patent Application Publication 2010 / 077634 and U.S. Patent No. 8,217,149, each of which is incorporated herein by reference in its entirety.
[0201] In some cases, anti-PD-L1 antibodies, (a) The HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 3), AWISPYGGSTYYADSVKG (SEQ ID NO: 4), and RHWPGGFDY (SEQ ID NO: 5), respectively, and (b) Each contains the HVR-L1, HVR-L2, and HVR-L3 sequences of RASQDVSTAVA (sequence number 6), SASFLYS (sequence number 7), and QQYLYHPAT (sequence number 8), respectively.
[0202] In one embodiment, the anti-PD-L1 antibody is (a) The following: Heavy chain variable region (VH) containing the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO: 9), and (b) The following: Light chain variable region (VL) containing the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO: 10) Includes.
[0203] In some examples, the anti-PD-L1 antibody comprises (a) a VH containing an amino acid sequence or sequence of SEQ ID NO: 9 having at least 95% sequence identity with the sequence of SEQ ID NO: 9 (e.g., at least 95%, 96%, 97%, 98%, or 99% sequence identity), (b) a VL containing an amino acid sequence or sequence of SEQ ID NO: 10 having at least 95% sequence identity with the sequence of SEQ ID NO: 10 (e.g., at least 95%, 96%, 97%, 98%, or 99% sequence identity), or (c) the VH in (a) and the VL in (b).
[0204] In one embodiment, the anti-PD-L1 antibody is (a) Heavy chain amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (Sequence ID 1), and (b) Light chain amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 2) Includes atezolizumab.
[0205] In some cases, the anti-PD-L1 antibody is avelumab (Chemical Abstract Service (CAS) registry number 1537032-82-8). Avelumab, also known as MSB0010718C, is a human monoclonal IgG1 anti-PD-L1 antibody (Merck KGaA, Pfizer).
[0206] In some cases, the anti-PD-L1 antibody is durvalumab (CAS Registry No.: 1428935-60-7). Also known as MEDI4736, durvalumab is an Fc-optimized human monoclonal IgG1 kappa anti-PD-L1 antibody (MedImmune, AstraZeneca) described in International Publication No. 2011 / 066389 and U.S. Patent Application Publication No. 2013 / 034559.
[0207] In some cases, the anti-PD-L1 antibody is MDX-1105 (Bristol Myers Squibb). MDX-1105, also known as BMS-936559, is an anti-PD-L1 antibody described in International Publication No. 2007 / 005874.
[0208] In some cases, the anti-PD-L1 antibody is LY3300054 (Eli Lilly).
[0209] In some cases, the anti-PD-L1 antibody is STI-A1014 (Sorrento). STI-A1014 is a human anti-PD-L1 antibody.
[0210] In some cases, the anti-PD-L1 antibody is KN035 (Suzhou Alphamab). KN035 is a single-domain antibody (dAB) generated from a camel phage display library.
[0211] In some cases, anti-PD-L1 antibodies contain a cleavable moiety or linker that, when cleaved (e.g., by a protease in the tumor microenvironment), activates the antibody-antigen-binding domain, allowing it to bind to the antigen, for example, by removing an unbinding stereomolecule. In some cases, the anti-PD-L1 antibody is CX-072 (CytomX Therapeutics).
[0212] In some examples, the anti-PD-L1 antibody comprises six HVR sequences (e.g., three heavy-chain HVRs and three light-chain HVRs) and / or heavy-chain variable domains and light-chain variable domains derived from the anti-PD-L1 antibody described in U.S. Patent Application Publication No. 20160108123, International Publication No. 2016 / 000619, International Publication No. 2012 / 145493, U.S. Patent No. 9,205,148, International Publication No. 2013 / 181634, or International Publication No. 2016 / 061142.
[0213] Furthermore, in certain contexts, anti-PD-L1 antibodies exhibit reduced or minimal effector function. In even more specific contexts, minimal effector function is attributed to "effector-less Fc mutations" or aglycosylation mutations. In further examples, effector-less Fc mutations are N297A or D265A / N297A substitutions within the constant region. In even more examples, effector-less Fc mutations are N297A substitutions within the constant region. In some cases, isolated anti-PD-L1 antibodies are aglycosylated. Antibody glycosylation is typically either N-linked or O-linked. N-linked refers to binding to the side chain of the asparagine residue in the carbohydrate moiety. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid other than proline) are recognition sequences for enzymatic binding of the carbohydrate moiety to the asparagine side chain. Therefore, the presence of any of these tripeptide sequences within a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the binding of a hydroxyamino acid from sugars, N-acetylgalactosamine, galactose, or xylose, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Removal of glycosylation sites from antibodies is conveniently achieved by modifying the amino acid sequence so that one of the aforementioned tripeptide sequences is removed (for N-linked glycosylation sites). This modification can be carried out by substituting an asparagine, serine, or threonine residue within the glycosylation site with another amino acid residue (e.g., glycine, alanine, or a conservative substitution).
[0214] B. PD-1 binding antagonist In some cases, a PD-1 axis-binding antagonist is a PD-1-binding antagonist. For example, in some cases, a PD-1-binding antagonist inhibits the binding of PD-1 to one or more of its ligand-binding partners. In some cases, a PD-1-binding antagonist inhibits the binding of PD-1 to PD-L1. In other cases, a PD-1-binding antagonist inhibits the binding of PD-1 to PD-L2. In yet another case, a PD-1-binding antagonist inhibits the binding of PD-1 to both PD-L1 and PD-L2. A PD-1-binding antagonist can be, but is not limited to, an antibody, its antigen-binding fragment, an immunoadhesin, a fusion protein, an oligopeptide, or a small molecule. In some cases, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin containing an extracellular or PD-1 binding moiety of PD-L1 or PD-L2 fused to a constant region (e.g., the Fc region of an immunoglobulin sequence)). For example, in some cases, the PD-1 binding antagonist is an Fc fusion protein. In some cases, the PD-1 binding antagonist is AMP-224. Also known as B7-DCIg, AMP-224 is a PD-L2-Fc fusion soluble receptor described in International Publication Nos. 2010 / 027827 and 2011 / 066342. In some cases, the PD-1 binding antagonist is a peptide or small molecule compound. In some cases, the PD-1 binding antagonist is AUNP-12 (Pierre Fabre / Aurigene). See, for example, International Publication Nos. 2012 / 168944, 2015 / 036927, 2015 / 044900, 2015 / 033303, 2013 / 144704, 2013 / 132317, and 2011 / 161699. In some examples, PD-1-binding antagonists are small molecules that inhibit PD-1.
[0215] In some examples, the PD-1 conjugated antagonist is an anti-PD-1 antibody. Various anti-PD-1 antibodies may be used in the methods and uses disclosed herein. In any of the examples herein, the PD-1 antibody can conjugate to human PD-1 or a variant thereof. In some examples, the anti-PD-1 antibody is a monoclonal antibody. In some examples, the anti-PD-1 antibody is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments. In some examples, the anti-PD-1 antibody is a humanized antibody. In other examples, the anti-PD-1 antibody is a human antibody. Examples of anti-PD-1 antagonist antibodies include nivolumab, pembrolizumab, MEDI-0680, PDR001 (spartalizumab), REGN2810 (semiprimab), BGB-108, prorugolimab, canrelizumab, cintilimab, tislerizumab, tripalimab, dostallimab, retifanlimab, sasamlimab, and pemprimab. Examples include CS1003, HLX10, SCT-I10A, zimbererimab, valstilimab, genolimuzumab, BI754091, cetrelimab, YBL-006, BAT1306, HX008, buzigalimab, AMG404, CX-188, JTX-4014, 609A, Sym021, LZM009, F520, SG001, AM0001, ENUM 244C8, ENUM 388D4, STI-1110, AK-103, and hAb21.
[0216] In some cases, the anti-PD-1 antibody is nivolumab (CAS registry number: 946414-94-4). Nivolumab (Bristol-Myers Squibb / Ono), also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, is an anti-PD-1 antibody described in International Publication No. 2006 / 121168.
[0217] In some cases, the anti-PD-1 antibody is pembrolizumab (CAS registry number: 1374853-91-4). Pembrolizumab (Merck) is also known as MK-3475, Merck 3475, lambrolizumab, SCH-900475, and KEYTRUDA®, and is an anti-PD-1 antibody described in International Publication No. 2009 / 114335.
[0218] In some cases, the anti-PD-1 antibody is MEDI-0680 (AMP-514; Astra Zeneca). MEDI-0680 is a humanized IgG4 anti-PD-1 antibody.
[0219] In some cases, the anti-PD-1 antibody is PDR001 (CAS registry number 1859072-53-9; Novartis). PDR001 is a humanized IgG4 anti-PD-1 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
[0220] In some cases, the anti-PD-1 antibody is REGN2810 (Regeneron). REGN2810 is a human anti-PD-1 antibody.
[0221] In some cases, the anti-PD-1 antibody is BGB-108 (BeiGene).
[0222] In some cases, the anti-PD-1 antibody is BGB-A317 (BeiGene).
[0223] In some cases, the anti-PD-1 antibody is JS-001 (Shanghai Junshi). JS-001 is a humanized anti-PD-1 antibody.
[0224] In some cases, the anti-PD-1 antibody is STI-A1110 (Sorrento). STI-A1110 is a human anti-PD-1 antibody.
[0225] In some cases, the anti-PD-1 antibody is INCSHR-1210 (Incyte). INCSHR-1210 is a human IgG4 anti-PD-1 antibody.
[0226] In some cases, the anti-PD-1 antibody is PF-06801591 (Pfizer).
[0227] In some cases, the anti-PD-1 antibody is TSR-042 (also known as ANB011; Tesaro / AnaptysBio).
[0228] In some cases, the anti-PD-1 antibody is AM0001 (ARMO Biosciences).
[0229] In some cases, the anti-PD-1 antibody is ENUM 244C8 (Enumeral Biomedical Holdings). ENUM 244C8 is an anti-PD-1 antibody that inhibits PD-1 function without blocking the binding of PD-L1 to PD-1.
[0230] In some cases, the anti-PD-1 antibody is ENUM 388D4 (Enumeral Biomedical Holdings). ENUM 388D4 is an anti-PD-1 antibody that competitively inhibits the binding of PD-L1 to PD-1.
[0231] In some cases, anti-PD-1 antibodies are listed in International Publication No. 2015 / 112800, International Publication No. 2015 / 112805, International Publication No. 2015 / 112900, U.S. Patent Application Publication No. 20150210769, International Publication No. 2016 / 089873, International Publication No. 2015 / 035606, International Publication No. 2015 / 085847, International Publication No. 2014 / 206107, International Publication No. 2012 / 145493, and U.S. Patent Application Publication No. 9,205. The anti-PD-1 antibody described in International Publication No. 148, International Publication No. 2015 / 119930, International Publication No. 2015 / 119923, International Publication No. 2016 / 032927, International Publication No. 2014 / 179664, International Publication No. 2016 / 106160 and International Publication No. 2014 / 194302 contains six HVR sequences (e.g., three heavy chain HVRs and three light chain HVRs) and / or heavy chain variable domains and light chain variable domains.
[0232] Furthermore, in certain specific contexts, anti-PD-1 antibodies exhibit reduced or minimal effector function. In even more specific contexts, minimal effector function is attributed to "effector-less Fc mutations" or aglycosylation mutations. In further examples, effector-less Fc mutations are N297A or D265A / N297A substitutions within the constant region. In some cases, isolated anti-PD-1 antibodies are aglycosylated.
[0233] C.PD-L2 binding antagonist In some cases, PD-1 axis-binding antagonists are PD-L2-binding antagonists. In some cases, PD-L2-binding antagonists are molecules that inhibit the binding of PD-L2 to its ligand-binding partner. In certain contexts, the PD-L2-binding ligand partner is PD-1. PD-L2-binding antagonists can be, but are not limited to, antibodies, their antigen-binding fragments, immunoadhesins, fusion proteins, oligopeptides, or small molecules.
[0234] In some examples, the PD-L2-binding antagonist is an anti-PD-L2 antibody. In any of the examples herein, the anti-PD-L2 antibody can bind to human PD-L2 or a variant thereof. In some examples, the anti-PD-L2 antibody is a monoclonal antibody. In some examples, the anti-PD-L2 antibody is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments. In some examples, the anti-PD-L2 antibody is a humanized antibody. In other examples, the anti-PD-L2 antibody is a human antibody. In further specific contexts, the anti-PD-L2 antibody has reduced or minimal effector function. In further specific contexts, minimal effector function is due to an "effector-less Fc mutation" or aglycosylation mutation. In further specific contexts, the effector-less Fc mutation is an N297A or D265A / N297A substitution within the constant region. In some cases, isolated anti-PD-L2 antibodies are non-glycosylated.
[0235] Detection and evaluation of V.ctDNA Methods for treating urothelial carcinoma in a patient are provided herein, comprising administering a treatment regime to the patient comprising a PD-1 axis-coupled antagonist (e.g., atezolizumab), which includes determining the presence and / or level of ctDNA in a biological sample obtained from the patient. Related compositions for use (e.g., pharmaceutical compositions), kits, and products are also provided. Any of the methods, compositions for use, kits, or products described herein may include any suitable approach for detecting ctDNA. In some examples, ctDNA may be detected using targeted approaches (e.g., PCR-based approaches, cancer personalized profiling by deep sequencing (CAPP-Seq) or integrated digital error suppression (iDES), TAM-Seq, Safe-Seq, or double-strand sequencing). In other examples, ctDNA may be detected using untargeted approaches (e.g., by digital karyotype analysis, personalized analysis of rearranged ends (PARE), or detection of DNA methylation and / or hydroxymethylation in ctDNA).
[0236] Any suitable biological sample can be used for the detection of ctDNA. In some cases, ctDNA may be evaluated in blood, serum, or plasma. In certain cases, any of the approaches disclosed herein may involve the detection of ctDNA in plasma. In other cases, ctDNA may be evaluated in non-blood samples, such as cerebrospinal fluid, saliva, sputum, pleural fluid, urine, feces, or semen.
[0237] ctDNA can be extracted from biological samples using any suitable approach. For example, blood can be collected in EDTA tubes and / or cell-stabilized tubes (e.g., Steck tubes). The blood can be processed within a suitable time frame from collection from the patient (e.g., within about 2 hours for EDTA tubes or within about 4 hours for cell-stabilized tubes (e.g., Steck tubes)).
[0238] As one non-limiting example, ctDNA can be extracted as described in Reinert et al. JAMA Oncol. 5(8):1124-1131, 2019. Briefly, blood samples can be processed within two hours of collection into EDTA tubing by first double centrifugation of blood at 3000 g for 10 minutes at room temperature, followed by centrifugation of plasma at 30000 g for 10 minutes. Plasma can be divided equally into 5 mL cryotubes and stored at -80°C. cfDNA can be extracted using the QIAamp® Circulating Nucleic Acid kit (Qiagen) and eluted into DNA Suspension Buffer (Sigma). cfDNA samples can be quantified, for example, using the QUANT-iT® High Sensitivity dsDNA Assay Kit (Invitrogen) or using a fluorometer (e.g., QUBIT® fluorometer). Other approaches for extracting ctDNA are known in the art.
[0239] In some cases, ctDNA can be detected using PCR-based approaches, hybridization-based approaches, methylation-based approaches, or fragment mix approaches.
[0240] In some cases, ctDNA can be detected using PCR-based approaches, such as digital PCR (dPCR) (e.g., digital droplet PCR (ddPCR) or beaming dPCR). For example, PCR-based approaches may include the detection of one or more mutations associated with cancer (e.g., urothelial carcinoma) by sequencing (e.g., next-generation sequencing) or mass spectrometry. PCR-based approaches may be targeted or untargeted. PCR-based approaches may include the detection of somatic variants in a panel of cancer-related genes, e.g., a panel containing 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 325, 350, 375, 400 or more genes. Exemplary PCR-based approaches include personalized ctDNA multiplexed polymerase chain reaction (mPCR) approaches, TAM-SEQ®, and Safe-Seq.
[0241] In certain cases, a personalized ctDNA multiplexed polymerase chain reaction (mPCR) approach may be used to detect ctDNA. In some cases, a personalized ctDNA mPCR approach includes one or more (e.g., 1, 2, 3, or all 4) of the following steps: (a) (i) sequencing DNA obtained from a tumor sample obtained from a patient to generate tumor sequence reads; and (ii) sequencing DNA obtained from a normal tissue sample obtained from a patient to generate normal sequence reads; (b) identifying one or more patient-specific variants by calling somatic variants identified from tumor sequence reads and excluding germline variants and / or CHIP variants, wherein the germline variants or CHIP variants are identified from normal sequence reads or from publicly available databases; (c) designing an mPCR assay for the patient to detect a set of patient-specific variants; and (d) analyzing a biological sample obtained from the patient using the mPCR assay to determine whether ctDNA is present in the biological sample. In some cases, sequencing is WES or WGS. In some cases, sequencing is WES. In some cases, patient-specific variants are SNVs or short indels. In some cases, patient-specific variants are SNVs. In some cases, the set of patient-specific variants contains at least two patient-specific variants (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100 or more). In some cases, the set of patient-specific variants contains at least one patient-specific variant.In some examples, the patient-specific variant set contains at least two patient-specific variants. In some examples, the patient-specific variant set contains at least eight patient-specific variants. In some examples, the patient-specific variant set contains 2 to 200 patient-specific variants. In some examples, the patient-specific variant set contains 8 to 50 patient-specific variants. In some examples, the patient-specific variant set contains 8 to 32 patient-specific variants. In some examples, the patient-specific variant set contains 16 patient-specific variants. In some examples, analyzing a biological sample obtained from a patient using an mPCR assay involves sequencing the amplicons produced by the mPCR assay to identify patient-specific variants in the biological sample. In some examples, the presence of at least one patient-specific variant in the biological sample identifies the presence of ctDNA in the biological sample. In some cases, the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more patient-specific variants in a biological sample identifies the presence of ctDNA in the biological sample. In certain cases, the presence of two patient-specific variants in a biological sample identifies the presence of ctDNA in the biological sample. In some cases, the presence of 0 or 1 patient-specific variants in a biological sample indicates that ctDNA is not present in the biological sample.
[0242] In some cases, the personalized ctDNA mPCR approach is the Natera SIGNATERA® ctDNA test or the ArcherDx Personalized Cancer Monitoring (PCM®) test. In some cases, the personalized ctDNA mPCR approach may be as described in one or more of U.S. Patents 10,538,814; 10,557,172; 10,590,482; and / or 10,597,708.
[0243] In other examples, ctDNA can be detected using hybridization capture-based approaches, such as personalized cancer profiling by deep sequencing (CAPP-Seq) (e.g., Newman et al. Nat. Med. 20(5):548-554, 2014) or integrated digital error suppression (iDES) CAPP-Seq (e.g., Newman et al. Nat. Biotechnol. 34(5):547-555, 2016).
[0244] In other examples, ctDNA may be detected using methylation or fragment mix approaches (e.g., Guardant LUNAR assay, GRAIL assay, Freenome assay, or cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) (see, e.g., Nuzzo et al. Nature Med. 26:1041-1043, 2020)). Methylation-based approaches may include, for example, whole-genome bisulfite sequencing approaches or targeted methylation assays. In some examples, methylation approaches include targeted methylation assays such as the GRAIL assay (see, e.g., Liu et al. Annals Oncol. 31(6):745-759, 2020). In some examples, methylation-based approaches may also provide primary tissue information (see, e.g., Liu et al. ibid. and Guo et al. Nat. Genet. 49(4):635-642, 2017).
[0245] Evaluation of VI.TMB Methods for treating urothelial carcinoma (e.g., MIUC) in a patient are provided herein, comprising administering to the patient a therapeutic regimen comprising a PD-1 axis-coupled antagonist (e.g., atezolizumab), which includes determining a tTMB score in a sample obtained from the patient. Related compositions for use (e.g., pharmaceutical compositions), kits, and products are also provided. Any of the methods, compositions for use, kits, or products described herein may include any suitable approach for determining the tTMB score. For example, the tTMB score may be determined by using whole exome sequencing, whole genome sequencing, or by using a targeted panel (e.g., a FOUNDATIONONE® panel). For example, in some cases, WES may be used to design a personalized mPCR assay for detecting ctDNA and to determine the patient's tTMB score. In some aspects, the tTMB score may be determined as disclosed in International Patent Application Publication PCT / US2017 / 055669, which is incorporated herein by reference in its entirety. In other contexts, a bTMB score may be determined from a blood sample obtained from a patient. Any suitable approach may be used to determine a patient's bTMB score. For example, in some contexts, a bTMB score may be determined as described in International Patent Application Publication PCT / US2018 / 043074, which is incorporated herein by reference in its entirety.
[0246] In some cases, tumor samples obtained from patients have been determined to have a tissue tTMB score equal to or greater than the baseline tTMB score. Any appropriate baseline tTMB score may be used.
[0247] In some cases, the baseline tTMB score is the tTMB score in a baseline population of individuals with urothelial carcinoma, the population of individuals consisting of a first subset of individuals who have been treated with PD-1 axis-linked antagonist therapy and a second subset of individuals who have either (i) never been treated or (ii) have been treated with non-PD-L1 axis-linked antagonist therapy that does not include a PD-L1 axis-linked antagonist. In some cases, the baseline tTMB score significantly divides each of the first and second subsets of individuals based on a significant difference in responsiveness to PD-L1 axis-linked antagonist therapy compared to responsiveness to (i) treatment in the absence of treatment or (ii) non-PD-L1 axis-linked antagonist therapy. Responsiveness may be in relation to improved ORR, CR rate, pCR rate, PR rate, improved survival (e.g., DFS, DSS, metastasis-free survival, PFS, and / or OS), improved DOR, improved time to decline in function and QoL, and / or ctDNA elimination. Improvements (e.g., in relation to objective response rate (e.g., ORR, CR, and / or PR), survival (e.g., DFS, DSS, metastasis-free survival, PFS, and / or OS), DOR, improved time to decline in function and QoL, and / or ctDNA elimination) may be compared to an appropriate standard, e.g., observation or standard treatment (e.g., treatment without a PD-1 axis-binding antagonist (e.g., placebo)). In some cases, improvements (e.g., in relation to objective response rate (e.g., ORR, CR, and / or PR), survival (e.g., DFS, DSS, metastasis-free survival, PFS, and / or OS) or DOR) may be compared to observation.
[0248] In some cases, the baseline tTMB score is a pre-assigned tTMB score. In some cases, the baseline tTMB score is between approximately 5 and approximately 100 mutations per Mb (mut / Mb), e.g., approximately 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 4 8, approximately 49, approximately 50, approximately 51, approximately 52, approximately 53, approximately 54, approximately 55, approximately 56, approximately 57, approximately 58, approximately 59, approximately 60, approximately 61, approximately 62, approximately 63, approximately 64, approximately 65, approximately 66, approximately 67, approximately 68, approximately 69, approximately 70, approximately 71, approximately 72, approximately 73, approximately 74, approximately 75, approximately 76, approximately 77, approximately 78, approximately 79, approximately 80, approximately 81, approximately 82, approximately 83, approximately 84, approximately 85, approximately 86, approximately 87, approximately 88, approximately 89, approximately 90, approximately 91, approximately 92, approximately 93, approximately 94, approximately 95, approximately 96, approximately 97, approximately 98, approximately 99 or approximately 100 mut / Mb. For example, in some cases, the baseline tTMB score is between approximately 8 mut / Mb and approximately 30 mut / Mb (e.g., approximately 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or approximately 30 mut / Mb). In some cases, the baseline tTMB score is between approximately 10 mut / Mb and approximately 20 mut / Mb (e.g., approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or approximately 20 mut / Mb). In a particular case, the baseline tTMB score could be 10 mut / Mb, 16 mut / Mb, or 20 mut / Mb. In certain cases, the baseline tTMB score may be 10mut / Mb. The baseline tTMB score may be a tTMB value equivalent to any of the pre-assigned tTMB scores mentioned above.
[0249] In some cases, tumor samples from patients have a tTMB score of approximately 5 mut / Mb or higher. For example, in some cases, the tTMB score from tumor samples is between approximately 5 mut / Mb and approximately 100 mut / Mb (for example, approximately 5, approximately 6, approximately 7, approximately 8, approximately 9, approximately 10, approximately 11, approximately 12, approximately 13, approximately 14, approximately 15, approximately 16, approximately 17, approximately 18, approximately 19, approximately 20, approximately 21, approximately 22, approximately 23, approximately 24, approximately 25, approximately 26, approximately 27, approximately 28, approximately 29, approximately 30, approximately 31, approximately 32, approximately 33, approximately 34, approximately 35, approximately 36, approximately 37, approximately 38, approximately 39, approximately 40, approximately 41, approximately 42, approximately 43, approximately 44, approximately 45, approximately 46, approximately 47, approximately This is approximately 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 mut / Mb). In some cases, tumor samples from patients have a tTMB score of approximately 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 mut / Mb or higher. For example, in some cases, tumor samples from patients have a tTMB score of approximately 10 mut / Mb or higher. In some embodiments, the baseline tTMB score is 10 mut / Mb. In some cases, the tTMB score from tumor samples is between approximately 10 mut / Mb and 100 mut / Mb. In some cases, the tTMB score from tumor samples is between approximately 10 mut / Mb and 20 mut / Mb. In some cases, tumor samples from patients have a tTMB score of approximately 16 mut / Mb or higher.In some cases, tumor samples from patients have a tTMB score of approximately 16 mut / Mb or higher, with a baseline tTMB score of 16 mut / Mb. In other cases, tumor samples from patients have a tTMB score of approximately 20 mut / Mb or higher. In some cases, tumor samples from patients have a tTMB score of approximately 20 mut / Mb or higher, with a baseline tTMB score of approximately 20 mut / Mb.
[0250] In some cases, the tTMB score or baseline tTMB score is expressed as the number of counted somatic mutations per a specified number of sequenced bases. For example, in some cases, the specified number of sequenced bases is between approximately 100kb and approximately 10Mb. In some cases, the specified number of sequenced bases is approximately 1.1Mb (e.g., approximately 1.125Mb), as evaluated by, for example, a FOUNDATIONONE® panel. In some cases, the tTMB score or baseline tTMB score is an equivalent TMB value. In some cases, the equivalent TMB value is determined by WES. In other cases, the equivalent TMB value is determined by WGS.
[0251] In some cases, the test covers approximately 300 genes (for example, at least approximately 300 to approximately 400 genes, e.g., approximately 300) that cover at least approximately 0.05 Mb to approximately 10 Mb (e.g., 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Mb). The coding regions (a diverse set of 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400 genes) are simultaneously sequenced to a typical median depth of at least approximately 500x (e.g., 500x, 550x, 600x, 650x, 700x, 750x, 800x, 850x, 900x, 950x, or 1,000x) of exon coverage. In other examples, the test simultaneously sequences the coding regions of approximately 400 genes, approximately 425 genes, approximately 450 genes, approximately 475 genes, approximately 500 genes, approximately 525 genes, approximately 550 genes, approximately 575 genes, approximately 600 genes, approximately 625 genes, approximately 650 genes, approximately 675 genes, approximately 700 genes, approximately 725 genes, approximately 750 genes, approximately 775 genes, approximately 800 genes, approximately 825 genes, approximately 850 genes, approximately 875 genes, approximately 900 genes, approximately 925 genes, approximately 950 genes, approximately 975 genes, approximately 1000 genes, or more than 1000 genes. In some examples, the set of genes is a set of genes from the FOUNDATIONONE® panel (see, for example, Frampton et al. Nat. Biotechnol. 31:1023-31, 2013, which is incorporated herein by reference in its entirety). In some examples, the set of genes is a set of genes from the FOUNDATIONONE® CDx panel.In some embodiments, the test sequence is greater than approximately 10 Mb of the individual's genome, for example, greater than approximately 10 Mb, greater than approximately 15 Mb, greater than approximately 20 Mb, greater than approximately 25 Mb, greater than approximately 30 Mb, greater than approximately 35 Mb, greater than approximately 40 Mb, greater than approximately 45 Mb, greater than approximately 50 Mb, greater than approximately 55 Mb, greater than approximately 60 Mb, greater than approximately 65 Mb, greater than approximately 70 Mb, greater than approximately 75 Mb, greater than approximately 80 Mb, greater than approximately 85 Mb, greater than approximately 90 Mb, greater than approximately 95 Mb, greater than approximately 100 Mb, greater than approximately 200 Mb, greater than approximately 300 Mb, greater than approximately 400 Mb, greater than approximately 500 Mb, greater than approximately 600 Mb, greater than approximately 700 Mb, greater than approximately 800 Mb, greater than approximately 900 Mb, greater than approximately 1 Gb, greater than approximately 2 Gb, greater than approximately 3 Gb, or about 3.3 Gb. In some cases, the test simultaneously sequences the coding regions of 315 cancer-related genes, as well as introns from 28 genes that are frequently rearranged or modified in cancer, to a typical median coverage depth of over 500-fold. In some cases, each covered sequencing read corresponds to a unique DNA fragment, enabling highly sensitive and specific detection of genomic modifications that occur infrequently due to tumor heterogeneity, low tumor purity, and small tissue samples. In other cases, the presence and / or level of somatic mutations is determined by WES. In some cases, the presence and / or level of somatic mutations is determined by WGS.
[0252] A patient's tTMB score may be determined based on the number of somatic changes in tumor samples obtained from the patient. In some cases, the somatic changes are silent mutations (e.g., synonymous changes). In other cases, the somatic changes are non-synonymous SNVs. In other cases, the somatic changes are passenger mutations (e.g., changes that do not have a detectable effect on clonal fitness). In some cases, the somatic changes are variants of unknown significance (VUS), e.g., changes whose pathogenicity cannot be confirmed or ruled out. In some cases, the somatic changes have not been identified as being related to the cancer phenotype.
[0253] In some cases, somatic changes are not associated with, or are not known to be associated with, effects on cell division, proliferation, or survival. In other cases, somatic changes are associated with effects on cell division, proliferation, or survival.
[0254] In some cases, the number of somatic changes excludes functional changes within the subgenome range.
[0255] In some cases, a functional change is a change that affects (e.g., promotes) cell division, proliferation, or survival compared to a reference sequence (e.g., a wild-type or non-mutant sequence). In some cases, a functional change is identified by its inclusion in a database of functional changes, e.g., the COSMIC database (see Forbes et al. Nucl. Acids Res. 43(D1):D805-D811, 2015, which is incorporated herein by reference in its entirety). In other cases, a functional change is a change that has a known functional state (e.g., exists as a known somatic change in the COSMIC database). In some cases, a functional change is a change that is likely to have a functional state (e.g., truncation in a tumor suppressor gene). In some cases, a functional change is a driver mutation (e.g., a change that gives a selective advantage to a clone in its microenvironment by increasing cell survival or replication). In other cases, a functional change is a change that can cause the expansion and proliferation of a clone. In some cases, a functional change is a change that can cause one, two, three, four, five, or all six of the following: (a) self-sufficiency in proliferation signaling; (b) decreased, e.g., insensitivity to anti-proliferative signaling; (c) decreased apoptosis; (d) increased replication capacity; (e) persistent angiogenesis; or (f) tissue invasion or metastasis.
[0256] In some examples, the functional change is not a passenger mutation (e.g., not a change that has a detectable effect on the fitness of a cell clone). In some examples, the functional change is not a variant of unknown significance (VUS) (e.g., not a change for which its pathogenicity cannot be confirmed or excluded).
[0257] In some examples, multiple (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more) functional changes in preselected tumor genes in a pre-determined set of genes are excluded. In some examples, all functional changes in preselected genes (e.g., tumor genes) in a pre-determined set of genes are excluded. In some examples, multiple functional changes in multiple preselected genes (e.g., tumor genes) in a pre-determined set of genes are excluded. In some examples, all functional changes in all genes (e.g., tumor genes) in a pre-determined set of genes are excluded.
[0258] In some examples, the number of somatic changes excludes germline mutations within the subgenome range.
[0259] In some examples, the germline change is a SNP, base substitution, insertion, deletion, indel or silent mutation (e.g., synonymous mutation).
[0260] In some cases, germline changes are excluded by using methods that do not use a comparison to the corresponding normal sequence. In other cases, germline changes are excluded by methods that include the use of algorithms. In some cases, germline changes are so identified by being included in a database of germline changes, such as the dbSNP database (see Sherry et al. Nucleic Acids Res. 29(1):308 - 311, 2001, which is incorporated herein by reference in its entirety). In other cases, germline changes are so identified by being included in two or more counts in the ExAC database (see Exome Aggregation Consortium et al. bioRxiv preprint, October 30, 2015, which is incorporated herein by reference in its entirety). In some cases, germline changes are so identified by being included in the 1000 Genome Project database (see McVean et al. Nature 491, 56 - 65, 2012, which is incorporated herein by reference in its entirety). In some cases, germline changes are so identified by being included in the ESP database (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA).
[0261] VII. Pharmaceutical Compositions and Formulations Also provided herein are pharmaceutical compositions and formulations that include a PD - 1 axis - binding antagonist (e.g., atezolizumab) and optionally include a pharmaceutically acceptable carrier.
[0262] The pharmaceutical compositions and formulations described herein may be prepared, for example, in the form of lyophilized formulations or aqueous solutions, by mixing an active ingredient having a desired purity (e.g., a PD-1 axially coupled antagonist) with one or more optionally included pharmaceutically acceptable carriers (see, for example, Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)).
[0263] An exemplary atezolizumab formulation contains glacial acetic acid, L-histidine, polysorbate 20, and sucrose, with a pH of 5.8. For example, atezolizumab may be supplied in a 20 mL vial containing 1200 mg of atezolizumab formulated in glacial acetic acid (16.5 mg), L-histidine (62 mg), polysorbate 20 (8 mg), and sucrose (821.6 mg), with a pH of 5.8. In another example, atezolizumab may be supplied in a 14 mL vial containing 840 mg of atezolizumab formulated in glacial acetic acid (11.5 mg), L-histidine (43.4 mg), polysorbate 20 (5.6 mg), and sucrose (575.1 mg), with a pH of 5.8.
[0264] VIII. Products or Kits In another context, products or kits comprising a PD-1 axially coupled antagonist (e.g., atezolizumab) are provided herein. In some examples, the product or kit further includes a package insert containing instructions for using the PD-1 axially coupled antagonist to treat or delay the progression of urothelial carcinoma in a patient. In some examples, the product or kit further includes a package insert containing instructions for using the PD-1 axially coupled antagonist in combination with one or more additional therapeutic agents to treat or delay the progression of urothelial carcinoma in a patient. Any of the PD-1 axially coupled antagonists and / or any additional therapeutic agents described herein may be included in the product or kit.
[0265] In some examples, the PD-1 axially coupled antagonist and any additional therapeutic agents are contained in the same container or in separate containers. Suitable containers include, for example, bottles, vials, bags, and syringes. Containers may be formed from a variety of materials such as glass, plastic (e.g., polyvinyl chloride or polyolefin), or metal alloy (e.g., stainless steel or Hastelloy). In some examples, the container holds the formulation, and labels on or associated with the container may indicate instructions for use. The product or kit may further include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, and accompanying documentation with instructions for use. In some examples, the product further includes one or more other active ingredients (e.g., additional chemotherapeutic agents or antineoplastic agents). Suitable containers for one or more active ingredients include, for example, bottles, vials, bags, and syringes.
[0266] Either the product or the kit may include instructions for administering a PD-1 axially coupled antagonist and / or any additional therapeutic agent to a patient in accordance with any of the methods described herein, for example, any of the methods described in Section II above.
[0267] In another context, the Product is provided herein, comprising a PD-1 axially coupled antagonist and instructions for administering the PD-1 axially coupled antagonist for the treatment of urothelial carcinoma in a patient requiring treatment for urothelial carcinoma, wherein the treatment comprises the administration of an effective dose of a therapeutic regimen comprising the PD-1 axially coupled antagonist, the therapeutic regimen being an adjuvant therapy, and the patient has been identified as likely to benefit from the therapeutic regimen based on the presence of ctDNA in a biological sample obtained from the patient.
[0268] In another aspect, the Product is provided herein, comprising a PD-1 axially coupled antagonist and instructions for administering the PD-1 axially coupled antagonist for the treatment of urothelial carcinoma in a patient requiring treatment for urothelial carcinoma, wherein the treatment comprises (a) determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen comprising the PD-1 axially coupled antagonist; and (b) administering to the patient an effective amount of a treatment regimen comprising the PD-1 axially coupled antagonist, based on the presence of ctDNA in the biological sample, the treatment regimen being an adjuvant therapy.
[0269] In another aspect, a product is provided herein comprising a PD-1 axis-binding antagonist and instructions for administering the PD-1 axis-binding antagonist for the treatment of a patient having urothelial carcinoma who has been administered at least a first dose of a therapeutic regimen comprising the PD-1 axis-binding antagonist, wherein the therapeutic regimen is a neoadjuvant therapy or an adjuvant therapy, and the ctDNA was present in a biological sample obtained from the patient prior to or concurrently with the first dose of the therapeutic regimen. In some embodiments, the therapeutic regimen is a neoadjuvant therapy. In other embodiments, the therapeutic regimen is an adjuvant therapy.
[0270] Examples Example 1: Clinical outcomes in patients with ctDNA-positive urothelial carcinoma treated with adjuvant immunotherapy Historically, despite advances in tumor staging, radiographic imaging, and tissue-based prognostic biomarkers, determining postoperatively which patients have residual disease and which are cured has been challenging. As a result, many surgically cured patients are unnecessarily exposed to the toxicity of adjuvant therapy, and other patients with residual disease may not receive additional treatment until disease progression becomes detectable by imaging (potentially missing the opportunity to receive timely adjuvant therapy aimed at cure). Detection of ctDNA immediately after surgical resection may overcome these limitations by enabling early identification of patients with minimal residual disease (MRD) at the highest risk of radiographic recurrence. Whether the MRD status assessed by ctDNA can identify which patients are likely to benefit from adjuvant therapy and which are likely to be exempt from additional treatment has not yet been investigated in a randomized setting.
[0271] This example describes the results of IMvigor010 (NCT02450331), a global, open-label, randomized phase III trial of atezolizumab as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) of either the bladder or upper urinary tract. IMvigor010 did not demonstrate significant disease-free survival (DFS) or overall survival (OS) benefits in unselected patients. Therefore, this presented an ideal situation for investigating whether patients with ctDNA-mediated MRD(+) who are at high risk of relapse can obtain clinical benefit from adjuvant therapy with immune checkpoint inhibitors (e.g., PD-1 axis-binding antagonists such as atezolizumab).
[0272] A. Objectives and evaluation items i. Primary effectiveness objectives The primary efficacy objective of this study was to evaluate the efficacy of atezolizumab adjuvant therapy compared to observation in MIUC, based on disease-free survival (DFS) defined as local (pelvic) or urinary tract recurrence, distant UC metastasis, or death from any cause.
[0273] ii. Secondary effectiveness objectives A secondary efficacy objective of this study was to evaluate the efficacy of atezolizumab adjuvant therapy compared to observation in MIUC, based on overall survival (OS), defined as the time from randomization to death from any cause.
[0274] iii. Exploratory effectiveness objectives The prospective exploratory objective for this study was to evaluate the usefulness of ctDNA in identifying patients who may benefit from atezolizumab treatment. ctDNA was measured at the start of treatment (C1D1) and at 9 weeks (C3D1).
[0275] B. Research Design IMvigor010 was a global, open-label, randomized, controlled phase III study designed to evaluate the efficacy and safety of atezolizumab adjuvant therapy compared to observation in 809 MIUC patients at high risk of recurrence after resection. The primary endpoint was investigator-assessed disease-free survival (DFS), defined as the time from randomization to recurrence or death from invasive urothelial carcinoma.
[0276] Patients were randomized in a 1:1 ratio to either the atezolizumab group or the observation group. Treatment with atezolizumab (1200 mg every 3 weeks) was administered for one year or until UC relapse or unacceptable toxicity (or patients were observed). Imaging assessments for disease relapse were performed at baseline, every 12 weeks at 3 years, every 24 weeks at 4–5 years, and at 6 years. Disease relapse assessments in the observation group followed the same schedule as in the atezolizumab group. This study enrolled 809 patients (406 in atezolizumab and 403 in observation). 581 patients were included in the ctDNA C1D1 biomarker evaluable population (BEP, 72% of the intention-to-treat (ITT) population).
[0277] Crossover between the atezolizumab group and the observational group was not permitted.
[0278] Tumor tissues were collected from surgical resection specimens, preferably formalin-fixed paraffin-embedded (FFPE) tissue blocks (n = 138), followed by unstained FFPE tissue slides for storage (n = 443). Central evaluation of PD-L1 expression was performed using the VENTANA SP142 IHC assay. Tumors were classified as PD-L1-expressing (IC2 / 3 state) if PD-L1-expressing tumor infiltrating immune cells occupied more than 5% of the tumor area.
[0279] C. Materials and Methods i. Patients A total of 809 patients were enrolled in the IMvigor010 study (406 with atezolizumab and 403 under observation). 581 patients were included in ctDNA C1D1 BEP (72% of the ITT population).
[0280] ii. Inclusion Criteria The inclusion criteria required that patients be at high risk according to pathological staging (pT3 - T4a or N+ for patients not treated with neoadjuvant chemotherapy, or pT2 - T4a or N+ for patients treated with neoadjuvant chemotherapy). Patients had to have undergone surgical resection with lymph node dissection (cystectomy or ureterectomy), and according to postoperative negative imaging, there was no evidence of residual disease or metastasis.
[0281] iii. Study Treatments Treatment with atezolizumab (1200 mg every 3 weeks) was administered for 1 year or until UC recurrence or unacceptable toxicity (or patients were under observation). Imaging evaluations for disease recurrence were performed at baseline and every 12 weeks for 3 years, every 24 weeks in the 4th - 5th years, and at 6 years. Disease recurrence evaluations for patients in the observation group followed the same schedule as the atezolizumab group. Crossover between the atezolizumab group and the observation group was not allowed.
[0282] iv. Interim Analysis The median follow-up period was 21.9 months (calculated using the reverse Kaplan-Meier approach), ranging from 16 to 45 months. At the data cutoff, OS follow-up was not mature and was progressing in the ITT population. In the interim analysis, median OS was not reached; 118 patients (29.1%) in the atezolizumab group and 124 patients (30.8%) in the observation group died. 33.3% and 29.6% of patients with relapsed cancer received subsequent cancer treatment in the atezolizumab and observation groups, respectively. This included chemotherapy in 25.6% and 24.3% and immunotherapy in 8.6% and 20.3% respectively, corresponding to the expected treatment pattern for first-line progressive disease.
[0283] v. Blood collection and processing Plasma time points for day 1 of cycle 1 (C1D1) were collected at a median of 79 days post-surgical resection (IQR 65-92 days for MIBC patients), but these did not correlate with ctDNA levels (Figures 16A-16D). Since patients with upper urinary tract UC often undergo two surgeries, collection time analysis was performed only for patients with MIBC. Peripheral blood mononuclear cells (PBMCs) were collected in three 8.5 mL ACD tubes at the beginning of C1D1, and peripheral blood plasma was collected in two 6 mL EDTA tubes at the beginning of C1D1 and C3D1. Plasma was separated from the cell pellet within 30 minutes of collection and divided into fixed volumes for storage at -80°C. The Natera assay used in this study has been confirmed on frozen plasma using centrifuged and precipitated K2-EDTA collected blood samples within 2 hours of collection; however, it should be noted that the clinical version of this assay utilizes Streck collection tubes to stabilize cfDNA and allow for ambient transport within 7 days. A total of 1076 plasma samples (581 from C1D1 and 495 from C3D1) from 591 patients were used in this analysis, with a median plasma volume of 3.7 mL (IQR 3.2–4.2 mL) and 21.5 ng of extracted cfDNA per patient (IQR 13.2–34.2 ng). cfDNA extraction and library preparation steps were performed to identify ctDNA in patient plasma (see, e.g., Reinert et al. JAMA Oncol. 5(8):1124-31 (2019)).
[0284] co. Tumor tissue processing Tumor tissue was collected from surgically resected specimens, with formalin-fixed paraffin-embedded (FFPE) tissue blocks preferred (n=138), followed by unstained FFPE tissue slides for storage (n=443). Genomic DNA was extracted using the QIAamp® DNA FFPE Tissue Kit. Central evaluation of PD-L1 expression was performed using the VENTANA SP142 IHC assay. Tumors were classified as PD-L1 expressing (IC2 / 3 state) if PD-L1-expressing tumor-infiltrating immune cells accounted for 5% or more of the tumor area.
[0285] vii. Whole exome sequencing of tumor tissue and corresponding normal DNA For both tumor and normal sources, a median of 500 ng of genomic DNA (gDNA) was used for the whole exome sequencing workflow. Library preparation based on the Illumina-adapter was performed on this gDNA. Targeted exome capture was then performed using a custom capture probe set targeting approximately 19,500 genes. These targeted libraries were sequenced at 2 × 100 bp on the NovaSeq® platform to achieve 180-fold deduplication-free on-target mean coverage for tumor tissue and 50-fold for the corresponding normal samples. FastQ files were prepared using bcl2fastq2 and quality was verified using FastQC. Reads were mapped to the human reference genome hg19 using the Burrows-Wheeler Alignment tool (v.0.7.12) and quality was verified using Picard and MultiQC.
[0286] viii. Design of somatic cell variant calling and SIGNATERA® ctDNA assay Somatic variant calling was performed using a consensus variant calling method developed by Natera, with tumor tissue and corresponding normal sequencing data as input. Variants previously reported as germline in public datasets (1000 Genome Project, ExAC, ESP, dbSNP) were excluded, as were other collectibles. Paired WES data from tumors and corresponding normals were first analyzed for quality criteria and sample matching, and then processed through a bioinformatics pipeline enabling the identification of putative clonal somatic single nucleotide variants. Corresponding normal sequencing was performed to computationally remove putative germline and clonal hematopoiesis with undetermined potential mutations. A prioritized list of variants was used to design PCR amplicons based on optimized design parameters from a candidate pool of putative clonal variants specific to each patient's tumor DNA, ensuring specificity in the human genome, amplicon efficiency, and primer interactions. The tumor mutational load (TMB) was calculated as the total number of somatic mutations per megabase of captured exomes. TMB-positive patients were those with 10 mutations / Mb or greater (average of ctDNA BEP).
[0287] Following plasma cfDNA extraction and library preparation, multiplexed targeted PCR was performed on a fixed volume of the cfDNA library, followed by amplicon-based sequencing on an Illumina platform to achieve an average next-generation sequencing depth of over 100,000x per amplicon. Patients were considered ctDNA-positive if at least two or more mutations were observed in their plasma (Coombes et al. Clin Cancer Res. 25(14):4255-4263 (2019)). ctDNA(+) samples further reported sample mean tumor molecules per mL of plasma (sample MTM / mL), which is the average tumor molecule across all variants meeting the QC requirements per mL of plasma. As previously published, analytical studies of the Natera SIGNATERA® assay demonstrated high specificity and sensitivity exceeding 95% at a variant allele frequency of 0.01% (Coombes et al. Clin Cancer Res. 25(14):4255-4263 (2019)). The time required for the SIGNATERA® assay is (i) 2-3 weeks for the initial plasma sample, including tissue WES, assay design, and plasma ctDNA analysis / reporting, and (ii) 1 week for all subsequent plasma processing and ctDNA analysis / reporting.
[0288] ix. RNA treatment Microdissection of tumor regions was performed on formalin-fixed paraffin-embedded (FFPE) tissue using hematoxylin and eosin (H&E) as guides. RNA was extracted using the High Pure FFPET RNA Isolation Kit (Roche) and evaluated for quantity and quality using Qubit and Agilent Bioanalyzer. First-strand cDNA synthesis was initiated from total RNA using random primers, and then second-strand cDNA was generated using dUTP instead of dTTP in the master mix to facilitate the preservation of strand information. The library was enriched for the mRNA fraction by positive selection using a cocktail of biotinylated oligonucleotides corresponding to the coding regions of the genome. The library was sequenced using Illumina sequencing.
[0289] x. Generation and processing of RNA-seq data A complete transcriptome profile was created using TruSeq® RNA Access technology (Illumina). First, to remove ribosome reads, RNA-seq reads were aligned to ribosomal RNA sequences. The remaining reads were aligned to the human reference genome (NCBI Build 38) using GSNAP (Wu and Nacu. Bioinformatics. 26(7):873-881 (2010); Wu et al. Methods Mol Biol. 1418:283-334 (2016)) version 2013-10-10, allowing a maximum of two mismatches per 75 base pairs (parameters: '-M 2-n 10-B 2-i 1-N 1-w 200000-E 1-pairmax-rna=200000-clip-overlap'). To quantify gene expression levels, the number of reads mapped to the exons of each RefSeq gene was calculated using the functionality provided by the R / Bioconductor package GenomicAlignment. Raw counts were adjusted for gene length using transcripts per million (TPM) normalization, followed by log2 transformation. For N=728 patients for whom RNA-seq data was available, both raw and processed data were available under data sharing agreements. All analyses in this study used N=573 patients for whom both RNA-seq and ctDNA data were available.
[0290] xi. Unsupervised mRNA expression clustering TCGA subtypes were assigned according to a previously described method (Robertson et al. Cell. 171(3):540-556.e25(2017)). In summary, RNA expression data for samples were normalized using trimmed mean normalization of M values, transformed with voom, and log2 counts per million were obtained with relevant precision weights. The top 25% most variable genes were selected, ranked by standard deviation across all samples examined. Consensus clustering was performed, centering the 4660 genes by the median log2-normalized expression before classifying the samples into five clusters. Expression clustering analysis was performed using element C. ij This was performed using a consensus hierarchical clustering approach with a 1-C distance matrix representing the Spearman correlation between samples i and j across 4660 genes in R. The consensus matrix M K The clusters (K=5, where K=5 is the number of clusters) were calculated by iterating standard hierarchical clustering (K×500) using the mean linkage option and 80% resampling in the sample space. The clustering reproduced five distinct clusters, as reported in Robertson et al. Cell171(3):540-556.e25(2017), as indicated by the signatures shown on the heatmap.
[0291] xii. Gene Set Enrichment Analysis (GSEA) GSEA ranks all genes in a dataset based on differences in expression. After performing GSEA, competitive testing was conducted using the CAMERA enrichment method (Wu and Smyth. Nucleic Acids Res. 40(17):e133(2012)) to assess whether genes in a given set are highly ranked in terms of differences in expression compared to genes not present in the set. To identify enriched pathways, the Hallmark gene set collection from the Molecular Signature Database (Subramanian et al. Proc Natl Acad Sci US A102(43):15545-15550(2005)) was used. Pathways with adjusted P-values < 0.05 were included.
[0292] xiii.Statistical analysis Before deblinding clinical data for the primary trial analysis, a ctDNA statistical analysis plan (ctDNA SAP) was planned and finalized. The primary goals of the ctDNA study were to provide evidence that: 1) in ctDNA-positive patients at C1D1, atezolizumab provides improved DFS compared to the observation group; 2) the presence of ctDNA in plasma at C1D1 is associated with reduced DFS; 3) the presence of ctDNA in plasma at C3D1 is associated with reduced DFS; 4a) elimination of ctDNA in plasma up to C3D1 is associated with increased DFS; and 4b) elimination occurs at a higher rate in the atezolizumab group compared to the observation group. In this study, elimination was defined as the transition from ctDNA(+) at C1 to ctDNA(-) at C3 and was evaluated only in patients who were ctDNA(+) at C1. The primary analysis used a univariate approach with categorical ctDNA (ctDNA+ / -). Secondary objectives included ctDNA (sample mean tumor molecules per 1 mL of plasma) as a continuous variable, and a multivariate approach to adjust for known risk factors. Secondary endpoints included overall survival (OS), and secondary biomarkers included PD-L1, TMB, and molecular gene signatures from RNA-seq, which are clinical and pathological risk factors. Formal testing of OS as a secondary endpoint in IMvigor010 was not permitted due to the hierarchical study design. The analysis plan required significance assessment to the primary analysis to be performed at a level of p-value < 0.05. Bonferroni correction was applied to the p-values for the four pre-specified primary objectives (a total of five hypotheses).
[0293] Hazard ratios (HRs) for recurrence or death were estimated using a univariate Cox proportional hazards model. For completeness, (Tables 1, 2, and 7) we provide additional estimates for 1) a stratified Cox model using the same stratification factors as described for the IMvigor010 primary clinical analysis (lymph node status, PD-L1 status, and tumor stage), and 2) a multivariate Cox regression analysis adjusting for lymph node status, PD-L1 status, tumor stage, prior neoadjuvant chemotherapy, and the number of resected lymph nodes. All Cox models used an "exact" method to handle tied event times. DFS and OS were compared between treatment groups using the log-rank test, and the Kaplan-Meier method was applied to DFS and OS using 95% CIs constructed by Greenwood's formula. [Table 1] C1D1 ctDNA status based on C1D1 BEP. C3D1 ctDNA status based on C1 / C3 BEP. * In the ctDNA statistical analysis plan, a univariate Cox proportional hazards model was specified in advance. † A stratified Cox proportional hazards model was used for the primary analysis of IMvigor010. Stratification factors included lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), and tumor stage (≤pT2 or pT3 / 4). ‡ In the ctDNA statistical analysis plan, multivariate Cox proportional hazards regression analysis was pre-specified. Stratification factors included lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), tumor stage (≤pT2 or pT3 / 4), prior neoadjuvant chemotherapy (with or without), and number of lymph nodes (<10 or ≥10). [Table 2] * In the ctDNA statistical analysis plan, a univariate Cox proportional hazards model was specified in advance. †A stratified Cox proportional hazards model was used for the primary analysis of IMvigor010. Stratification factors included lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), and tumor stage (≤pT2 or pT3 / 4). ‡ In the ctDNA statistical analysis plan, multivariate Cox proportional hazards regression analysis was pre-specified. Stratification factors included lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), tumor stage (≤pT2 or pT3 / 4), prior neoadjuvant chemotherapy (with or without), and number of lymph nodes (<10 or ≥10).
[0294] Descriptive statistics were used to summarize clinical features, including mean, median, and range for continuous variables, and frequency and percentage for categorical variables. Fisher's exact test (two-tailed) was used to evaluate the comparison of ctDNA exclusion between groups. The association between ctDNA positivity and baseline prognostic factors was measured using the Kruskal-Wallis rank-sum test for numerical variables and Fisher's exact test (two-tailed) for categorical variables. The association between C1D1 collection time and ctDNA status in days after surgery was measured using the Wilcoxon test (two-tailed). All statistical analyses were performed in R.
[0295] xiv. ABACUS Test Design This clinical trial was not designed to be analyzed concurrently with IMvigor010. The clinical aspects of ABACUS have been previously published (Powles et al. Nat Med. 25(11):1706-1714 (2019)). This ctDNA analysis was exploratory. The methodology of the study is briefly summarized as follows: This study was an open-label, international, multicenter, phase II trial evaluating the efficacy of two cycles (1200 mg Q3W) of preoperative atezolizumab in patients with histologically confirmed (T2-T4a) urothelial bladder cancer awaiting planned cystectomy. The design endpoints and inclusion criteria have been previously published (Powles et al. Nat Med. 25(11):1706-1714 (2019)). In short, eligibility criteria included MIBC patients who had refused or were unable to receive cisplatin-based neoadjuvant chemotherapy, had no evidence of disease progression, had an ECOG performance status of 0 or 1, and possessed adequate end-organ function. Key exclusion criteria included prior use of immune checkpoint inhibitors and contraindications to immunotherapy or cystectomy. All patients provided written informed consent, including the exploratory biomarker endpoints described herein. This study was approved by the relevant institutional ethics committees of each participating center and conducted in accordance with the principles of good clinical trial standards, the provisions of the Declaration of Helsinki, and other applicable local regulations (NCT02662309). This study was sponsored by Queen Mary University, London. The Barts Experimental Cancer Centre Clinical Trials Group had overall responsibility for the administration and day-to-day conduct of the trial, which was overseen by an independent Data Monitoring Committee (IDMC). Newly arising safety data were periodically reviewed by the IDMC.
[0296] D. Results i.IMvigor010 ctDNA biomarker evaluable population A total of 809 patients were enrolled in the IMvigor010 study (406 in the atezolizumab group; 403 in the observation group), with a median follow-up of 21.9 months. 581 patients were included in the ctDNA C1D1 BEP group (72% of the ITT population), with a median follow-up of 23.0 months (Figure 1A). Baseline characteristics of the ctDNA BEP population were comparable and well-balanced between groups (Table 3), and survival outcomes were as described for DFS (HR=0.88 (0.70-1.11); p=0.2720) (Figure 1B) and OS (HR=0.89 (0.66-1.21)) (Figure 1C). [Table 3] * Based on VENTANA SP142 immunohistochemical assay. †85 patients had missing data. ‡109 patients had missing data.
[0297] In C1D1, 37% (214 / 581) of patients were found to be ctDNA(+). ctDNA positivity identified patients with a higher risk of disease recurrence (observational group DFS HR=6.3 (4.45-8.92); p<0.0001) and shorter OS (observational group HR=8.0 (4.92-12.99)) compared to ctDNA(-) (Figures 2B and 2D). The C1D1 ctDNA(+) population included 116 patients in the atezolizumab group and 98 patients in the observational group, and baseline characteristics, including immunobiomarkers, were well-balanced between the groups (Table 4). Repeated analyses using a multivariate approach yielded similar results (Table 1). Postoperative C1D1 collection time (median 79 days) was not associated with a higher proportion of ctDNA positivity or higher ctDNA levels (Figures 16A-16D). No difference was observed in data collection time between ctDNA-negative and ctDNA-positive patients (Wilcoxon p=0.18, two-sided). ctDNA positivity in C1D1 preceded clinical recurrence on radiographic imaging by a median of 4.3 months (range 0.7–32.3 months) (Figure 3). [Table 4] JPEG2023551906000007.jpg107170 * Based on a VENTANA SP142 immunohistochemical assay. NA, unavailable.
[0298] ii. ctDNA positivity in C1D1 was associated with improved DFS with atezolizumab compared to observation. Patients with C1D1 and ctDNA(+) had improved DFS with adjuvant atezolizumab compared to patients who were observed (HR=0.58(0.43-0.79); p=0.0024, median DFS 4.4 vs. 5.9 months) (Figure 4A). Similarly, this ctDNA(+) patient population had improved OS with atezolizumab compared to patients who were observed (HR=0.59(0.41-0.86); median OS 15.8 vs. 25.8 months) (Figure 4B). In patients with ctDNA-negative (ctDNA(-)) disease, there were no differences in DFS or OS between the groups (HR=1.14(0.81-1.62); and HR=1.31(0.77-2.23), respectively (median values were not reached in either group)). Repeated analyses using a multivariate approach yielded similar results (Table 2).
[0299] To assess whether other important baseline clinical factors drive these outcomes, exploratory analyses were performed on baseline features including lymph node status, tumor stage, prior neoadjuvant chemotherapy, PD-L1 status, and the number of resected lymph nodes. Univariate analysis in the biomarker-evaluable population did not identify any subgroups with improved outcomes to atezolizumab (Figures 5A–5C). Furthermore, by adjusting for these clinical features in multivariate analyses of DFS and OS, it was confirmed that ctDNA could independently identify patients with improved outcomes to atezolizumab (Tables 1, 2, and 6). Finally, subgroups within the ctDNA(+) population did not provide clear evidence that any single clinical feature drove the improved outcomes seen in ctDNA(+) patients (Figures 6A, 6B, 7A, and 7B).
[0300] To support the findings using a binary cutoff for ctDNA, continuous ctDNA evaluation criteria were also assessed as a secondary exploratory target. Higher thresholds for sample MTM / mL (mean tumor molecules per mL of plasma) did not identify groups with substantially higher risk of recurrence or death (Figures 13A-13F), suggesting that the presence of any ctDNA is more appropriate than total ctDNA loading for identifying high-risk patients.
[0301] iii. Improved DFS in ctDNA(+) / TMB(+) patients and ctDNA(+) / PD-L1(+) patients In biomarker studies, across all patients (regardless of ctDNA status), high TMB (TMB+) did not predict the DFS benefit from atezolizumab (HR=0.84 (0.55~1.28)) (Figures 8A, 9A, and 9B). However, ctDNA(+) / TMB(+) patients showed an improved DFS hazard ratio compared to ctDNA(+) / TMB(-) (HR=0.72 (0.50~1.04)) (HR=0.34 (0.19~0.6)) (Figure 8B). Similar findings were observed not only when OS was measured in the same population (ctDNA(+) / TMB(+)HR=0.47 (0.22~0.99) vs. ctDNA(+) / TMB(-)HR=0.63 (0.4~0.97)) (Figures 8C and 8D), but also when a multivariate approach was used.
[0302] Similarly, high PD-L1 (PD-L1+) status did not enhance DFS benefits in biomarker study populations (unrelated to ctDNA status) (HR=1.09 (0.76~1.56)) (Figures 8E, 10A, and 10B). However, ctDNA(+) / PD-L1(+) showed an improved DFS hazard ratio (HR=0.52 (0.33~0.82)) compared to ctDNA(+) / PD-L1(-) (HR=0.70 (0.46~1.06)) (Figure 8F). Similar findings were observed when OS was measured in the same population (ctDNA(+) / PD-L1(+) HR=0.46 (0.26~0.82) vs. ctDNA(+) / PD-L1(-) HR=0.79 (0.48~1.30)) (Figures 8G and 8H). The multivariate approach yielded similar results.
[0303] To assess changes in ctDNA status in response to treatment, patients with plasma samples from both C1D1 and C3D1 were examined (485 patients, 60% of ITT). This C1D1 / C3D1 BEP was analyzed for imbalances and clinical factors between the atezolizumab and observation groups. Baseline characteristics were generally well-balanced with no imbalances observed (Table 5). [Table 5] * The patient had ctDNA samples at C1 and C3. †VENTANA SP142 immunohistochemical assay.
[0304] In C3D1, 38.4% (186 / 485) of patients were ctDNA(+), and these patients were found to have a higher risk of disease progression and relapse compared to those with ctDNA(-) (observational group DFS HR = 8.65 (5.67~13.18); p < 0.0001) (Figures 11A~11D). C3D1 ctDNA positivity was also a negative prognostic factor for OS (observational group OS HR = 12.74 (6.26~25.93); p < 0.0001). Similar results were obtained using a multivariate approach (Table 1).
[0305] iv. Changes in ctDNA status from baseline (C1D1) to treatment-dependent (C3D1); ctDNA elimination was associated with improved DFS.
[0306] ctDNA elimination was quantified and compared between treatment groups in patients defined as being ctDNA(+) at C1D1 and achieving ctDNA(-) status by C3D1. Elimination occurred in patients who subsequently became ctDNA(-) by C3D1, while non-elimination occurred in patients who remained ctDNA(+) at C3D1. Elimination was observed in 18.2% (18 / 99) of patients in the atezolizumab group compared to 3.8% (3 / 79) in the observation group (p=0.0204) (Figure 12A). Patients in the atezolizumab group who had ctDNA eliminated had superior DFS and OS compared to patients who remained ctDNA positive (DFS HR=0.26 (0.12~0.56); p=0.0014; median DFS 5.7 months vs. not achieved; OS HR=0.14 (0.03~0.59)) (Figures 12B~12E and Table 6). Similar findings were observed using a univariate approach (Table 7). Overall, patients who were ctDNA(-) at both time points or who had ctDNA removed had longer DFS than patients who were ctDNA(+) at both time points or who became ctDNA(+) (Figures 12A~12E). [Table 6] ctDNA dynamics from C1D1 to C3D1 for the median DFS and OS in the atezolizumab group and the observation group, including patients who were ctDNA(+) at C1D1 and eliminated ctDNA by C3D1 (positive > negative), patients who were ctDNA(+) at C1D1 and did not eliminate ctDNA (positive > positive), patients who were ctDNA(-) at C1D1 and remained ctDNA(-) at C3D1 (negative > negative), and patients who were ctDNA(-) at C1D1 and became ctDNA(+) at C3D1 (negative > positive). [Table 7] Analysis based on patients with the C1D1 ctDNA(+) status. * In the ctDNA statistical analysis plan, a univariate Cox proportional hazards model was pre-specified. †IMvigor010 A stratified Cox proportional hazards model was used for the primary analysis. The stratification factors were lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), and tumor stage (≤pT2 or pT3 / 4). ‡In the ctDNA statistical analysis plan, a multivariate Cox proportional hazards regression analysis was pre-specified. The stratification factors were lymph node status (+ or -), PD-L1 status (IC0 / 1 or IC2 / 3), tumor stage (≤pT2 or pT3 / 4), prior neoadjuvant chemotherapy (with or without), and number of lymph nodes (<10 or ≥10).
[0307] When comparing patients with decreased ctDNA levels to those with increased levels, a higher frequency of decreased ctDNA was found in the atezolizumab group (44.4% compared to 19.0% in observation). Decreased ctDNA was associated with improved outcomes (Figures 14A-14E). Improvement in DFS / OS in patients who decreased ctDNA but retained ctDNA(+) was not as significant as that achieved by eliminating ctDNA (Figures 15A-15D).
[0308] The v.ABACUS ctDNA study confirmed that ctDNA is associated with clinical outcomes in neoadjuvant settings. To support the findings of the above study, the inventors investigated ctDNA data from a prospective phase II trial of neoadjuvant atezolizumab pre-cystectomy in patients with muscle-invasive urothelial carcinoma (Figures 17A-17C). The clinical characteristics of the patients and the efficacy endpoints of this trial have been previously published (Powles et al. Nat Med. 25(11):1706-1714 (2019)). Briefly, the patients received two cycles of atezolizumab three times a week, followed by cystectomy. The trial met its primary endpoint of complete pathological response, and ctDNA analysis was exploratory. 40 / 96 patients had plasma samples available at baseline (pre-neoadjuvant) for ctDNA analysis. Samples were collected before and after neoadjuvant atezolizumab (pre-cystectomy). Both trials used the same ctDNA methodology, but concurrent analysis with IMvigor010 was not specified beforehand, and therefore the results should be interpreted with caution. At baseline, 62.5% (25 / 40) of patients were ctDNA(+), which correlated with poor outcomes (Figures 17A-17C). Atezolizumab was associated with a decrease in ctDNA levels in patients who achieved pathological complete response (pCR) or major pathological response (MPR) (Figures 12F-12G). In patients who were ctDNA(+) at baseline and for whom plasma was available after neoadjuvant (n=17), cleavage was assessed. Atezolizumab was associated with ctDNA cleavage in 3 / 17 (18%) of patients (Figure 12H). Patients who did not respond did not show significant changes in ctDNA levels. These results in the neoadjuvant setting further support the association between ctDNA dynamics and clinical response to atezolizumab. Therefore, these data suggest that ctDNA positivity may be a useful predictive therapeutic marker for atezolizumab response in neoadjuvant settings.
[0309] vi. Biomarkers for transcriptional correlation of ctDNA-positive individuals and responses to atezolizumab within the ctDNA(+) population. To investigate the underlying mechanisms of the above findings, exploratory transcriptional analysis was performed on tumors in IMvigor010. Gene expression profiles correlated with C1D1 ctDNA positivity and clinical relapse. To identify genes expressed differently between ctDNA(+) and ctDNA(-) patients, linear modeling was first performed, followed by pathway enrichment analysis using the Hallmark gene set from MSigDB (Subramanian et al. Proc Natl Acad Sci US A102(43):15545-15550(2005)). Tumors derived from ctDNA(+) patients were enriched with cell cycle and keratin genes compared to ctDNA(-) patients (Figure 18A-18B), which may indicate a more aggressive cancer phenotype. Within the ctDNA(+) patient population in the atezolizumab group, non-relapsed patients were further enriched with interferon-inducible genes, while relapse was associated with angiogenesis and transforming growth factor β signaling (Figure 18C). Next, we investigated PD-L1 and TMB, which have previously been shown to be selective for response to immune checkpoint inhibitors across a wide range of cancers in metastatic settings. Their role in adjuvant settings is uncertain. In this study, neither TMB nor PD-L1 could identify subgroups that benefited from atezolizumab in the overall patient population (BEP). However, within the ctDNA(+) patient population, TMB(+) and PD-L1(+) were enriched for improved clinical outcomes with atezolizumab (Figures 6A, 6B, 7A, 7B, 8B, 8D, 8F, 8H and 19A-19D), which was not observed in ctDNA-negative patients (Figures 6A, 6B, 7A, 7B, 9A, 9B, 10A, 10B and 20A-20C). The tGE3 (CD274, IFNG, CXCL9) signature, previously shown to identify patients responsive to atezolizumab in metastatic situations, was also enriched for improved outcomes to atezolizumab within the ctDNA(+) population (Figure 18D). Resistance to immunotherapy in metastatic urothelial carcinoma is associated with high expression of the F-TBRS (panfibroblast TGFβ response) signature.Here, we also showed that in an adjuvant setting, atezolizumab was associated with worse outcomes in patients with ctDNA(+) and high F-TBRS (Figure 18E) and high angiogenic signature (Figure 18F). These data highlight that predictive biomarkers of response should be interpreted in the context of MRD in a postoperative setting.
[0310] vii. Correlation between TCGA subtype and recurrence in the ctDNA(-) population The TCGA study in urothelial carcinoma has identified molecular subgroups with distinct clinical features (Robertson et al. Cell. 171(3):540-556.e25(2017)). However, it remains unclear how these subtypes influence clinical outcomes from randomized data. Hierarchical clustering reproduced the biological features of the TCGA subgroups (Figure 21A), which were similarly distributed across ctDNA(+) and ctDNA(-) patients in BEP (Figure 22A). In patients without ctDNA selection, the TCGA classification did not identify a subgroup of patients with improved outcomes with atezolizumab (Figures 6A, 6B, 7A, and 7B). However, within the ctDNA(+) population, clinical outcomes appeared improved in the basal-squamous subgroup, and established biomarkers of response to immunotherapy were partially enriched (Figures 6A, 6B, 7A, 7B, 21B-21E, and 22A-22H) (Robertson et al. Cell 171(3):540-556.e 25(2017)). These findings were not observed in ctDNA(-) patients (Figures 6A, 6B, 7A, 7B, 9A, 9B, 10A, 10B, 20A-20C, and 21B-21E). These data suggest that TCGA analysis can be used to better predict outcomes in postoperative ctDNA(+) patients.
[0311] Since some ctDNA(-) patients experienced relapse (30.6% of those observed), an exploratory analysis of baseline clinical parameters and molecular characteristics of ctDNA(-) patients in the observation group was performed (Figures 21F-21I). Tumors from relapsed ctDNA(-) patients showed increased expression of extracellular matrix (ECM), stroma, and TGFβ-inducible genes (Figures 21F-21G), suggesting interference with pre-existing immunity. The luminal-invading TCGA subtype was also most prominent in relapsed ctDNA(-) patients (Figure 21H). While non-relapsed ctDNA(-) patients may have undergone successful surgery, gene expression analysis further revealed increased expression of interferon (IFN)-inducible genes in these patients (Figure 21G), suggesting that pre-existing immunity may also be related to preventing relapse. Finally, the anatomical location of relapse differed between ctDNA(-) and ctDNA(+) patients, with ctDNA(-) relapses associated with local relapse and ctDNA(+) relapses associated with distant relapse (Figure 21I). These data highlight that tumor-derived molecular characteristics may influence the relationship between ctDNA status and recurrence.
[0312] viii. Discussion This presentation presents a prospective exploratory analysis of patient DFS and OS based on ctDNA in the IMvigor010 Phase III trial to evaluate PD-L1 inhibitors as adjuvant therapy compared to observation in patients at high risk of recurrence postoperatively. Patients who were ctDNA(+) postoperatively had a 6-fold increased risk of recurrence and an 8-fold increased risk of death compared to patients who were ctDNA(-). This suggests that postoperative ctDNA positivity may be an alternative to MRD. Within this high-risk postoperative ctDNA(+) population, patients receiving atezolizumab showed approximately a 42% reduction in recurrence rate and a 41% reduction in mortality compared to observation. Furthermore, two cycles of atezolizumab treatment resulted in ctDNA elimination in 18% of ctDNA(+) patients compared to 3.8% in the observation group. Patients with ctDNA elimination in the atezolizumab group had sustained DFS compared to patients without elimination. These findings suggest an effect of atezolizumab on outcomes in ctDNA(+) patients, indicating that ctDNA elimination may be an alternative to treatment response. No difference in clinical outcomes with atezolizumab was detected in ctDNA(-) patients, suggesting that these lower-risk patients (63% of ITT) could omit adjuvant and atezolizumab treatment. These findings are clinically significant, and using validated blood tests to select high-risk groups of patients who may benefit from intervention is broadly appealing in postoperative settings.
[0313] Initiating individualized treatment based on MRD identification, rather than treating unselected patients or waiting for radiological recurrence, would represent a significant shift in postoperative cancer treatment. This example demonstrates a substantial improvement in clinical outcomes for ctDNA(+) patients treated with adjuvant atezolizumab. These individuals are more likely to have residual molecular disease after surgery. Furthermore, a parallel neoadjuvant atezolizumab study in UC (ABACUS study) has been presented, which also showed that ctDNA(+) patients had a poor prognosis. In this neoadjuvant context, a decrease in ctDNA levels is associated with the response, supporting the findings of the adjuvant study.
[0314] Protein and transcriptome biomarker analyses provided insights into the biology underlying ctDNA positivity and the response to atezolizumab in this population, highlighting the importance of immune and stromal composition. The relationship between tumor-based biomarkers and ctDNA emphasizes that predictive biomarkers of response should be interpreted in the context of MRD, improving our understanding of disease and treatment responses.
[0315] Previous studies have shown that tissue-based TMB and PD-L1 biomarkers can be used to predict the response to immune checkpoint inhibitors, particularly in metastatic situations. In IMvigor010, these tissue-based biomarkers did not identify patients who would benefit from atezolizumab. However, in the ctDNA(+) population, TMB(+) or PD-L1(+) had improved outcomes compared to TMB(-) or PD-L1(-) with atezolizumab. While we do not wish to be bound by theory, in adjuvant situations, predictive biomarkers of efficacy may be most applicable to patients with MRD after surgery. Some postoperative patients are in complete remission and therefore lack residual tumor, making tissue biomarker status irrelevant. However, within ctDNA(+) patients, TMB and PD-L1 may provide a correlation with the efficacy of checkpoint inhibition due to the effect of immunotherapy on residual tumor. PD-L1, TMB, and basal-squamous transcriptome signatures have been shown to potentially increase the proportion of improved outcomes with atezolizumab in the ctDNA(+) population. A multi-platform approach may be optimal for patient selection in the future. The principle of identifying treatable postoperative populations through blood sampling is an attractive intervention.
[0316] Numerous studies have evaluated the role of adjuvant therapy in MIUC without demonstrating a significant survival benefit. IMvigor010 was such a study, but it observed improvements in DFS and OS in ctDNA(+) patients treated with atezolizumab compared to observation. These findings suggest that a personalized approach using immunotherapy may be optimal for treating MRD(+) postoperative UC. While other adjuvant studies may be positive for DFS benefits in patients who have not been selected, a personalized approach to select MRD(+) patients for immunotherapy may be needed to demonstrate OS benefits and to identify MRD(-) patients who are at lower risk and less likely to benefit from unnecessary treatments. Sequential trials ("surveillance" or "monitoring") may increase the sensitivity of ctDNA detection in adjuvant settings, which is being investigated in prospective trials.
[0317] In summary, this Phase III trial demonstrated that postoperative ctDNA testing can identify ctDNA(+) patients at high risk of recurrence and death potentially due to MRD. ctDNA(+) patients had an elevated rate of ctDNA elimination in the treatment group and improved outcomes when also positive for TMB and PD-L1 immunobiometric markers. These novel findings demonstrate ctDNA as a marker for MRD and response to atezolizumab, linking ctDNA to tumor biology. Based on the overall data, adjuvant atezolizumab intervention can improve outcomes in selected postoperative MIUC patients and supports atezolizumab as an important new adjuvant therapy option.
[0318] Example 2: IMvigor011: A Phase III double-blind, multicenter, randomized trial of atezolizumab (anti-PD-L1 antibody) as an adjuvant therapy compared to placebo in patients with high-risk muscle-invasive bladder cancer who are ctDNA-positive after cystectomy. This example describes IMvigor011, a phase III randomized, placebo-controlled, double-blind trial designed to evaluate the efficacy and safety of atezolizumab adjuvant therapy compared to placebo in MIBC patients who are ctDNA-positive and at high risk of recurrence after cystectomy.
[0319] A. Objectives and evaluation items i. Primary effectiveness objectives The primary efficacy objective of this study is to evaluate the efficacy of atezolizumab. The following evaluation criteria were used to compare with placebo: ● Disease-free survival (DFS) as assessed by an independent review facility (IRF) in patients who were ctDNA positive within 20 weeks of cystectomy (primary analysis population). DFS is defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: ○ Localized (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes) ○Urinary tract recurrence in UC (including all pathological stages and grades) ○ Distant metastasis of ulcerative colitis ○ Death due to any cause
[0320] ii. Secondary effectiveness objectives The secondary efficacy objective of this study is to evaluate the efficacy of atezolizumab compared to placebo based on the following endpoints: ● Overall survival (OS) in patients who were ctDNA positive within 20 weeks after cystectomy (primary analysis population), defined as the time from randomization to death from any cause. ●DFS assessed by IRF in all randomized patients ●DFS as assessed by the principal investigator in the primary analysis population ●DFS as assessed by the principal investigator in all randomized patients ● Disease-specific survival as assessed by the principal investigator in the primary analysis population, defined as the time from randomization to death due to UC as assessed by the principal investigator. ● Distant metastasis-free survival, as assessed by the principal investigator in the primary analysis population, is defined as the time from randomization to the diagnosis of distant (i.e., non-local) metastasis or death from any cause. ●Time to decline in function and quality of life (QoL) in the primary analysis population and all randomized populations, defined as the time from randomization to the date on which a patient's score first decreased by 10 points or more from baseline on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Function Scale, Role Function Scale, and Global Health Status (GHS) / QoL Scale (separately). ● ctDNA exclusion in the primary analysis population, defined as the proportion of patients who are ctDNA-positive at baseline and ctDNA-negative on day 1 of cycle 3 or day 1 of cycle 5.
[0321] B. Research Design This describes IMvigor011, a global, randomized, placebo-controlled, double-blind phase III trial designed to evaluate the efficacy and safety of atezolizumab adjuvant therapy compared to placebo in MIBC patients who are ctDNA-positive and at high risk of recurrence after cystectomy (see Figure 23).
[0322] Patients aged 18 years or older with histologically confirmed muscle-invasive urothelial carcinoma of the bladder (also known as transitional cell carcinoma (TCC)) and an ECOG performance status of 2 or less are eligible. Patients with bladder as the primary site must have undergone radical cystectomy with lymph node dissection. Patients who have previously received NAC are eligible, but pathological examination of the cystectomy specimen must show a tumor staging of ypT2-4a or ypN+ and M0. Patients who have not previously received NAC must be ineligible for or have refused cisplatin-based adjuvant chemotherapy and must have a tumor staging of pT3-4a or pN+ and M0.
[0323] To prospectively examine for the presence of ctDNA after surgery, to screen for eligibility to enter the monitoring and treatment phases, and for ongoing ctDNA exclusion analysis or ongoing ctDNA monitoring during the study, this study requires the collection of tumor tissue specimens and blood samples from eligible patients. Tumor specimens will be collected from surgical resections (i.e., radical cystectomy or lymph node dissection) from patients who have provided informed consent and evaluated for PD-L1 expression by immunohistochemistry (IHC). Tumor specimens will also undergo whole exome sequencing (WES). Blood samples will be collected to measure both normal DNA and ctDNA in the patient's blood. Only patients whose tumors have a sufficient amount of viable tumor for WES and are evaluable for PD-L1 expression, as confirmed by the central pathology laboratory prior to patient enrollment in the study, are eligible. Patient tumor specimens will be sequenced against corresponding normal DNA to create a panel of multiple polymerase chain reaction (mPCR) assays for the top 16 clonal mutations specific to each patient's tumor tissue.
[0324] All eligible patients with individualized mPCR assays who agree to participate in the monitoring phase and who have no residual disease as assessed by IRF will be enrolled in the monitoring phase of the study, regardless of their plasma ctDNA status. Patients may be enrolled in the monitoring phase for a minimum of 6 weeks but not exceeding 14 weeks from the date of cystectomy.
[0325] Patients enrolled in the surveillance phase will undergo blood draws for plasma ctDNA testing and surveillance imaging for tumor recurrence. Blood draws will be performed every six weeks until 36 weeks from the enrollment date or 36 weeks from the date of cystectomy, whichever comes first. After reaching the most recent blood draw 36 weeks prior to cystectomy, blood draws will follow the subsequent schedule of surveillance imaging. Surveillance imaging in the surveillance phase will be performed every 12 weeks until 84 weeks from the enrollment date or 21 months from the date of cystectomy, whichever comes first. If disease recurrence is assessed by the principal investigator, the patient will not continue in the surveillance phase.
[0326] Blood samples from patients collected during the surveillance phase will be evaluated for the presence of up to 16 mutations identified from the primary tumor. Plasma samples evaluated to have two or more mutations will be considered ctDNA positive. If a patient has fully recovered from cystectomy, has no evidence of disease recurrence on imaging within 28 days prior to treatment initiation as determined by IRF evaluation, and has consented to participate in the treatment phase, the patient will enter the trial's treatment phase and be randomly assigned to treatment at the time of the first ctDNA-positive plasma sample. Only patients who are ctDNA positive will enter the treatment phase. Patients who are ctDNA negative will continue to be monitored until they are ctDNA positive, ctDNA negative, or have a radiological recurrence evaluated by the principal investigator within 21 months from the date of cystectomy.
[0327] Tumor tissue samples from patients are also prospectively tested for PD-L1 expression by the central laboratory during the screening period, and PD-L1 status (IHC score of IC0 / 1 versus IC2 / 3) is used as one of the stratification factors.
[0328] Patients entering the treatment phase will be randomly assigned to one of the following groups in a 2:1 ratio. ●Group A (experimental group): IV infusion of 1680 mg of atezolizumab every four weeks (Q4W) on day 1 of each 28-day cycle. ● Group B (control group): Placebo IV injection on day 1 of each 28-day cycle (Q4W)
[0329] Patients in both treatment groups will receive treatment with either atezolizumab (fixed dose of 1680 mg) or the corresponding placebo for 12 cycles or up to one year (whichever comes first). Treatment will be administered by IV infusion on day 1 of each 28-day cycle.
[0330] Atezolizumab / placebo will be discontinued in the event of disease relapse as assessed by IRF, unacceptable toxicity, withdrawal of consent, or termination of the study.
[0331] Randomization is stratified by the following factors: ● Lymph node status (positive vs. negative) ● Tumor stage after cystectomy (pT2 or less vs. pT3 / pT4) ●PD-L1 IHC status (IHC score of IC0 / 1 versus IC2 / 3) ○Using the VENTANA PD-L1 (SP142) Assay, PD-L1 expression (corresponding to the presence of discriminable PD-L1 staining of any intensity in tumor-infiltrating immune cells covering more than 5% of the tumor area, including IC2 / 3, tumor cells, and associated intratumoral and adjacent peritumoral stroma) is evaluated by the central laboratory. ● Time from cystectomy to the first ctDNA-positive sample (≤20 weeks vs. >20 weeks)
[0332] Randomization will take place within 14 days of confirmation that the patient's plasma sample is ctDNA positive. Administration of the study drug will begin within 4 calendar days of randomization.
[0333] All patients entering the treatment phase will undergo scheduled assessments for tumor recurrence at baseline and every 9 weeks (±7 days) during the first year after randomization. After completing the treatment / placebo phase, disease status assessments for tumor recurrence will be conducted every 9 weeks (±7 days) in year 2, every 12 weeks (±10 days) in year 3, every 24 weeks (±10 days) in years 4 and 5, and in year 6 (approximately 48 weeks after the last assessment in year 5).
[0334] Patients who remain ctDNA-negative 21 months after the date of cystectomy will not be randomly assigned to treatment and will not continue in the trial.
[0335] C. Materials and Methods i. Inclusion criteria To be enrolled in the study, patients must meet the following criteria: Inclusion criteria for the monitoring phase ● Histologically confirmed MIUC (also known as TCC) in the bladder
[0336] Patients with carcinomas exhibiting a mixed histological type must have a predominant transitional epithelial pattern. ●The TNM classification for pathological examination of surgically resected specimens (based on the AJCC Cancer Staging Manual, 7th Edition; Edge et al. 2010) is as follows: ○For patients previously treated with NAC: Tumor stage ypT 2-4a or ypN+ and M0 ○For patients who have not previously received NAC: Tumor stage pT 3-4a or pN+ and M0 ● Surgical resection of MIUC in the bladder ○ Radical cystectomy can be performed via open surgery, laparoscopy, or robotic approach. ○ Cystectomy must include bilateral lymph node dissection, the extent of which is at the discretion of the treating surgeon, but optimally it should extend at least from the central common iliac artery proximal to the Cooper's ligament distally, to the pudenofemoral nerve laterally, and to the obturator nerve inferiorly. The method of urinary diversion for patients undergoing cystectomy is at the discretion of the surgeon and the patient's choice. Patients with negative surgical resection margins (i.e., R0 resection) or those with carcinoma in situ at the distal ureteral or urethral stump are eligible. Patients with positive R2 margins (defined as a tumor identified in the stained perivelial fat margin surrounding the cystectomy specimen) or R1 margins (defined as evidence of microscopic disease identified in the tumor margin) are excluded, with the exception of carcinoma in situ at the distal ureteral or urethral margins. ● Patients who have not received previous platinum-based NAC, have refused cisplatin-based adjuvant chemotherapy, or are ineligible ("unsuitable") for this treatment. Patients who have received at least three cycles of platinum-containing regimens will be considered to have received previous NAC treatment. ○Cisplatin ineligibility is defined by one of the following criteria: ■ Renal impairment (glomerular filtration rate (GFR) < 60 mL / min); GFR should be assessed by direct measurement (i.e., creatinine clearance or ethylenediamine tetraacetate) or, if unavailable, by calculation from serum / plasma creatinine (Cockcroft-Gault formula). ■25dB of hearing loss at two adjacent frequencies (measured by a hearing test) ■ Peripheral neuropathy of grade 2 or higher (i.e., sensory changes or paresthesia including stabbing pain (parasthesis)) ■2 ECOG Performance Status ● Availability of surgical tumor specimens (e.g., of appropriate quality and quantity) suitable for use in determining ctDNA status and for exploratory biomarker studies evaluated by central laboratory testing. Representative formalin-fixed paraffin-embedded (FFPE) tumor blocks submitted with relevant pathology reports; two FFPE tumor blocks are recommended if available. Patients with fewer than 20 (but not fewer than 16) slides available at baseline may still be eligible for the study after Medical Monitor approval is obtained. ●For the development of the ctDNA assay, tumor tissue samples were submitted within 10 weeks of cystectomy. ●A ctDNA assay was developed based on corresponding normal DNA obtained from tumor tissue specimens and blood. ●Postoperative blood samples were submitted for screening to identify somatic mutations in tumor tissue and for plasma preparation to determine ctDNA status. ●Definitive diagnosis of MIUC demonstrated through IHC-mediated central examination of tumor PD-L1 expression and representative tumor tissue specimens. ● Absence of residual disease and metastasis, as confirmed by negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scans of the pelvis, abdomen, and chest within four weeks prior to registration. ○Confirmation of disease-free status is evaluated by independent central radiological review of imaging diagnostic data. ○ Imaging of the upper urinary tract is required and may include one or more of the following: intravenous pyelography (IVP), CT urography, renal ultrasound with retrograde pyelography, ureteroscopy, or MRI urography. However, if the upper urinary tract is covered in abdominal and pelvic imaging, separate imaging of the upper urinary tract by one of these methods is not required. Imaging must be completed within four weeks prior to registration. ● Complete recovery from cystectomy and registration within 14 weeks post-cystectomy. ○At least 6 weeks must have passed since the surgery.
[0337] Additional inclusion criteria for treatment stages Patients enrolled in the monitoring phase must meet the following criteria for randomization to the treatment phase of the trial. ● Plasma samples were evaluated as ctDNA-positive, defined as the presence of two or more mutations based on a patient-specific ctDNA mPCR assay. ●ECOG performance status of 2 or less ● Absence of residual disease and metastasis, as confirmed by negative baseline CT or MRI scans of the pelvis, abdomen, and chest within 4 weeks prior to randomization. ○Confirmation of disease-free status is evaluated by independent central radiological review of imaging diagnostic data. ○Imaging of the upper urinary tract is required and may include one or more of the following: IVP, CT urography, renal ultrasound with retrograde pyelography, ureteroscopy, or MRI urography. However, if the upper urinary tract is covered in abdominal and pelvic imaging, separate imaging of the upper urinary tract in any of these forms is not required. Imaging must be completed within four weeks prior to registration.
[0338] ii. Exclusion criteria Patients who meet any of the following criteria will be excluded from trial enrollment: ● A history of severe allergic reactions, anaphylactic reactions, or other hypersensitivity reactions to chimeric antibodies, humanized antibodies, or fusion proteins. ● Known hypersensitivity to any component of the biopharmaceutical or atezolizumab preparation produced in Chinese hamster ovary cells. ● Any approved anti-cancer therapy, including chemotherapy or hormone therapy, administered within three weeks prior to trial enrollment. ○Hormone replacement therapy or oral contraceptives are acceptable. ● Adjuvant chemotherapy or radiotherapy for ulcerative colitis after cystectomy Patients who received primary chemoradiotherapy for bladder preservation before cystectomy are eligible and will be treated in the same way as patients who previously received NAC.
[0339] Patients in the monitoring phase who meet any of the following additional medical criteria will be excluded from being introduced to the treatment phase. ●Previous treatment with CD137 agonists or immune checkpoint blockade therapy, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies. ● Treatment with a systemic immunostimulant (including, but not limited to, IFN and IL-2) before day 1 of cycle 1, within 6 weeks, or within 5 half-lives of the drug (whichever is shorter).
[0340] iii. Experimental treatments The investigational drug (IMP) for this study is atezolizumab. The placebo is identical in appearance to atezolizumab and contains the same excipients, but does not contain the atezolizumab active ingredient. Atezolizumab / placebo will be administered by IV infusion at a fixed dose of 1680 mg on day 1 of each 28-day (±3-day) cycle, for 12 cycles or 1 year, whichever comes first. This dose level corresponds to a dose based on average body weight of approximately 20 mg / kg.
[0341] iv.Statistical analysis The primary efficacy endpoint is disease-free survival (DFS), assessed by the Intra-Risk Frequency (IRF), defined as the time from randomization to the first occurrence of a DFS event. DFS is analyzed in the primary analysis population, defined as randomized patients with ctDNA-positive samples obtained within 20 weeks post-cystectomy. Data from patients without a DFS event are censored on the last day the patient is assessed as alive and recurrence-free. Data from patients without post-baseline disease assessment are censored on the day of randomization.
[0342] We will compare disease-free survival (DFS) between treatment groups using a stratified log-rank test. The null and alternative hypotheses are the survival function S in group A (atezolizumab) and group B (placebo), respectively. A (t) and S B It can be expressed in terms of (t). H0:S A (t)=S B (t) vs H1:S A (t) ≠ S B (t)
[0343] HR, that is, λ A and λ B λ represents the hazards for DFS events in group A and group B, respectively. A / λ BThe HRs were estimated using a stratified Cox regression model with the same stratification variables used for the stratified log-rank test, and 95% confidence intervals (CIs) are provided. Results from unstratified analyses are also provided. An HR < 1 indicates a therapeutic benefit in favor of atezolizumab. Stratification factors for the primary analysis population include lymph node status, tumor stage after cystectomy, PD-L1 IHC status, and time from cystectomy to the first ctDNA-positive sample; however, stratification factors may be combined for analytical purposes if necessary to minimize small layer cell sizes.
[0344] The Type I error (α) for this study is 0.05 (two-sided). Type I error is adjusted for the primary endpoint, DFS as assessed by IRF, and for the important secondary endpoints, OS in the primary analysis population and DFS as assessed by IRF in all randomized populations. To adjust for Type I error with α=0.05 (two-sided) for the IRF-assessed DFS and OS endpoints, treatment groups are compared in a hierarchical manner as follows: Step 1: IRF-assessed DFS in the primary analysis population is assessed with α=0.05 (two-sided). Step 2: If the IRF-assessed DFS analysis results for the primary analysis population are statistically significant, α=0.05 is carried over to the OS analysis for the primary analysis population. If the IRF-assessed DFS results for the primary analysis population are not statistically significant, a formal treatment comparison of OS is not performed. Step 3: If the OS results in the primary analysis population are statistically significant in either the interim or final OS analysis, α=0.05 is carried over to the analysis of DFS assessed by IRF in all randomized populations. If the OS results in the primary analysis population are not statistically significant in either the interim or final analysis, a formal treatment comparison of DFS assessed by IRF in all randomized populations is not performed.
[0345] The Kaplan-Meier method is used to estimate the median DFS for each treatment group and to construct Kaplan-Meier curves. The Brookmeyer-Crowley methodology is used to construct the 95% confidence interval (CI) for the median DFS for each treatment group. For each treatment group, the DFS rate at various time points (i.e., every 6 months after randomization) is estimated using the Kaplan-Meier method, and the 95% CI is calculated using Greenwood's formula. The 95% CI of the difference in rates between two groups is estimated using standard approximation methods.
[0346] Further analyses, including time-series analysis and subgroup analysis, will be performed on both DFS assessment items evaluated by the above IRF.
[0347] If both the IRF-assessed DFS and OS analysis results for the primary analysis population are statistically significant, the IRF-assessed DFS is formally analyzed for all randomized populations (i.e., all patients randomly assigned to treatment, regardless of the length of time between cystectomy and ctDNA positivity). In that scenario, a nominal amount of α (i.e., 0.0001) is assigned to each OS interim analysis (Haybittle-Peto boundary) to maintain family-specific Type I error adjustment for IRF-assessed DFS in all randomized populations. Since the primary analysis population is included in the analysis of all randomized populations, this approach for Type I error adjustment takes into account the results of open-label studies prior to the analysis of IRF-assessed DFS in all randomized populations.
[0348] The secondary efficacy endpoint is overall survival (OS), defined as the time from randomization to death from any cause. OS is analyzed in the primary analysis population, defined as randomized patients with ctDNA-positive samples obtained within 20 weeks after cystectomy. The method for comparing OS between treatment groups is the same as the method for comparing treatments for the primary efficacy endpoint, disease-free survival (DFS), assessed by IRF. The statistical significance thresholds in the intermediate and final OS analyses are determined based on the Lan-DeMets run of the O'Brien-Fleming use function. OS is also analyzed in all randomized populations as an exploratory analysis using the same method as for the OS in the primary analysis population.
[0349] ctDNA elimination, defined as the proportion of patients who are ctDNA-positive at baseline and ctDNA-negative on day 1 of cycle 3 or day 1 of cycle 5, is analyzed in the primary analysis population. For each treatment group, estimates of the proportion of patients with ctDNA elimination and its 95% CI are calculated using the Clopper-Pearson method. The CI of the difference in proportions between the two groups is determined using a normal approximation of the binomial distribution. The proportions are compared between the two groups using a stratified Cochran-Mantel-Haenszel test.
[0350] Other embodiments Some embodiments of the technology described herein may be defined according to any of the following numbered embodiments.
[0351] 1. A method for treating urothelial carcinoma in a patient requiring treatment for urothelial carcinoma, the method comprising administering to the patient an effective amount of a therapeutic regimen comprising a PD-1 axis-coupled antagonist, the therapeutic regimen being an adjuvant therapy, and the patient having been identified as likely to benefit from the therapeutic regimen based on the presence of circulating tumor DNA (ctDNA) in a biological sample obtained from the patient.
[0352] 2. A method for treating urothelial carcinoma in patients who require treatment for urothelial carcinoma, (a) Determining whether ctDNA is present in the biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen including a PD-1 axis-binding antagonist; (b) Based on the presence of ctDNA in the biological sample, administer to the patient an effective dose of a therapeutic regimen comprising a PD-1 axis-binding antagonist, wherein the therapeutic regimen is adjuvant therapy. Methods that include...
[0353] 3. A method for identifying a patient having urothelial carcinoma who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, the method comprising determining whether ctDNA is present in a biological sample obtained from the patient, wherein the presence of ctDNA in the biological sample identifies the patient as a patient who may benefit from treatment with a treatment regimen comprising a PD-1 axis-coupled antagonist, the treatment regimen being adjuvant therapy.
[0354] 4. A method for selecting treatment for a patient with urothelial carcinoma, (a) Determining whether ctDNA is present in the biological sample obtained from the patient, the presence of ctDNA in the biological sample indicating that the patient is likely to benefit from a treatment regimen including a PD-1 axis-binding antagonist; (b) Selecting a treatment regimen containing a PD-1 axis-binding antagonist based on the presence of ctDNA in the biological sample, wherein the treatment regimen is adjuvant therapy. Methods that include...
[0355] 5. The method according to Embodiment 3 or 4, further comprising administering to the patient an effective amount of a therapeutic regimen containing a PD-1 axially coupled antagonist.
[0356] 6. The method according to any one of Embodiments 1 to 5, wherein the biological sample is obtained before or concurrently with the administration of the first dose of the therapeutic regimen.
[0357] 7. The method according to Embodiment 6, wherein the biological sample is obtained on day 1 (C1D1) of cycle 1 of the treatment regimen.
[0358] 8. The method according to any one of Embodiments 1 to 7, wherein the biological sample is obtained within approximately 30 weeks of surgical excision.
[0359] 9. The method according to Embodiment 8, wherein the biological sample is obtained within approximately 20 weeks of surgical excision.
[0360] 10. The method according to Embodiment 8 or 9, wherein the biological sample is obtained approximately 2 to 20 weeks after surgical excision.
[0361] 11. The method according to any one of Embodiments 1 to 10, wherein the biological sample is a blood sample, plasma sample, serum sample, urine sample, cerebrospinal fluid (CSF) sample, nasal swab sample, saliva sample, stool sample, or vaginal fluid sample.
[0362] 12. The method according to Embodiment 11, wherein the biological sample is a plasma sample.
[0363] 13. A method for monitoring the response of a patient having urothelial carcinoma who has been administered at least a first dose of a therapeutic regimen comprising a PD-1 axis-coupled antagonist, the method comprising determining whether ctDNA is present in a biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen, and whether ctDNA is present in a biological sample obtained from the patient at a time after the administration of the first dose of the therapeutic regimen, thereby monitoring the patient's response.
[0364] 14. The method according to Embodiment 13, wherein the absence of ctDNA in the biological sample obtained from the patient at a time after administration of the first dose of the treatment regimen indicates that the patient is responding to the treatment regimen.
[0365] 15. A method for identifying a patient with urothelial carcinoma who may benefit from a treatment regimen comprising a PD-1 axis-coupled antagonist, wherein the treatment regimen is a neoadjuvant therapy or adjuvant therapy, the patient has been administered at least a first dose of the treatment regimen, and ctDNA is present in a biological sample obtained from the patient prior to or concurrently with the first dose of the treatment regimen, and the method is: A method comprising determining whether ctDNA is present in a biological sample obtained from the patient at a time after administration of the first dose of the therapeutic regimen, wherein the absence of ctDNA in the biological sample at a time after administration of the therapeutic regimen identifies the patient as one who may benefit from treatment with a therapeutic regimen comprising a PD-1 axis-binding antagonist.
[0366] 16. The method according to any one of embodiments 13 to 15, wherein the treatment regimen is adjuvant therapy.
[0367] 17. The method according to any one of embodiments 13 to 16, wherein the time after administration of the first dose of the treatment regimen is day 1 of cycle 3 (C3D1) or day 1 of cycle 5 (C5D1) of the treatment regimen.
[0368] 18. The method according to any one of embodiments 13 to 17, wherein the biological sample obtained from the patient before or concurrently with the first dose of the treatment regimen and / or the biological sample obtained from the patient at the time after the administration of the first dose of the treatment regimen is a blood sample, plasma sample, serum sample, urine sample, CSF sample, nasal swab sample, saliva sample, stool sample or vaginal fluid sample.
[0369] 19. The method according to Embodiment 18, wherein the biological sample obtained from the patient before or concurrently with the administration of the first dose of the therapeutic regimen and / or the biological sample obtained from the patient at the time after the administration of the first dose of the therapeutic regimen is a plasma sample.
[0370] 20. The method according to any one of Embodiments 1-12 and 15-19, wherein the benefit relates to improved disease-free survival (DFS), improved overall survival (OS), improved disease-specific survival, or improved distant metastasis-free survival.
[0371] 21. The method according to Embodiment 20, relating to an improved DFS.
[0372] 22. The method according to Embodiment 20, relating to an improved OS, wherein the aforementioned benefit is...
[0373] 23. The method according to any one of Embodiments 20 to 22, wherein the improvement is either in relation to observation or in relation to adjuvant therapy with placebo.
[0374] 24. The method according to any one of Embodiments 1 to 23, wherein the presence of ctDNA is determined by a polymerase chain reaction (PCR)-based approach, a hybridization capture-based approach, a methylation-based approach, or a fragment mix approach.
[0375] 25. The method according to Embodiment 24, wherein the presence of ctDNA is determined by a personalized ctDNA multiplexed polymerase chain reaction (mPCR) approach.
[0376] 26. The personalized ctDNA mPCR approach described above (a) (i) To generate tumor sequence reads, DNA obtained from tumor samples obtained from the patient is sequenced; (ii) To generate normal sequence reads, DNA obtained from normal tissue samples obtained from the patient is sequenced; (b) Identifying one or more patient-specific variants by calling somatic variants identified from the tumor sequence reads and excluding germline variants or clonal hematopoietic (CHIP) variants with undetermined potential, wherein the germline variants or CHIP variants are identified from the normal sequence reads or from publicly available databases; (c) Design an mPCR assay for the patient to detect a set of patient-specific variants; (d) Analyze the biological sample obtained from the patient using the mPCR assay to determine whether ctDNA is present in the biological sample. The method according to Embodiment 25, including the method described in Embodiment 25.
[0377] 27. The method according to Embodiment 26, wherein the sequencing is whole exome sequencing (WES) or whole genome sequencing (WGS).
[0378] 28. The method according to Embodiment 27, wherein the sequence determination is WES.
[0379] 29. The method according to any one of embodiments 26 to 28, wherein the patient-specific variant is a single nucleotide variant (SNV) or a short indel.
[0380] 30. The method according to any one of embodiments 26 to 29, wherein the set of patient-specific variants comprises at least two patient-specific variants.
[0381] 31. The method according to Embodiment 30, wherein the set of patient-specific variants comprises 2 to 200 patient-specific variants.
[0382] 32. The method according to Embodiment 31, wherein the set of patient-specific variants comprises 16 patient-specific variants.
[0383] 33. The method according to any one of embodiments 26 to 32, wherein the analysis of the biological sample obtained from the patient using the mPCR assay comprises sequencing the amplicons produced by the mPCR assay to identify patient-specific variants in the biological sample.
[0384] 34. The method according to any one of Embodiments 25 to 33, wherein the personalized ctDNA mPCR approach is the SIGNATERA® ctDNA test or the ArcherDx Personalized Cancer Monitoring (PCM®) test.
[0385] 35. The method according to any one of embodiments 25 to 34, wherein the presence of at least one patient-specific variant in the biological sample identifies the presence of ctDNA in the biological sample.
[0386] 36. The method according to Embodiment 35, wherein the presence of two patient-specific variants in the biological sample identifies the presence of ctDNA in the biological sample.
[0387] 37. The method according to any one of Embodiments 1 to 36, wherein the urothelial carcinoma is muscle-invasive urothelial carcinoma (MIUC).
[0388] 38. The method according to any one of Embodiment 37, wherein the MIUC is muscle-invasive bladder cancer (MIBC) or muscle-invasive urothelial carcinoma (muscle-invasive UTUC).
[0389] 39. The method according to Embodiment 37 or 38, wherein the MIUC is histologically confirmed and / or the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
[0390] 40. The method according to any one of embodiments 37 to 39, wherein the patient has previously been treated with neoadjuvant chemotherapy.
[0391] 41. The method according to embodiment 40, wherein the patient's MIUC is ypT2~4a or ypN+ and M0 at the time of surgical resection.
[0392] 42. The method according to any one of embodiments 37 to 41, wherein the patient has not received prior neoadjuvant chemotherapy.
[0393] 43. The method according to Embodiment 42, wherein the patient is ineligible for cisplatin or has previously refused cisplatin-based adjuvant chemotherapy.
[0394] 44. The method according to embodiment 42 or 43, wherein the patient's MIUC is pT3-4a or pN+ and M0 at the time of surgical resection.
[0395] 45. The method according to any one of embodiments 1 to 44, wherein the patient has previously undergone surgical resection with lymph node dissection.
[0396] 46. The method according to embodiment 45, wherein the surgical resection is a cystectomy or a nephroureterectomy.
[0397] 47. The method according to any one of Embodiments 1 to 46, wherein the patient has no evidence of residual disease or metastasis as evaluated by postoperative radiographic imaging.
[0398] 48. The method according to any one of Embodiments 1 to 47, wherein a tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells, which constitute about 1% or more of the tumor sample.
[0399] 49. The method according to Embodiment 48, wherein the tumor sample has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising about 1% to less than 5% of the tumor sample.
[0400] 50. The method according to Embodiment 48, wherein the tumor sample has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising about 5% or more of the tumor sample.
[0401] 51. The method according to Embodiment 50, wherein the tumor sample has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells, which comprise about 5% to less than 10% of the tumor sample.
[0402] 52. The method according to Embodiment 48 or 50, wherein the tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising about 10% or more of the tumor sample.
[0403] 53. The method according to any one of Embodiments 1 to 47, wherein a tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising less than 1% of the tumor sample.
[0404] 54. The method according to any one of Embodiments 1 to 53, wherein a tumor sample obtained from the patient has been determined to have a tissue tumor gene mutational load (tTMB) score equal to or greater than the reference tTMB score.
[0405] 55. The method according to Embodiment 54, wherein the reference tTMB score is a pre-assigned tTMB score.
[0406] 56. The method according to Embodiment 55, wherein the pre-assigned tTMB score is between approximately 8 mut / Mb and approximately 30 mut / Mb.
[0407] 57. The method according to Embodiment 56, wherein the pre-assigned tTMB score is approximately 10 mutations per megabase (mut / Mb).
[0408] 58. The method according to any one of embodiments 48 to 57, wherein the tumor specimen is obtained from surgical excision.
[0409] 59. The method according to any one of Embodiments 1 to 58, wherein the patient has an increased expression level of one or more genes selected from PD-L1, IFNG, and CXCL9 in a biological sample obtained from the patient, compared to a reference expression level of the said one or more genes.
[0410] 60. The method according to Embodiment 59, wherein the patient has increased expression levels of two or more genes selected from PD-L1, IFNG, and CXCL9 in the biological sample obtained from the patient, compared to the reference expression levels of the two or more genes.
[0411] 61. The method according to Embodiment 60, wherein the patient has increased expression levels of PD-L1, IFNG, and CXCL9 compared to the reference expression levels of PD-L1, IFNG, and CXCL9 in the biological sample obtained from the patient.
[0412] 62. The method according to any one of embodiments 59 to 61, wherein the expression levels of PD-L1, IFNG, and / or CXCL9 are mRNA expression levels.
[0413] 63. The method according to any one of Embodiments 1 to 62, wherein the patient has a reduced expression level of one or more pan-F-TBRS genes selected from ACTA2, ACTG2, TAGLN, TNS1, CNN1, TPM1, CTGF, PXDC1, ADAM12, FSTL3, TGFBI, and ADAM19 in a biological sample obtained from the patient.
[0414] 64. The method according to Embodiment 63, wherein the patient has reduced expression levels of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 or 12 of the pan-F-TBRS genes in the biological sample obtained from the patient, compared to the reference expression levels of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 or 12 of the pan-F-TBRS genes.
[0415] 65. The method according to Embodiment 63 or 64, wherein the expression level of one or more pan-F-TBRS genes is the mRNA expression level.
[0416] 66. The method according to any one of embodiments 59 to 65, wherein the biological sample obtained from the patient is a tumor sample.
[0417] 67. The method according to any one of embodiments 1 to 66, wherein the tumor of the patient has a basal squamous epithelium subtype.
[0418] 68. The method according to Embodiment 67, wherein the patient has an increased expression level of one or more genes selected from CD44, KRT6A, KRT5, KRT14, COL17A1, DSC3, GSDMC, TGM1, and PI3, compared to a reference expression level of said one or more genes.
[0419] 69. The method according to any one of embodiments 1 to 68, wherein the PD-1 axial coupling antagonist is selected from a PD-L1 coupling antagonist, a PD-1 coupling antagonist, and a PD-L2 coupling antagonist.
[0420] 70. The method according to embodiment 69, wherein the PD-1 axis coupled antagonist is a PD-L1 coupled antagonist.
[0421] 71. The method according to Embodiment 70, wherein the PD-L1-binding antagonist is an anti-PD-L1 antibody.
[0422] 72. The method according to Embodiment 71, wherein the anti-PD-L1 antibody is atezolizumab, durvalumab, avelumab, or MDX-1105.
[0423] 73. The method according to Embodiment 72, wherein the anti-PD-L1 antibody is atezolizumab.
[0424] 74. The method according to Embodiment 73, wherein the atezolizumab is administered intravenously at a dose of 840 mg every two weeks.
[0425] 75. The method according to Embodiment 73, wherein the atezolizumab is administered intravenously at a dose of 1200 mg every three weeks.
[0426] 76. The method according to Embodiment 73, wherein the atezolizumab is administered intravenously at a dose of 1680 mg every four weeks.
[0427] 77. The method according to Embodiment 76, wherein the atezolizumab is administered on day 1 of each 28-day (±3-day) cycle during 12 cycles or one year, whichever comes first.
[0428] 78. The method according to embodiment 69, wherein the PD-1 axially coupled antagonist is a PD-1 binding antagonist.
[0429] 79. The method according to Embodiment 78, wherein the PD-1 conjugated antagonist is an anti-PD-1 antibody.
[0430] 80. The method according to Embodiment 79, wherein the anti-PD-1 antibody is nivolumab, pembrolizumab, MEDI-0680, spartalizumab, semiprimab, canrelizumab, cintilimab, tislerizumab, tripalimab, or dostallimab.
[0431] 81. The method according to any one of Embodiments 1 to 80, further comprising administering an additional therapeutic agent to the patient.
[0432] 82. The method according to Embodiment 81, wherein the additional therapeutic agent is selected from the group consisting of immunotherapeutic agents, cytotoxic agents, growth inhibitors, radiotherapeutic agents, anti-angiogenic agents and combinations thereof.
[0433] 83. A PD-1 axis-coupled antagonist for use in the treatment of urothelial carcinoma in a patient requiring treatment for urothelial carcinoma, wherein the treatment comprises the administration of an effective dose of a therapeutic regimen comprising the PD-1 axis-coupled antagonist, the therapeutic regimen being an adjuvant therapy, and the patient has been identified as likely to benefit from the therapeutic regimen based on the presence of ctDNA in a biological sample obtained from the patient.
[0434] 84. A PD-1 axially coupled antagonist for use in the treatment of urothelial carcinoma in patients requiring treatment for urothelial carcinoma, wherein the treatment is (...
Claims
1. 1. A medicament for treating muscle invasive urothelial carcinoma (MIUC) in a patient in need of such treatment, comprising an effective amount of an anti-PD-L1 antibody, wherein the anti-PD-L1 antibody is atezolizumab, the patient has undergone surgical resection, and the patient has been identified as likely to benefit from a therapeutic regimen comprising the anti-PD-L1 antibody based on the presence of circulating tumor DNA (ctDNA) in a biological sample obtained from the patient.
2. 1. A kit for identifying a patient having MIUC who may benefit from a therapeutic regimen comprising an anti-PD-L1 antibody, the kit comprising a means for determining whether ctDNA is present in a biological sample obtained from the patient, the presence of ctDNA in the biological sample identifying the patient as one who may benefit from treatment with a therapeutic regimen comprising an anti-PD-L1 antibody, the patient having undergone surgical resection, and the anti-PD-L1 antibody being atezolizumab.
3. 1. A kit for selecting a treatment for a patient with MIUC, comprising: (a) determining whether ctDNA is present in a biological sample obtained from the patient, wherein the presence of ctDNA in the biological sample indicates that the patient is likely to benefit from a therapeutic regimen comprising an anti-PD-L1 antibody; (b) selecting a therapeutic regimen comprising an anti-PD-L1 antibody based on the presence of ctDNA in the biological sample, wherein the patient has undergone surgical resection and the anti-PD-L1 antibody is atezolizumab; A kit comprising the steps of:
4. The kit of claim 2 or 3, further comprising administering to the patient an effective amount of a therapeutic regimen comprising the anti-PD-L1 antibody.
5. The medicament or kit according to any one of claims 1 to 4, wherein the biological sample is a blood sample, a plasma sample, a serum sample, a urine sample, a cerebrospinal fluid (CSF) sample, a nasal swab sample, a saliva sample, a stool sample or a vaginal fluid sample.
6. The medicament or kit according to any one of claims 1 to 5, wherein the benefit relates to improved disease-free survival (DFS), improved overall survival (OS), improved disease-specific survival or improved distant metastasis-free survival, optionally with the improvement being versus observation or versus adjuvant therapy with placebo.
7. The medicament or kit according to any one of claims 1 to 6, wherein the presence of ctDNA is determined by a polymerase chain reaction (PCR)-based approach, such as a personalized ctDNA multiplexed polymerase chain reaction (mPCR) approach, a hybridization capture-based approach, a methylation-based approach or a fragmentomics approach.
8. The personalized ctDNA mPCR approach comprises: (a) (i) sequencing DNA from a tumor sample obtained from the patient to generate tumor sequence reads; (ii) sequencing DNA from a normal tissue sample obtained from the patient to generate normal sequence reads; (b) identifying one or more patient-specific variants by calling somatic variants identified from the tumor sequence reads and excluding germline variants or clonal hematopoietic with undetermined potential (CHIP) variants, wherein the germline variants or CHIP variants are identified from the normal sequence reads or from a publicly available database; (c) designing an mPCR assay for said patient that detects the set of patient-specific variants; (d) analyzing a biological sample obtained from the patient using the mPCR assay to determine whether ctDNA is present in the biological sample; The medicament or kit according to claim 7, comprising:
9. The medicament or kit according to claim 8, wherein the sequencing is whole exome sequencing (WES) or whole genome sequencing (WGS).
10. The medicament or kit according to any one of claims 7 to 9, wherein the presence of at least one patient-specific variant in said biological sample identifies the presence of ctDNA in said biological sample.
11. The pharmaceutical or kit according to any one of claims 1 to 10, wherein the MIUC is muscle-invasive bladder cancer (MIBC) or muscle-invasive urothelial carcinoma (muscle-invasive UTUC).
12. The pharmaceutical or kit according to any one of claims 1 to 11, wherein the patient has undergone surgical resection with lymph node dissection, optionally the surgical resection being a cystectomy or a nephroureterectomy.
13. The medicament or kit according to any one of claims 1 to 12, wherein the patient has no evidence of residual disease or metastasis as assessed by post-operative radiological imaging.
14. The pharmaceutical or kit according to any one of claims 1 to 13, wherein a tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising about 1% or more of the tumor sample.
15. The pharmaceutical or kit according to any one of claims 1 to 13, wherein a tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells comprising less than 1% of the tumor sample.
16. The pharmaceutical or kit of any one of claims 1 to 15, wherein a tumor sample obtained from the patient has been determined to have a tissue tumor mutation burden (tTMB) score that is equal to or greater than a reference tTMB score.
